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Breast cancer-related lymphoedema (BCRL) is a chronic condition with associated 
physical and psychological sequelae.  BCRL affects up to 25% of breast cancer 
patients, yet the aetiology is incompletely understood.  The work described within 
this thesis will help further advance the understanding of the pathophysiology of 
BCRL, with a focus on whether patients are predisposed to developing BCRL. 
 
Studies were conducted using qualitative and quantitative lymphoscintigraphy to 
assess the lymphatic system in breast cancer patients.  The first study investigated 
muscle lymph flow in the upper limb.  Lymphatic clearance rates were measured to 
investigate whether there was an abnormality in lymph flow prior to axillary lymph 
node surgery in patients who subsequently developed BCRL. Secondly, patients 
were assessed for the presence of upper limb lymphovenous communications to 
determine if these acted as a protective mechanism against the development of 
BCRL.  Finally, in order to determine if there was a global dysfunction of the 
lymphatic system in patients previously treated for breast cancer, lower limb 
lymphatic function was assessed.  
 
The first study demonstrated that those who went on to develop BCRL had a higher 
pre-operative muscle lymph flow compared with those who did not, indicating an 
underlying constitutional difference. The second study showed evidence of the 
presence of lymphovenous communications in several breast cancer patients 
studied, however the numbers were too small to show any correlation with the 
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development of BCRL. The final study showed that patients with BCRL had 
significantly impaired lower limb lymph flow compared with non-BCRL patients. 
Intriguingly, several non-BCRL patients were also found to have impaired lower 
lymph flow, raising the question of whether systemic treatment with chemotherapy 
was a significant contributory factor to this phenomenon. 
 
In conclusion, these studies add evidence in support of the hypothesis that 
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Breast cancer is the most common cancer in the UK, with approximately 50,000 
new cases of breast cancer diagnosed each year (www.cancerresearchuk.org). It is 
the leading cause of cancer death globally in women.1  The lifetime risk of 
developing breast cancer in the UK and USA is currently 1 in 8.2   
 
1.1 Classification of breast cancer 
Breast cancer is a heterogeneous disease, which consists of several subtypes with 
distinctive molecular features and clinical characteristics.  Patient age, tumour size, 
tumour grade, lymph node status, lymphovascular invasion and receptor status are 
the major factors considered when assessing prognosis and determining the most 
suitable treatment for breast cancer patients.3  
1.1.1 Histopathology 
Breast cancer is divided into non-invasive and invasive cancer.  Non-invasive cancer 
(carcinoma in situ) is a proliferation of epithelial cells that have not breached the 
basement membrane and myoepithelial layer.  Ductal carcinoma in situ (DCIS) is the 
most common form of in situ disease, comprising approximately 85% of non-
invasive disease.  It usually involves a single duct system and its microscopic 
appearance is very variable.  It is considered a true precursor of invasive breast 
cancer.  It is classified into high, intermediate and low-grade categories, which 
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differ in aggression and potential for subsequent development of invasive disease.  
Non-invasive ‘lobular’ proliferative changes are divided into lobular carcinoma in 
situ (LCIS) and atypical lobular hyperplasia (ALH). LCIS is a more extensive form of 
ALH, which has the potential to progress to invasive carcinoma.4,5    
 
Histological criteria and immunohistological (IHC) analysis is performed on tumour 
specimens.  The World Health Organisation (WHO) classification describes 18 
distinct histological types of invasive cancer.6 Invasive ductal carcinoma, not 
otherwise specified, also known as no special type (NST), is the most common and 
accounts for 70-80% of all breast cancers. Other breast cancer types include lobular 
carcinoma (10-15% of cases), medullary (5%), mucinous (2%) and tubular carcinoma 
(1%).2  In addition to the histological type, tumour grade (an assessment of 
differentiation and proliferative activity), tumour size and receptor status are 
collected.  The classification of different subtypes helps guide therapy and has been 
valuable for prognostication.7 
1.1.2 Receptor status 
Breast tumours may express receptors of which the three most important are 
oestrogen (ER), progesterone (PR) and human epidermal growth factor 2 (HER2).  
Oestrogens stimulate breast tumour proliferation and 60-70% of breast cancers are 
ER-positive.8 ER-positive tumour patients have a lower risk of mortality than ER-
negative patients. The NSABP 06 trial found improved disease free survival (DFS) 
and overall survival (OS) in ER positive patients.9 The Survival, Epidemiology and 
End Results (SEER) programme analysed data from 155,175 breast cancer patients 
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with known receptor status. Patients were categorised as ER+/PR+ (63%), ER+/PR- 
(13%), ER-/PR+ (3%) and ER-/PR- (21%). There was a higher relative risk of 
morbidity comparing ER+/PR+ patients to all other patients across the majority of 
other tumour characteristics (tumour size, grade, stage and number of positive 
nodes).  ER negativity appeared to be a greater determinant of morbidity compared 
to PR negativity.10  Although this study was limited due to differing assays and 
techniques for determining receptor positivity and absence of full adjuvant 
hormonal therapy and chemotherapy, other studies have confirmed better survival 
in patients with ER+ tumours (Table 1). 
 
 Number of 
patients 
Follow-up (years) 
Five year overall survival (%) 
ER positive ER negative 
Survival, 
epidemiology and 











26,944 5 85 69 
NSABP 06
9




Table 1 5-year overall survival in prospective studies comparing oestrogen (ER) 
positive and negative patients 
NSABP, National Surgical Adjuvant Breast and Bowel Project; ER, oestrogen receptor 
 
HER2 is part of the epidermal growth factor receptor (EGFR) family and is 
overexpressed in 15-20% of breast cancers.12  There is a significant correlation 
between HER2 overexpression and poorer prognosis, with decreased DFS and OS in 
node-positive patients.13 In a systematic review by Mirza et al, HER2 overexpression 
showed independent prognostic significance in node-negative disease.14 However, 
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at present there is no consensus on the association between HER2 status and other 
prognostic factors (e.g. tumour size, lymphovascular invasion and response to 
hormonal therapy). There has been a lack in standardisation of assay methodology, 
which has contributed to conflicting conclusions from older studies.  
 
Tumours that do not express ER, PR or HER2 are called triple-negative breast 
cancers (TNBC), and account for approximately 15% of all breast cancers. Although 
described as one group, TNBCs consist of a heterogeneous group of different 
tumour types. TNBC patients tend to be younger, have larger tumours at 
presentation, increased nodal positivity, higher tumour grade and a poorer 
prognosis. There is a significantly lower OS and DFS up to 5 years from diagnosis.  
There is a rapid rise in recurrence rates in the first 1-3 years, with a shorter time 
from distant recurrence to progression and death. However, after 10 years, TNBC 
patients are less likely to relapse than ER positive patients, suggesting a more 
aggressive but potentially curable entity.15,16 Receptor status is used in the selection 
of appropriate systemic therapy (sections 1.2.4.2 and 1.2.4.3).   
1.1.3 Molecular classifications 
Gene expression profiling has allowed a move towards molecular profiling of breast 
cancer.  Seminal work by Perou et al in 2000 classified breast cancer based on gene 
expression profiling, describing four molecular subtypes: luminal, HER2 
overexpression, basal-like and normal breast tissue-like.17 Further work has found 
subgroups and other subtypes and there are currently six recognised subtypes: 
luminal A, luminal B, HER2 overexpression, basal-like, normal breast tissue-like and 
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claudin-low.18  Microarray-based gene expression profiling has been used to predict 
the outcomes for patients, and it is the proliferation-related component of 
prognostic signatures that predict the outcome.19  Mammaprint (70-gene signature, 
Amsterdam) and Oncotype DX (polymerase chain reaction-based assay of 21 genes) 
are examples of platforms that have been approved for clinical application to 
predict disease outcome.  They also help determine which patients might benefit 
from chemotherapy due to the correlation of chemo-sensitivity and the genetic 
profile of certain breast tumours.20,21 
 
Molecular taxonomy is constantly evolving and is still a work in progress.  Gene 
expression has led to an improved understanding of signalling pathways and has 
allowed the development of targeted therapies, with the aim of a more 
personalised approach to breast cancer treatment.       
 
1.2 Management of breast cancer 
1.2.1 Diagnosis 
Breast cancer diagnosis is based on a multi-disciplinary ‘triple assessment’ approach.  
This comprises clinical assessment, imaging and histopathological assessment.   
 
Clinical assessment includes taking a detailed history and examination. The main 
imaging techniques used are mammography, ultrasound (US) and magnetic 
resonance imaging (MRI).  Mammography is the most commonly used modality to 
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image breast cancer and can identify changes in breast density and calcifications.  
This is less useful in patients with dense breasts. The overall sensitivity and 
specificity has been estimated to be 60-95%.22 Ultrasound imaging is generally used 
in addition to mammography in patients with dense breasts. 
 
Magnetic resonance imaging is the most sensitive imaging modality for detecting 
and staging breast cancer.  It is more sensitive than other modalities in the 
assessment and detection of multicentric/multifocal disease, especially in cases of 
lobular carcinoma.23,24 However, MRI has been shown to overestimate the tumour 
size and has limited availability as well as increased cost compared to 
mammography and US.25,26  The aim of breast conserving surgery (BCS) is to 
completely excise the tumour and obtain clear margins. A lower re-excision rate is 
beneficial to both patients and healthcare resources.  There is limited evidence 
from randomised control trials (RCTs) for the use of MRI in pre-operative imaging 
and planning surgery for breast cancer. Many studies were non-randomised and 
retrospective with inconsistent methodology.  
 
Table 2 summarises the two main RCTs for routine MRI use in breast cancer; the 
COMICE and MONET trials, and two of the largest observational studies.27-30  They 
concluded that routine MRI does not decrease the re-excision rate following wide 
local excision. Counter-intuitively, MRI in non-palpable tumours was actually found 
to significantly increase the re-excision rate, which the authors were not able to 
fully explain. There is more evidence to support MRI in patients with lobular cancer 
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and those at high risk of cancers. In 2010 the European Society of Breast Cancer 
Specialists (EUSOMA) group evaluated the available evidence and reached a 
consensus for use of MRI in all breast cancer patients.  Plana et al conducted a 
more recent systematic review and meta-analysis, with similar conclusions to the 
EUSOMA group.25 The key recommendations are summarised in Table 3 with the 
corresponding levels of evidence.  
 
Once imaging techniques have identified a suspicious lesion, samples of cells/tissue 
are required to confirm the diagnosis.  Patients have either core biopsy or fine-
needle aspiration cytology (FNAC) of suspicious breast tissue or axillary nodes. This 
is usually performed using US or X-ray guidance.  Core biopsy is the gold standard 
for tissue diagnosis.31,32 
 
Once the diagnosis has been confirmed, the triple assessment findings are usually 
discussed and reviewed by a multidisciplinary panel.  Treatment options are then 
discussed with the patient and a suitable management plan formulated. 
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Table 2 Main trials investigating potential benefit of additional MRI scanning in pre-operative assessment of breast cancer patients 








Re-excision rate Significance 
p 
Conclusion 
MRI No MRI MRI group No-MRI group 





RCT – palpable 
breast cancers 
1623 816 807 19% 19% 0.77 
No benefit with additional MRI 
imaging 








418 207 211 34% 12% 0.008 
Significantly higher re-excision 







349 173 176 13.8% 19.4% 0.17 







577 130 447 21.6% 13.8% 0.20 





Recommendations for MRI  Level of evidence 
Pre-operative MRI in newly diagnosed lobular cancer 2a 
Pre-operative MRI for patients aged > 60 years with > 1cm discrepancy 
in size between mammogram and ultrasound 
2b 
Verification of pre-operative MRI findings with percutaneous biopsy EPO 
Any changes to therapeutic planning resulting from pre-operative MRI 
findings should be decided by MDT 
EPO 
High risk patients; annual MRI offered to: 
 BRCA1, BRCA2 and TP53 mutation carriers 
 1
st
 degree relatives with >50% risk for BRCA1, BRCA2 and TP53 
mutation 
 previous mantle radiotherapy patients 
 patients inconclusively tested for BRCA mutation with > 20-
30% lifetime risk  
 patients undergoing prophylactic mastectomy to screen for 









Patients due to have NAC with potentially operable large tumours 
should have pre-chemotherapy MRI 
1 
Post NAC patients for measurement of residual disease. This should be 
> 2weeks after last NAC cycle and < 2 weeks before surgery 
EPO 
Table 3 EUSOMA key recommendations for MRI24 
MRI, magnetic resonance imaging; MDT, multi-disciplinary team; NAC; neo-adjuvant chemotherapy; 
EPO, expert panel opinions 
 
1.2.2 Surgery 
The surgical management of breast cancer has seen significant changes over the 
past 150 years.  Axillary lymph node dissection has been an integral part of breast 
cancer surgery for more than a century.  Current surgical treatment of patients with 
invasive breast cancer includes excision of the primary tumour and axillary lymph 
node staging or clearance.   
1.2.2.1 Surgery to the breast  
In the late 19th century patients often presented with late stage breast cancer as 
social norms prevented women from seeking medical attention early.33  Halsted 
  
29 
believed the major mechanism of tumour spread was by lymphatic permeation and 
advocated that extensive surgery was necessary to treat breast cancer.  The radical 
mastectomy became the mainstay of treatment for breast cancer, which involved 
removal of the breast, lymph nodes and pectoralis muscles.34  Halsted’s surgical 
procedure had lower recurrence rates than any other series at the time and 
remained the gold standard of surgical treatment for the next 50 years (Table 4). 
 
Surgeon Year Number of patients Local recurrence rates 
Billroth 1867 - 76 170 82% 
Fischer 1871 – 78 147 75% 
Volkmann 1874 - 78 131 60% 
Bergmann 1882 - 87 114 51-60% 
Halsted 1889 - 94 50 6% 
Table 4 Local recurrence rates for breast cancer in the 19th Century34   
 
The radical mastectomy was challenged in later years due to the advent of 
radiotherapy and further insight into human anatomy, dismissing lymphatic 
permeation as the major cause of tumour spread. In 1948 Patey and Dyson 
published studies that compared radical mastectomy with modified radical 
mastectomy (MRM), where the pectoralis minor was sacrificed but the pectoralis 
major was preserved.  They found comparable survival and local recurrence rates 
(LRR), but with improved cosmesis and decreased blood loss in patients undergoing 
MRM.  They showed that less extensive surgery was equally effective.35,36 Patey and 
Dyson also looked at the use of radiotherapy in combination with breast cancer 
surgery.  The local recurrence rates were comparable but the side effects were high 
  
30 
in these patients, and they concluded that radiotherapy should not be routinely 
used until further clinical trials were conducted.36  
 
The National Surgical Adjuvant Breast and Bowel Project trial (NSABP B-04) 
compared outcomes of radical mastectomy and MRM, with and without 
radiotherapy, in the primary treatment of breast cancer.  The results revolutionised 
breast cancer surgery by proving that radical mastectomy and its accompanying 
functional and cosmetic morbidity were unnecessary in terms of providing the 
patient with good overall and disease-free survival outcomes.37  
 
Current surgical options to treat breast cancer include modified radical mastectomy 
(with or without breast reconstruction) and breast conserving surgery (BCS).  
Mastectomy is performed in patients with large tumours (especially in women with 
small breasts), some centrally placed tumours involving the nipple and areolar, 
multicentric disease, associated extensive DCIS or positive margins after BCS 
despite one or two further re-excisions.  Mastectomy rates are variable, both 
internationally and in the UK.38  In the developed world, 25-30% of cancers are 
treated with mastectomy.39 Nipple-sparing and skin-sparing mastectomies have 
raised concerns regarding local recurrence rates.   These procedures are now 
thought to be oncologically safe in carefully selected patients, although longer-term 




It was not until the 1970s that Veronesi et al conducted a randomised trial, which 
aimed to demonstrate that radiotherapy combined with breast conserving surgery 
achieved comparable results to radical mastectomy. The results showed similar 
overall and breast-specific survival rates in both groups.43 In patients with stage I or 
II cancer, BCS with radiotherapy has become the treatment of choice, with several 
trials showing comparable results to mastectomy regarding LRR and overall 
survival.44-48  There were six RCTs which formed the basis of the National Institutes 
of Health (NIH) consensus statement recommending the increased use of BCS and 
radiotherapy (Institute Gustave-Roussy (IGR-Paris),47 NSABP 06,49 Milan-World 
Health Organisation,50 European Organisation for the Research and Treatment of 
Cancer (EORTC) 10801,48 Danish,51 and U.S. National Cancer Institute trials46).  The 
results of the pooled data from the main trials are summarised in Table 5.  Breast 
screening programmes have significantly impacted the stage at which patients are 
diagnosed with cancer, with larger numbers of patients presenting at earlier stages 
who are suitable for BCS.52  The increased use of neo-adjuvant chemotherapy (NAC) 
and endocrine therapy to downstage tumour size has also increased the number of 
patients suitable for BCS.  Approximately two-thirds of patients diagnosed with 








Node negative patients 
(n = 7287) 




radiotherapy BCS + 
radiotherapy 







6 1976 – 1986 1223 1197 27.8 47.9 20.1 




4 1981 – 1991 986 970 14.3 25.9 11.6 




7 1989 - 1999 3675 3612 15.6 31.0 13.6 
Table 5 10-year locoregional recurrence (LRR) and distant recurrence pooled data from randomised trials of patients undergoing breast-
conserving  surgery (BCS) with or without radiotherapy56 
(
1
 NSABP 06, St. George’s, Ontario COG, Scottish, West Midlands, CRC UK, 
2
 Uppsala-Orebro, Int Milan III, Tampere, SweBCG 91-RT, 
3
 NSABP B21, GBSG V Germany, BASO II, 
CALGB 9343, ABCSG 8a, PRIME trials)
  
33 
1.2.2.2 Surgery to the axilla 
Histopathological examination of lymph nodes removed during surgery provides 
accurate prognostic information and helps determine the most appropriate 
adjuvant therapy. Axillary surgery is also therapeutic by removing lymph nodes 
containing metastatic disease thereby decreasing the risk of axillary nodal 
recurrence.  It is estimated that 30-40% of early breast cancer patients have axillary 
lymph nodal involvement.57 Surgical options for the axilla include axillary lymph 
node dissection (ALND), four-node axillary sampling (4NAS), blue dye assisted four-
node axillary sampling and sentinel lymph node biopsy (SLNB).58-62  
 
Axillary lymph node dissection was previously the standard approach for axillary 
lymph node surgery.  It can be performed to level one, two or three, based on the 
anatomical relationship of the axillary nodes to pectoralis minor. ALND is associated 
with significant morbidity, e.g. seroma formation, limited upper limb and shoulder 
mobility, sensory loss and lymphoedema.  In patients in whom there is no axillary 
nodal involvement, these complications significantly affect quality of life without an 
associated clinical benefit.  As a result alternative methods were sought to reduce 
the morbidity of this procedure in such patients.63    
 
In most cases, lymphatic spread of cancer from the breast to the axillary nodes is 
systematic from levels 1 to 3 with skip metastases occurring infrequently.64,65 The 
sentinel node (SLN) is the first node(s) to receive lymph from the site of the tumour 
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and should be the first node to be involved if there is metastatic spread.  Hence an 
alternative method of staging the axilla is SLNB.    
 
The first SLNB was performed in 1951 by Gould during a parotidectomy.66  The 
technique was then used in penile cancer by Cabanas in the 1970s.67  Morton et al 
adapted the procedure for cutaneous melanoma, which was presented at a World 
Health Organisation conference for melanoma in 1989.  This is believed to be the 
turning point when SLNB was accepted by the surgical community.63 In 1994, 
Guiliano and colleagues introduced SLNB into the management of breast cancer 
patients.  They reported accurate predicted nodal status in 96% of patients in 
whom blue dye mapping identified the sentinel nodes.68  Krag et al investigated the 
use of radioisotopes and gamma probe for localisation of the SLN and then 
collaborated with the National Cancer Institute to develop clinical guidelines, which 
are still widely used.69-71 Further work regarding localisation techniques was done 
by McMasters et al to establish whether blue dye, radioisotope or a combination of 
the two was superior.  They concluded that a combination of blue dye and 
radioisotope gave the highest identification rate of the SLN with the lowest false 
negative rate.72  The same group conducted a multicentre study looking at the best 
method of radioisotope injection, and concluded that intradermal injection rather 
than peritumoural or subdermal injection was superior in identification of the 
SLN.73  The SLN(s) is identified by injection of a radio-tracer and blue dye into the 
dermis of the periareolar region.  When the axilla is surgically exposed, visual 
inspection and a hand-held gamma probe allows identification of the nodes that 
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have taken up tracer and dye and nodes that are radioactive and/or blue are 
subsequently removed.   
 
The NSABP B32 was one of the largest prospective trials that compared ALND with 
SLNB in a group of 5611 breast cancer patients.  The results showed equivalence in 
the two groups for overall survival (OS), disease-free survival (DFS) and regional 
control, and concluded that SLNB was appropriate, safe and effective in patients 
with node negative disease.74 SLNB has been validated in other prospective, 
multicentre, international trials and long-term DFS and OS are summarised in Table 
6. SLNB is the current recommended standard of care for a clinically and 
radiologically node negative axilla.74-77   
 
Newer technologies have allowed more detailed examination of the sentinel node 
including serial sectioning haematoxylin & eosin (H&E) staining, polymerase chain 
reaction (PCR) and immunohistochemistry (IHC).  SLN involvement is staged 
according to the American Joint Committee on Cancer (AJCC) classification.  Tumour 
deposits < 0.2 mm are referred to as isolated tumour cells (ITCs). Micrometastases 
refer to deposits > 0.2 mm but < 2mm.  Tumour deposits > 2 mm are referred to as 
macrometastases.78 Patients with ITCs are considered node negative and those with 
micro- or macrometastases node positive.  If the SLN is found to be tumour-free, 
this would indicate that the rest of the axillary nodes do not contain metastases79,80 
and patients do not need to undergo further axillary treatment.81  If the SLN is 
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found to be positive, then patients usually progress to have completion ALND, 
which takes place in approximately 50% of patients undergoing SLNB.76,79  
 
Controversy surrounding this approach remains and it is argued that selected early-
stage breast cancer patients receiving adjuvant therapy may not require completion 
axillary lymph node dissection (cALND) for regional control.75,82   
 
The American Society of Clinical Oncologists (ASCO) guidelines (2005) reported 
further axillary involvement in 20-35% of patients with micrometastases in the SLN, 
recommending completion ALND (cALND) in this group.83,84  This has been 
challenged by other studies reporting low axillary recurrence rates of 0 - 3.7% in 
patients with micrometastatic disease in SLNs with follow-up periods ranging from 
30 to 60 months.85,86  The International Breast Cancer Study Group (IBCSG) trial 23-
01 randomised patients with micrometastases in SLNs into two groups; cALND and 
no further surgery.  This study demonstrated a 2% local recurrence rate in the no 
further surgery group and comparable rates of disease-free survival and overall 
survival at 5 years.87 The Agency for Health Technology Assessment and Research 
(AATRM) 048/13/200 conducted a multicentre randomised controlled trial 
comparing patients with SLN micrometastatic disease who underwent cALND 
(control group) with those who did not (study group). This study found no 
significant difference in 5-year disease-free survival between the groups and 
reported an axillary recurrence rate of 1% in the control group and 2.5% in the 




 Recruitment years Number of patients Follow-up 
SLNB* (95% CI) 
% 






































Table 6 Long term disease free survival (DFS) and overall survival (OS) in randomised controlled trials validating SLNB 
*SLNB followed by ALND in node positive patients;** SLNB followed by ALND; CI, confidence interval 
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The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial assessed 
the local and regional recurrence in patients with positive SLNB, comparing patients 
who were randomised to cALND with those who had no further surgery.   The trial 
concluded similar, low 5-year LRR in patients who underwent cALND and those who 
did not (3.1% vs. 1.6% respectively).  Regional recurrence rates were similarly very 
low with 0.5% in cALND group and 0.9% in SLNB group. This was a pivotal trial, but 
there were several limitations that could have potentially biased the results.  Firstly, 
the study aimed to recruit 1900 patients, but was stopped early due to low accrual 
and event rates and only 891 patients were randomised, with 813 patients 
receiving treatment. The patients recruited were clinically node negative stage one 
or two patients and treated with BCS.  This excluded mastectomy patients and 
those with stage III disease, so the patient group was not representative of patients 
with more widespread/aggressive disease, who would have been more likely to 
have axillary nodal involvement.  Approximately 45% of the patients in the SLNB 
group had micrometastases, which also indicates minimal axillary involvement and 
is associated with a lower local recurrence rate.  All patients had opposing 
tangential field whole breast irradiation, which included treatment to level 1 and 
some of level 2 nodes in the axilla.  Lastly, over 95% of all patients had adjuvant 
systemic therapy, with just below 60% receiving chemotherapy, which is also 
known to decrease the local recurrence rates.75 This may not be wholly reflective of 
adjuvant systemic treatment in patients with similar clinical presentation in other 
units, which would potentially make the results of this trial less pertinent.
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Glechner et al (2013) conducted a systematic review and meta-analysis of SLNB 
only versus cALND in patients with early invasive breast cancer and positive SLNB.  
The meta-analysis included 50,120 patients and they found similar 5-year overall 
survival and LRR in the two groups, with higher quality of life (QoL) in SLNB only 
patients. They suggested that for women with early invasive breast cancer (T1 or T2 
disease) undergoing BCS with radiotherapy and systemic therapy, SLNB alone was 
an option that could be discussed with the patient as an alternative to completion 
ALND.90 
 
Four node axillary sampling (4NAS) is a procedure that involves the removal of four 
palpably enlarged axillary lymph nodes and examining them for evidence of 
metastatic disease.91  Chetty et al conducted a RCT of 466 patients, randomising 
patients undergoing BCS to ALND or 4NAS, with selective use of axillary 
radiotherapy in patients undergoing 4NAS. They reported no difference in DFS and 
OS (median follow-up 4.1 years), and no difference in time to axillary or breast 
recurrence (p = 0.94 and 0.97, respectively).92 Blue dye assisted 4NAS is a technique 
that is a targeted four node sampling assisted with blue dye. In the era of SLNB and 
blue-dye, perhaps the use of 4NAS no longer has a place, although this technique 
may be an acceptable and cost-effective method for staging the axilla in the 
absence of radioisotope facilities.  
1.2.3 Radiotherapy 
Patients may have radiotherapy administered after breast conserving surgery or 
mastectomy.56 The Early Breast Cancer Trialists Collaborative Group (EBCTCG) 
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publish 5-yearly updates of randomised trials of radiation for breast-conserving 
surgery and mastectomy. Table 5 summarises the results from the 2011 update of 
the main randomised trials regarding 10-year locoregional or distant recurrence in 
node negative breast cancer patients undergoing BCS with or without 
radiotherapy.56 In the context of BCS, radiotherapy to the conserved breast halves 
the local recurrence rate and decreases breast cancer-related deaths by a sixth.56 
Post-mastectomy radiotherapy (PMRT) to the chest wall is recommended if there is 
thought to be a high risk of locoregional recurrence, i.e. ≥ 4 positive axillary lymph 
nodes, T3/T4 lesions or invasion of skin or underlying muscle.93-95 Patients usually 
receive external beam radiotherapy (EBRT) to the breast or chest wall, with a dose 
of 40 Gray in 15 fractions.81 The Danish and British Columbia randomised trials 
compared LRR, DFS and OS in post-mastectomy women undergoing radiotherapy in 
addition to adjuvant tamoxifen or chemotherapy. Patients having radiotherapy in 
addition to adjuvant treatment had a lower LRR rate compared with several other 
non-randomised series.96-98 They reported a locoregional recurrence relative risk 
reduction of approximately two-thirds (Table 7). The reduction in 10-year overall 
survival was reported as 9%, but the impact of PMRT on overall survival has been 
debated. There has been a change in adjuvant systemic treatment since these trials 
recruited and their results may not be translatable to current practice. The use of 
PMRT in the intermediate-risk groups remains controversial. The SUPREMO trial 
closed recruitment in 2013 and is aiming to investigate the role of PMRT in 









Treatment after breast cancer 
surgery (n) 
Locoregional recurrence rate (%) Disease free survival (%) Overall survival (%) 
Chemotherapy 
+ PMRT 
Chemotherapy  Chemotherapy 
+ PMRT 
Chemotherapy  Chemotherapy 
+ PMRT 










1982 – 1989 852 856 9 32 48 34 54 45 
British Columbia 




1979 - 1986 164 154 10 26 48 31 47 37 
Table 7 Results from Danish and British Columbia trials comparing locoregional recurrence; disease-free survival and overall survival in pre-





Treatment after breast cancer 
surgery (n) 
Locoregional recurrence rate (%) Disease free survival (%) Overall survival (%) 
Tamoxifen + 
PMRT 
Tamoxifen Tamoxifen + 
PMRT 
Tamoxifen Tamoxifen + 
PMRT 










1982 - 1990 686 689 7 36 36 24 45 36 
Table 8 Results from the Danish trial comparing locoregional recurrence; disease-free survival and overall survival in post-menopausal 
women receiving tamoxifen with or without post-mastectomy radiotherapy (PMRT) 
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Standard EBRT requires daily radiation for a period of at least 3 weeks, which can 
be a burden to patients and on healthcare resources.  There have been trials 
evaluating an alternative, more conservative radiotherapy technique with 
accelerated partial breast irradiation (PBI) in intraoperative radiotherapy (IORT).  
TARGIT-A was a randomised, non-inferiority trial comparing single-dose targeted 
IORT (TARGIT) with whole breast EBRT in patients with invasive ductal carcinoma 
(NST). There were significantly fewer non-breast cancer deaths in the TARGIT group 
and no difference in breast cancer mortality or wound-related complications. 
However, there was a significant increase in 5-year LRR in the TARGIT group 
compared with the EBRT group (3.3% vs. 1.3%, p = 0.04).100 The ELIOT trial similarly 
randomised early breast cancer patients to IORT and whole breast EBRT.  They 
found a significantly higher LRR after a median follow-up of 5.8 years of 4.4% in the 
IORT group compared with 0.4% in the EBRT group (p < 0.0001).101  PBI is not 
recommended outside of clinical trials and it should remain investigational until 
more evidence for its safety and efficacy has been evaluated.  
 
Patients may be given radiotherapy to the axillary or supraclavicular fossa (SCF) 
nodes.  Patients with negative sentinel nodes or those who have undergone ALND 
do not require radiotherapy to the axilla.  Radiotherapy has been thought to be 
potentially less invasive than completion ALND in patients who are found to have 
positive SLNs, but it was not known if this would be more effective.  The ‘After 
mapping of the Axilla: Radiotherapy or Surgery?’ (AMAROS) trial from the European 
Organisation for Research and Treatment of Cancer (EORTC), enrolled patients with 
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positive SLNs and then randomised them to either undergo cALND or axillary nodal 
irradiation.102 Results showed that the local recurrence rate was very low in both 
groups with rates of 0.43% in patients undergoing ALND and 1.19% in those 
undergoing axillary radiotherapy, with a median follow-up of 6.1 years.  The overall 
survival and disease-free survival was not significantly different in either group (OS; 
93.3% ALND patients and 92.5% axillary radiotherapy, DFS: 86.9% ALND and 82.6% 
axillary radiotherapy).102 SCF recurrence is more common in patients with heavily 
node positive axillae.  The SCF should be irradiated in patients with 4 or more nodes 
involved to decrease the morbidity associated with SCF recurrence.81,103       
1.2.4 Systemic therapy 
Chemotherapy, endocrine therapy and biologically targeted therapies have 
contributed to a marked decrease in recurrence and mortality from breast cancer.  
Patients can receive a combination of some or all of these treatments in both the 
adjuvant and neo-adjuvant settings.   
1.2.4.1 Chemotherapy 
Chemotherapy plays an essential role in the adjuvant and neo-adjuvant treatment 
of intermediate and high-risk breast cancer patients.104  In the 1970s the Milan 
group demonstrated that breast cancer recurrence could be reduced by the 
addition of adjuvant chemotherapy, using CMF (cyclophosphamide, methotrexate 
and 5-fluorouracil).105  Anthracycline-containing regimens were investigated by the 
NSABP in the 1990s, with the aim of reducing the duration of treatment, the 
number of hospital visits and morbidity.  The results of the NSABP B-15 trial 
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concluded that the results for CMF and AC (doxorubicin and cyclophosphamide) 
were equivalent.106 AC became the ‘gold-standard’ at that time.  Over the following 
years, CMF and AC became the standards against which other regimens were 
compared.  Taxanes (paclitaxel and docetaxel) were developed in the 1980s and 
initially used in metastatic breast cancer.  Henderson et al found that AC followed 
by paclitaxel was more effective than AC alone.107  The Breast Cancer International 
Research Groups (BCIRG) -001 trial replaced 5-fluorouracil in FAC with docetaxel (T), 
and the results showed that TAC was more effective than FAC in node positive 
patients.107,108 The French Adjuvant group modified this regimen further, 
substituting doxirubcin for epirubicin, and following three cycles of FEC with three 
cycles of docetaxel.109  FEC-T is now a commonly used regimen for patients with 
positive axillary lymph nodes in the UK.  The Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) was established in 1985 to co-ordinate the meta-
analyses of randomised trials of patients receiving adjuvant treatment.  Although 
there is no one gold standard chemotherapy regimen, the EBCTCG has drawn some 
important conclusions. Treatment with CMF or 4AC (4 cycles of doxorubicin and 
cyclophosphamide) has been found to be approximately equivalent, with a relative 
reduction of breast cancer mortality rates by 20-25%.  Also, chemotherapy agents 
given in addition to 4AC were more effective than standard regimens, e.g. addition 
of taxanes, with a further proportional reduction of 15-20% in mortality rates.  The 
EBCTCG concluded that the 10-year risk of death from breast cancer is reduced by 
about a third when comparing patients receiving effective chemotherapy compared 
with those who did not receive chemotherapy.110   
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Patients with locally advanced breast cancer may receive neo-adjuvant 
chemotherapy (NAC) to downstage primary operable tumours towards more 
conservative surgery or convert an unresectable, locally advanced tumour into an 
operable one.111 NAC is as effective as adjuvant chemotherapy with regard to 
survival benefit in patients with locally advanced disease.112 The regimens 
prescribed are similar to those used in the adjuvant setting. Patients are usually re-
assessed after 2-3 cycles of NAC and if the tumour is responding, then 
chemotherapy is continued for a total of 6-8 cycles.113 The key trials comparing NAC 
and adjuvant chemotherapy are summarised in Table 9. Patients showing a 
pathological complete response (pCR) demonstrate improved overall survival,114 
and this is more likely in ER-negative than ER-positive tumours.115 Odds of pCR were 
highest for the triple negative and HER2+/hormone receptor negative subtypes, 
with evidence of an influential effect on achieving pCR in the latter subtype through 
inclusion of HER2-directed therapy with NAC.116 However, if the tumour does not 
show improvement or shows progression despite NAC, then patients should 
proceed directly to surgery. 
 
Chemotherapy is the mainstay of systemic treatment for TNBC, but there is 
currently no standard chemotherapy regimen. Some TNBC patients show a pCR 
after NAC, but on the whole, the TNBC group has a worse outcome after 




There are significant toxicities associated with chemotherapeutic drugs, which can 
cause both long and short-term mortality and morbidity.  Side effects include 
nausea, vomiting, myelo-suppression, cardiotoxicity and secondary malignancy.62 
The vast heterogeneity in breast cancer means it is difficult to predict how patients 
will respond to different regimens.  The benefits and harm of chemotherapy need 
to be determined by weighing the risk of future relapse against co-existing co-












Local Regional Recurrence (%) Overall Survival (%) 
NAC Adjuvant NAC Adjuvant 
NSABP B18
117
 1988-1993 1523 AC 114 15 13 69 70 
ECTO
118
 1996-2002 1355 AT & CMF 76 4.6 4.1 84 82-85 
EORTC 10902
119
 1991-1999 698 FEC 120 14 13 65 66 
Institut Curie
120
 1986-1990 414 FAC 105 27 19 65 60 
Table 9 Summary of randomised controlled trials in patients receiving neo-adjuvant and adjuvant chemotherapy 
NSABP, National Surgical Adjuvant Breast and Bowel Project; ECTO, European cooperative trial in operable breast cancer; EORTC, European Organization for Research and 
Treatment of Cancer; NAC, neo-adjuvant chemotherapy; AC, doxorubicin, cyclophosphamide; AT, doxorubicin, paclitaxel; CMF, cyclophosphamide, methotrexate, 




1.2.4.2 Endocrine therapy 
Endocrine therapy aims to prevent the growth stimulation effects of oestrogen 
signalling in breast cancer.  Tamoxifen was first discovered in the 1950s and initially 
assessed as a contraceptive. Tamoxifen acts by binding to the oestrogen receptor 
and inhibiting the expression of oestrogen-regulated genes, which are essential for 
tumour growth in oestrogen-dependent tumours.  It was initially used in post-
menopausal women with advanced breast cancer. The NSABP trials assessed 
progression-free survival in pre- and post-menopausal women with early breast 
cancer and positive results led to tamoxifen being the gold standard for women 
with ER positive breast cancer.121  A recent meta-analysis by the EBCTCG has 
concluded that a five-year course of tamoxifen reduces the 15-year risk of breast 
cancer recurrence and mortality by approximately a third. The reduction was 
greater in patients with strongly ER-positive tumours compared with marginally ER-
positive tumours.122 There have been trials investigating the advantage of long-
term of tamoxifen treatment (> 5 years), with early results from the ATLAS 
(Adjuvant Tamoxifen Longer Against Shorter) and aTTom (adjuvant Tamoxifen – To 
offer more?) trials indicating small but significant reductions in local recurrence.  
ATLAS reported local recurrence rates of 21.4% vs. 25.1% and aTTom 16.7% vs. 
19.3% in patients with extended tamoxifen treatment compared with those with 
only 5 years.123,124 More mature data will be needed before firm conclusions and 
guidelines can be agreed.  There have been several RCTs evaluating endocrine 
treatment, duration of therapy and sequencing. The key published trials are 




Table 10 Key trials evaluating endocrine treatments, duration of therapy and sequencing RCT, randomised control trial; NSABP, National Surgical 
Adjuvant Breast and Bowel Project; EBC, early breast cancer; -ve, negative; +ve, positive; PFS, progression free survival; DFS, disease free survival; OS, overall survival. 
 




Treatment Primary outcome 





Node – ve pre-menopausal 
Node +ve/-ve EBC post-menopausal 
1285 
2 years tamoxifen vs. no 
treatment 




ER +ve EBC node –ve pre and post-
menopausal 
2644 5 years tamoxifen vs. placebo 







Continued adjuvant treatment in ER +ve EBC 
node –ve pre and post-menopausal 
1172 
Further 5 years tamoxifen vs. 
placebo 
No additional benefit in DFS or relapse-free 
survival (at 7 years follow-up) 
Meta-analysis of ABCSG-8 
(Austrian Breast and Colorectal 
Study Group), ARNO-95 (Arimidex-




2006 Hormone sensitive EBC post-menopausal 4006 
Anastrazole or tamoxifen after 
2-3 years tamoxifen 
Significant improvement in DFS and OS in 
patients switching to anastrazole 
ATAC (Arimidex, Tamoxifen, Alone 




2010 EBC post-menopausal 9366 
Anastrazole vs. tamoxifen vs. 
anastrazole + tamoxifen 
Improved DFS, time to recurrence and decreased 
incidence of contralateral breast cancer for 
anastrazole vs. tamoxifen (p = 0.04, 0.001 and 
0.01 respectively) No improvement in OS. 




2005 EBC post-menopausal 8010 Letrozole vs. tamoxifen Improved DFS and OS for letrozole (p < 0.001) 




2004 EBC post-menopausal 4742 
5 years tamoxifen vs. 2-3 years 
tamoxifen + exemestane 





 2005 Receptor +ve, post-menopausal women 5187 
Previous tamoxifen followed by 
letrozole vs. placebo 
Improved DFS and distant DFS for letrozole 
patients  
Improved OS in node +ve patients 




2011 Receptor +ve, post-menopausal women 9779 
2-3 years tamoxifen and 
exemestane vs. 5 years 
exemestane 
No difference in DFS at 5 years 
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Aromatase inhibitors (AIs) prevent the conversion of androgens to oestrogens in 
peripheral tissues, which is most relevant in post-menopausal women in whom this 
is the main source of oestrogen. The ATAC trial compared anastrazole with 
tamoxifen and 10-year results showed an absolute rate reduction of 4.3% in breast 
cancer recurrences and 2.6% reduction in distant metastasis in patients taking 
anastrazole.128 The Breast International Group (BIG) 1-98 trial compared letrozole 
with tamoxifen, and showed improved DFS in favour of letrozole.129 However, only 
the BIG 1-98 trial showed a significant improvement in OS in patients taking 
letrozole (85.4% vs. 81.4%) after median follow-up of 8.7 years.129 A meta-analysis 
of trials comparing AIs with tamoxifen in post-menopausal women concluded that 
AIs resulted in significantly lower recurrence rates, either as monotherapy or after 
2-3 years of tamoxifen (AI switch).133   
 
Several trials assessed the benefit of sequential AIs after tamoxifen and results 
showed superiority over first-line AI therapy with a reduction in relapse-free 
survival and OS.127  The TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial 
and one arm of the BIG 1-98 trial compared patients receiving five years of AI with 
those receiving AI switch and demonstrated no difference in DFS.132,134 Endocrine 
therapy is the most important systemic treatment in ER-positive patients and 
significantly decreases recurrence and breast cancer mortality.124,135 Table 11 




Menopausal status at time of diagnosis Recommendation 
Pre-menopausal 5 years tamoxifen 
Post-menopausal 5 years anastrazole or letrozole 
Post-menopausal women after 5 years 
tamoxifen 
Consider anastrazole, letrozole or exemestane in high 
risk patients 
Women after 5 years of aromatase inhibitor No level 1 evidence at present 
Consider continuing current treatment in high risk 
patients 
Table 11 Recommendations for adjuvant endocrine treatment 
1.2.4.3 Biologically-targeted therapy 
Trastuzumab is a recombinant humanised monoclonal antibody that inhibits the 
HER2 receptor by binding to it.  It causes decreased tumour proliferation and 
suppresses angiogenesis and has significantly improved survival in metastatic breast 
cancer. There were two pivotal trials which demonstrated that trastuzumab was 
effective as both a single agent in patients with metastatic breast cancer who had 
previously had chemotherapy and also when used in combination with other 
chemotherapy agents.136,137 Table 12 summarises the main RCTs testing adjuvant 
trastuzumab in HER2 positive patients. Longer-term follow-up from these studies 
has confirmed that in patients with tumours overexpressing HER2, trastuzumab 
consistently decreases local recurrence and improves overall survival by 
approximately a third.138-142 The HERA trial evaluated extended trastuzumab 
treatment (2 years vs. 1 year) and reported no added benefit from extended 
treatment.143  Lapatinib is a newer therapy, which interrupts HER2 and EGFR 
pathways. It is used in combination with other chemotherapy agents in patients 
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2147 AC-T 0.64 0.63 
2148 T and P and H (concurrently) 0.75 0.77 






Standard adjuvant chemotherapy 
then H 
0.76 0.85 (NS)  
Table 12 Adjuvant trastuzumab randomised controlled trials 
AC, anthracycline; T, taxane; H, trastuzumab (Herceptin); P, carboplatin; DFS, disease-free survival; 
OS, overall survival; NS, not significant. 
 
1.3 Anatomy of the lymphatic system of the upper limb 
The lymphatic system begins in the interstitium in the form of capillary vessels, or 
initial lymphatics, organised as an anastomosing network or plexus. The initial 
lymphatics, diameter 80-130 m, possess a thin wall of endothelial cells supported 
by an incomplete basement membrane.145 The outer surface is tethered to the 
surrounding tissues by anchoring filaments which assist in dilating the vessels, e.g. 
in oedema.146,147 The edges of the endothelial cells overlap to form valves which 
allow fluid to enter under pressure gradients. The density of the initial lymphatics is 
highest in the upper dermis of the skin, the density decreasing progressively in the 
deeper dermis and subcutis. The initial lymphatics eventually join into larger vessels, 
the pre-collectors and collectors, often running alongside the veins, and passing 
centrally to the regional lymph nodes. Collector lymphatics possess smooth muscle 
in their walls and have a thin external connective tissue coat, similar to small 
veins.148 In the larger vessels, valves ensure unidirectional flow of lymph. The 
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superficial lymphatics may pierce the deep fascia and enter the deep lymphatic 
system. Deep lymph vessels follow the main neurovascular bundles to the lateral 
axillary nodes (often passing through 2 or 3 cubital nodes at the elbow).148,149 The 
efferent lymphatics leading from the apical group of axillary lymph nodes (see 
below) drain into the subclavian lymphatic trunk or duct, which joins the 
bloodstream at the subclavian vein via a lymphaticovenous anastomosis near the 
junction of the internal jugular vein.   
 
The axillary nodes receive more than 75% of the lymph from the breast.  There are 
between 20-40 axillary nodes, which are divided into five main groups; 
anterior/pectoral, posterior/subscapular, lateral, central and apical groups (Figure 
1). Collectively, these drain the entire upper limb, breast and trunk above the 
umbilicus.  The nodes are described in relation to pectoralis minor in the surgical 
setting.  Those lying below and lateral to the pectoralis minor are called level 1, 
those posterior to the muscle level 2, and the nodes between the lower border of 
the clavicle and the upper border of pectoralis minor are level 3 nodes (Figure 2). 








Figure 1 Levels of clearance.   




Superficial lymphatic vessels begin in cutaneous plexuses of the hand, and in the 
forearm run alongside the superficial veins.  The superficial lymphatics pierce the 
deep fascia and enter the lateral axillary nodes or deep lymphatic vessels.  Deep 
lymph vessels follow the main neurovascular bundles to the lateral axillary 
nodes.148,149   
 
A Pectoralis major muscle 
B Level 1 nodes 
C Level 2 nodes 
D Level 3 nodes 
E Supraclavicular nodes 






Figure 2 Lymphatic drainage of the upper limb 




1.4 Physiology of lymphatics 
The lymphatic system has three main functions: preservation of fluid balance, 
defence and nutritional.147 Lymph has a daily circulating volume estimated at 2-3 
litres.151 The lymphatic system is one of the major routes for absorption of nutrients 
from the gastrointestinal tract, and is principally responsible for the absorption of 
digested fats in the form of chylomicra.  The defence function acts to carry foreign 
material such as viruses, bacteria and antigens to the lymph nodes.  Here, they are 
filtered and phagocytosed, potentially stimulating an immune response leading to 
entry of lymphocytes into the efferent lymph for transport to the bloodstream.  For 
this reason, efferent lymph has a higher white cell count than afferent lymph. 147 
 
The exact filling mechanism of lymphatic fluid entering the initial lymphatics is 
unclear, but is often likened to that of the filling of a Pasteur pipette.  The initial 
lymphatic plexus is emptied by compression secondary to tissue movement and 
then re-expands due to the tension in the tethering filaments.  This causes the 
intra-lymphatic pressure to fall below the interstitial fluid pressure and this 
pressure gradient drives interstitial fluid into the lumen of the lymphatic capillaries.  
Up to a certain point, the higher the interstitial fluid pressure and volume, the 
greater the lymph flow.  Interstitial pressure and volume are influenced by capillary 
filtration rate and provide the functional link between capillary filtration and lymph 
flow; lymph drainage and capillary filtration rate are normally in balance to avoid 




The pressure in the venous outlet at the neck is higher than in the lymphatic system, 
so lymph has to be pumped along the lymphatics.  Flow along the initial lymphatics 
(lacking smooth muscle in their walls) is promoted extrinsically by deformation of 
tissues by smooth muscle contraction, arterial pulsation or (in the chest and 
abdomen) respiration and peristalsis. The lymphatic vessels containing abundant 
smooth muscle show spontaneous contractions of 8-15 cycles per minute, and can 
pump up to 40-50 mm Hg.147  The valves exist in all lymph channels to prevent 
retrograde flow and each segment of lymph vessel between valves acts as a 
separate pump.  These segments are likened to mini-hearts linked in series, 
maintaining an intrinsic pumping mechanism.  The frequency of contraction and 
stroke volume increases with distension.  This allows each lymphatic segment to 
increase output in response to the increased output from the segment before it.  
Larger lymphatics are also under sympathetic control, which allows a further 
increase in the frequency of lymphatic contraction.  In haemorrhage, increased 
lymphatic contraction frequency and contractility allows enhancement of transfer 
of interstitial fluid into the depleted circulation.146 147 
1.4.1 Physiology of lymph production 
Lymph is derived from interstitial fluid that flows into lymphatics, and the 
interstitial fluid derives from the blood plasma. The capillary wall is semi-permeable 
and fluid containing water, plasma proteins and small molecules such as 
electrolytes leaks out continuously.  This filtration is described by the Starling 
principle of fluid exchange, which can be stated as:  
Net filtration rate (Jv)  (net hydrostatic drive – net osmotic suction) 
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The movement of fluid out of a capillary is thus driven by the balance of the 
hydrostatic and colloid osmotic pressures on either side of the capillary wall.  The 
proportionality factor represents the surface area and hydraulic conductance of the 
capillary wall. The traditional view has been that arteriolar end of capillaries filter 
fluid and the venular end of capillaries re-absorb most of it, thereby preserving 
tissue volume. This view is no longer supported by modern evidence, which has 
shown that fluid moves from capillary to interstitial space along the entire length of 
the vessel in the steady state, falling almost to zero at the venular end but with no 
re-absorption.152 There is a slight excess of filtration over absorption, and it is this 
excess fluid, containing small amounts of protein, that makes up lymph.147 A shift in 
the balance of the forces in the Starling equation will result in a shift in the filtration 
rate.  If the net filtration rate increases then lymph flow would have to increase to 
prevent tissue swelling.  A higher filtration rate therefore represents higher lymph 
production if the tissue volume is constant.151 
 
Approximately 8 litres of fluid is filtered per day and enters the lymphatic system as 
afferent lymph. Perhaps half of this volume is removed by absorption as it passes 
through lymph nodes, leaving ~4 litres to re-enter the bloodstream in the neck.147 
The plasma volume is itself only ~3 litres and so the entire plasma volume, 
excluding plasma protein, leaves the blood stream and recirculates via the 




Introduction to breast cancer-related lymphoedema 
Breast cancer-related lymphoedema (BCRL) presents as a chronic swelling of the 
arm following axillary lymph node surgery as part of the surgical treatment for 
breast cancer. It was originally described by Handley in 1908 as the brawny arm of 
breast-cancer, producing discomfort and misery.154 In 1921, Halsted described the 
same condition as a complication of radical mastectomy and coined the phrase 
‘elephantiasis chirurgica’ or ‘surgical elephantiasis’.155 Although dramatic swelling 
on the scale of ‘elephantiasis chirurgica’ is now rare, lymphoedema following breast 
cancer surgery remains a poorly understood and incurable problem.156  
 
The initial treatment-related trauma to the axilla (either surgery or radiotherapy) is 
generally agreed to be the catalyst in the development of BCRL, but notably the 
majority of patients do not develop BCRL.  The aetiology of the condition remains 
incompletely defined and factors other than the primary initiating events are yet to 
be identified.1 
 
This thesis aims to further understand the pathophysiology of BCRL.  Before 
considering the pathophysiology and aims of this thesis, a clinical overview of BCRL 




1.5 Definition of BCRL 
The morbidity of BCRL spans across physical, functional and psychological domains 
and as such should be defined with multi-dimensional methodology including 
subjective and objective findings.1 Current definitions are largely focused on 
quantitative between-arm volume differences or circumferential measurements.  
These methods do not necessarily identify patients with more subtle swelling, 
which is only noticeable on physical examination.  These methods would also 
exclude the subjective findings by patients.1,157 The nature of BCRL also means that 
it can be patchy, spare certain parts of the upper limb,158 and may also progress 
towards fibrosis and muscle atrophy,159 making the volume measurement 
inaccurate as a sole diagnostic tool.  The lack of a standard definition in the 
literature and the lack of a standardised and reliable method of quantifying 
lymphoedema have resulted in the absence of a universally accepted definition of 
BCRL.157  Since there is no consensus, it makes it difficult to reliably draw 
meaningful comparisons between clinical studies.160  
 
The definition of BCRL used throughout this thesis is the presence of any one of the 
following: 
 Arm volume difference of 10% or more between the pre-operative 
(baseline) and post-operative arm measurement of the affected side 




There is a natural asymmetry in upper limb volume depending on arm dominance 
with the dominant arm being 3-5% bigger than the non-dominant arm.161,162 This 
will also be taken into account when comparing both upper limbs.163  
 
1.6 Clinical features of BCRL 
It has been reported that 75% of cases of BCRL occur within the first year after 
surgery and 90% of cases will present within three years.164,165 There have been 
reports of latent periods of greater than 20 years, indicating a possible substantial 
delay between initial surgery and the onset or reporting of swelling.58,59 The onset 
of BCRL can be gradual or sudden and patients sometimes report a precipitating 
factor, such as lifting something heavy with the arm or a graze leading to a minor 
infection.156 After an initial rapid expansion (when capillary filtration rate exceeds 
lymph drainage), the arm volume tends to plateau and then remains in a steady 
state.166 
 
In cases of mild BCRL when the upper limb volume increase does not appear 
significant, examination may reveal decreased visibility of the subcutaneous veins 
on the dorsum of the hand and forearm and fullness and rounding of the medial 
elbow and upper arm contours, indicating the thickening of tissues.  It is also 
important to assess the distribution of swelling along the length of the limb, which 
varies between patients.58  Lymphoedema is often described as a brawny and non-
pitting oedema, but in the early stages the swelling is often soft and pits easily on 
pressure. Given time, the skin texture may continue to change, although the rate of 
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change varies widely.  These changes can range from deepening of skin creases to 
hyperkeratosis and papillomatosis, which leads to the picture of ‘elephantiasis’, at 
which point the swelling is usually fixed and resistant to conservative measures.167 
The International Society of Lymphology has developed a three stage scale for 
classification of a lymphoedematous limb168 (Table 13). 
 
The appearance of oedema may sometimes represent local tumour recurrence 
within the axilla in 15% of patients, which should be borne in mind when patients 
present with swelling of the upper limb. 58,156 
 
Stage Description Characteristics 
I No or minimal fibrosis Oedema pits on pressure and reduces 
with limb elevation 
II Substantial fibrosis Oedema does not pit on pressure, 
elevation alone rarely reduces swelling 
III Lymphostatic 
elephantiasis 
Absent pitting, trophic skin changes, 
further deposition of fat and fibrosis, 
warty overgrowths 
Table 13 Clinical classification of lymphoedema (International Society of 
Lymphology)168 
 
1.7 Epidemiology of BCRL 
The reported prevalence of BCRL in the literature shows wide variation.  The 
population of breast cancer patients examined comprise those who have had 
surgery ranging from radical mastectomy to breast-conserving surgery, and have 
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had various levels of axillary lymph node dissection as well as differing regimens of 
radiotherapy, chemotherapy and endocrine therapy.  This by itself may account for 
part of the variation in the prevalence of BCRL.1 From earlier studies there are 
documented rates of BCRL ranging from 6.7 to 62.5% in a review of nine series 
published between 1908 and 1950.169 A subsequent series of radical mastectomies 
from 1940 to 1961 was reviewed by Hughes and Patel, who reported a BCRL rate of 
49.2%.170 The majority of these patients underwent radical mastectomies with or 
without radiotherapy to the axilla.   
 
As surgical intervention became more conservative, the rates of BCRL were also 
found to fall, although they were still very variable.  More recent data from larger 
series with a regular follow-up period provide a more accurate prevalence of BCRL.  
Mortimer et al (1996) reported a rate of BCRL of 28% in 1249 patients who had 
undergone ALND and were followed up for a period of 9.5 years.171 A similar rate of 
24% was found by Schunemann et al (1998) in a series of 5657 patients who were 
followed up for 11 years.172 A lower rate of BCRL was found by Herd-Smith et al 
(2001) in a study of 1278 patients treated from 1989-1997, with a prevalence of 
16% 173 with a more recent prospective single site study by Clark et al (2005) 
reporting a rate of 20.7% after 36 months follow-up.174  DiSipio et al (2013) have 
conducted a systematic review and meta-analysis of 72 studies with 29,612 women 
from 2000-2012 and estimated an incidence of 19.9% (range 8.4% - 21.4%) in 
patients undergoing ALND.175 These figures have led to the often-quoted 1 in 5 risk 




1.8 The burden of BCRL 
Breast cancer is the most common cancer affecting women worldwide with 1.38 
million women diagnosed every year.176 In all, approximately 40% of patients will be 
node-positive and may require axillary lymph node clearance.  With an estimated 
20-25% risk of BCRL, it is clear that this remains a significant clinical problem.  BCRL 
presents as a chronic swelling of the arm, either local or regional, and can be 
associated with significant physical, functional, psychological and social morbidity. 
1,60    
1.8.1 Physical morbidity 
Patients with BCRL may report symptoms such as sensations of fullness and 
discomfort in the arm.  Other symptoms include skin changes, decreased range of 
joint movement, pain and recurrent erysipelas or infections.1,60,156,177 Disabilities 
include limb heaviness, reduced movement and impaired function with the 
increased size and weight of the limb leading to progressive musculoskeletal and 
joint problems.178 A rare complication of BCRL is the development of cutaneous 
malignancy in long-standing lymphoedema such as squamous cell carcinoma, 
melanoma, Kaposi sarcoma and lymphoma.178  Stewart-Treves syndrome is a 
lymphangiosarcoma arising in the presence of chronic lymphoedema with an 
incidence of 0.03%.179 The mean survival is 24 months, with a five-year survival rate 
of approximately 10%.180-182 
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1.8.2 Psychological morbidity 
The disfiguring, disabling and chronic nature of BCRL places patients at risk of 
significant psychological and social sequelae.183 In one of the earliest studies to 
explore psychological morbidity associated with BCRL, patients were found to 
experience poorer adjustment to their illness and considerable difficulty with 
regard to home environment and sexual and interpersonal relationships.184  A study 
by Woods et al (1995) using the Psychosocial Adjustment to Illness Scale (PAIS) 
questionnaire, showed 86% of patients had a measurable psychosocial 
maladjustment at the time of referral with lymphoedema.185 A more recent 
prospective cohort study of 633 breast cancer patients showed that patients with 
BCRL had significantly worse emotional well-being and adjustment to life compared 
with those without BCRL.186  A review by McWayne et al (2005) found higher levels 
of anxiety, depression, increased frustration and anger, as well as a worse quality of 
life (QoL).183 Patients also experience problems with dress, with some reporting loss 
of interest in appearance with subsequent loss of self-esteem and avoidance of 
social activities leading to further social isolation.183,184  
1.8.3 Financial implications 
Lymphoedema causes significant morbidity and as such there is a financial cost, 
which has implications for health service providers and workforce planners.  The 
costs include routine care such as follow-up appointments and therapies, but there 
are additional economic concerns such as patients having to give up paid 
employment as they are no longer able to perform duties required of them 
involving the affected limb.187,188 In a survey of lymphoedema patients carried out 
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in the UK by Moffatt et al (2003), over 80% of patients had taken time off because 
of this, with 2% having to change jobs, and a further 8% having to give up work 
altogether.189  A study in the United States of America estimated the economic cost 
of BCRL and found that in a group of 1877 breast cancer patients studied, BCRL 
patients had significantly higher medical costs compared to non-BCRL patients 
($23,167 vs. $14,877 respectively).  These costs were attributed to imaging, 
increased outpatient care and multiple clinic visits.188   
 
1.9 Risk factors for BCRL 
The initiating factors of BCRL are accepted to be axillary surgery and radiotherapy, 
but the pathophysiology remains poorly understood.  It was traditionally thought 
that a ‘stopcock hypothesis’ explained the mechanism, with damage to the axillary 
drainage pathways impairing drainage of lymph from the whole arm causing 
interstitial fluid to build up in the arm.58,190 There are many other features of BCRL 
that do not fit with this traditional view.  This includes the fact that the majority of 
women who undergo axillary lymph node dissection and/or radiotherapy do not 
develop BCRL, it sometimes develops after many years, and the swelling is often 
non-uniform suggesting that this hypothesis is too simplistic.  It seems likely that 
many factors influence the risk of developing BCRL. 
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1.9.1 Surgical intervention 
1.9.1.1 Breast surgery 
There have been significant changes to breast cancer treatment over the past 125 
years with importance given to associated morbidity as well as mortality.  Halsted’s 
radical mastectomy resulted in an incidence of BCRL of up to 62.5%.160 With the 
introduction of more conservative approaches to the surgical management of 
breast cancer, the incidence of BCRL has decreased. A recent study has shown there 
to be no statistically significant difference in BCRL rates between MRM and BCS.191 
1.9.1.2 Axillary surgery 
Accurate assessment of axillary node status is essential for staging, prognosis and 
guiding (neo-)adjuvant treatment decisions.  ALND has previously been the 
standard approach for staging the axilla, but this method is associated with 
significant morbidity, including BCRL.  In addition to this, the majority of women 
with early-stage breast cancer are node negative, and these patients derive no 
benefit from an ALND. 76  
 
ALND is associated with significantly more morbidity than SLNB including pain, 
neurosensory changes, residual shoulder movement and BCRL.76,192,193 The rate of 
BCRL in patients undergoing SLNB has been quoted as low as 4-6%.194,195   Two 
randomised control trials have shown a significant reduction in the subjective rate 
of arm swelling in patients undergoing SLNB compared to those having ALND.79,196 
The ALMANAC trial was a multicentre randomised study comparing SLNB with 
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standard axillary treatment, i.e. level 1-3 ALND or 4NAS.  The results showed that 
patients undergoing standard axillary treatment reported moderate to severe BCRL 
more often than SLNB patients at 12 months post-surgery (subjective reporting of 
5% vs. 13%, p <0.01).  However, objective measures at 12 months post-surgery did 
not show a statistically significant difference between the two groups.76 The odds 
ratio for the development of BCRL in patients undergoing SLNB compared with 
ALND in the main prospective RCTs is summarised in Table 14, and shows 







Odds ratio (95% 
confidence interval) for 
BCRL 
Sentinella/GIVOM77 1999 – 2004 697 0.48 (0.3 – 0.8) 
Purushotham et al79 1999 – 2003 298 0.30 (0.18 – 0.68) 
NSABP B32197 1999 – 2004 3983 0.52 (0.43 – 0.65) 
ALMANAC76 1999 – 2003 1031 0.37 (0.23 – 0.60) 
Z0011198 1999 - 2004 891 0.52 (0.26 – 1.06) 
Table 14 Morbidity of sentinel lymph node biopsy vs. axillary lymph node 
dissection in key prospective randomised trials 
NSABP, National Surgical Adjuvant Breast and Bowel Project; ALMANAC, Axillary Lymphatic Mapping 
against Nodal Axillary Clearance, Z0011, The American College of Surgeons Oncology Group 
(ACOSOG) Z0011 trial 
  
 4NAS has been shown to produce lower rates of BCRL compared with ALND, with 
one recent study showing BCRL rates of 2.2% and 12.3% respectively.199       
1.9.2 Radiotherapy 
The pathophysiology of BCRL in patients undergoing radiotherapy is thought to be 
complex. It may include a radiotherapy-induced fibrosis, causing venous and 
lymphatic vessel obstruction and lymphocyte depletion or fatty replacement 
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following lymphocyte depletion leading to focal fibrosis.200,201 Whilst studies 
performed in vitro and in vivo in human and animal studies appear to show that 
lymphatic vessels are relatively insensitive to radiation, radiotherapy causes 
development of fibrosis of surrounding structures and delays the normal growth of 
lymphatics within tissues.202 Lymph nodes, however, have been found to be 
radiosensitive with radiation decreasing their filter function and altering their 
immune function.203 With this in mind, it is thought that early lymphoedema may 
be due to impairment of normal lymphatic regeneration, and late lymphoedema 
due to delayed soft tissue fibrosis.201  
 
The variables potentially contributing to the development of BCRL are the use of X-
ray irradiation vs. megavoltage irradiation, the dose of irradiation and the 
treatment field.172 Conventional X-ray radiotherapy was initially used after surgery 
with high rates of BCRL, but the change to megavoltage irradiation significantly 
decreased the incidence of BCRL.172  There is a marked relationship between dose 
of radiotherapy and incidence of morbidity.  Small changes in the percentage of 
dose administered can lead to significant increases in morbidity.200   The field of 
irradiation also affects the incidence and severity of BCRL.  Historically, the field 
would include the chest wall, axilla, supraclavicular fossa and internal mammary 
lymph nodes. Radiotherapy to the axilla considerably increases the incidence of 
BCRL,60,173,204,205 with reports of an incidence of BCRL of 38.3% in patients 




The AMAROS trial measured the rates of lymphoedema at 1, 3, and 5 years in 
patients with positive SLNs undergoing either cALND or axillary radiotherapy.102 The 
final analysis of the trial reported a 1-year rate of lymphoedema of 40% in the 
group undergoing ALND compared with 21.7% in the group of patients treated with 
axillary radiotherapy. This statistically significant difference was also seen at 3 years 
(29.8 vs. 16.7%) and 5 years (28.0 vs. 13.6%) respectively.  At 5 years, the axillary 
recurrence rate was 0.43% for patients undergoing cALND and 1.19% in the axillary 
radiotherapy group.  This suggests that radiotherapy can offer similar results to 
ALND, but with an accompanying significant reduction in rates of BCRL.102  
1.9.3 Chemotherapy 
Several studies have reported an association between BCRL and patients 
undergoing radiotherapy and adjuvant chemotherapy.200,204,206 Norman et al  (2010) 
conducted a study of 631 patients, and found an increased hazard ratio (HR) in 
patients undergoing ALND compared with SLNB (HR 2.61, 95% confidence interval 
(CI) 1.77 – 3.84) and patients receiving anthracycline-based chemotherapy had a HR 
of 1.46 (95% CI 1.04 – 2.04)  compared to those who did not receive chemotherapy.  
On multivariate analysis, the combination of ALND and chemotherapy increased the 
hazards ratio 4-5 fold for BCRL.165 Fontaine et al  (2011) were the first to publish a 
prospective analysis of BCRL in early breast cancer patients undergoing 
concomitant post-operative radiotherapy and anthracycline-based chemotherapy 
+/- taxanes.  The incidence of BCRL was 44% in the group receiving taxanes, three 
times higher than the non-taxane group, although a complete resolution of BCRL 
was seen in 13% of patients in the taxane group.207 Studies into the mechanism of 
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the development of oedema in patients receiving taxanes have been conducted 
with capillaroscopy and capillary filtration tests using 99mTc-albumin.  These have 
concluded that there is an abnormality in the capillary permeability and also a 
progressive accumulation of proteins in the interstitial space.208  It has also been 
suggested that the axillary radiotherapy administered to this group, in addition to 
treatment with anthracycline- and taxane-based chemotherapy, contributed to 
axillary fibrosis and the subsequent development of BCRL.207 
1.9.4 Nodal status 
Several retrospective studies have suggested that lymph node positivity is related 
to the development of BCRL,160,173,174,209,210 however, all these patients had axillary 
radiotherapy administered if they were found to be node positive, which by itself 
would affect the incidence of BCRL.  The total number of nodes removed rather 
than the specific surgical procedure has been found to have a greater correlation 
with BCRL.210-213  Meeske et al (2009) interviewed patients 18 months after 
treatment for breast cancer and observed that if >10 lymph nodes were removed, 
patients had a 2.6 fold increase in the risk of developing BCRL.212 A similar finding 
was observed by Larson et al (1986) where the risk of BCRL was 28% in patients in 
whom > 10 nodes were removed compared with 9% in patients in whom 1-10 
nodes were removed.210 A more recent prospective study by Kwan et al (2010) 
studied 997 patients and found that patients with BCRL had more positive lymph 
nodes compared with those without BCRL (3.3 vs. 0.8).206 However, a further study 
questioned this relationship. The association between nodal positivity and the 
development of BCRL was examined in a recent analysis of two prospective studies 
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of 212 patients undergoing ALND.  It was observed that positive nodal status was 
inversely related to upper limb volume in all patients after correcting for changes in 
the contralateral arm, raising the possibility that the inverse relationship may be 
due to node positive patients developing collateral lymphatic drainage prior to 
undergoing ALND.214  
1.9.5 Infection 
Infection has been identified as a risk factor for BCRL in various studies.214,215 A 
prospective study by Petrek et al (2001) identified self-reporting history of arm 
infection or arm injury as being significantly associated with late onset BCRL (> 3 
years after diagnosis) but the potential for recall bias limited its validity.215  
Although venepuncture is a potential source of infection, the association of 
increased risk of developing BCRL is largely anecdotal.174  There is no clear evidence 
of increased risk, but caution should be exercised using the limb at risk of 
developing BCRL, unless there are overriding clinical reasons. 
1.9.6 Patient factors 
There is conflicting evidence regarding age being a risk factor in the development of 
BCRL. Yen et al (2009) performed a population-based cohort study of elderly breast 
cancer survivors (aged 65-89 years) using self-reporting methods, with 14% 
reporting BCRL after four years follow-up. No association was found between 
increasing age and BCRL, but the presence of axillary metastases, number of nodes 
removed and more advanced tumour stage conferred an increased risk.213 A similar 
study using self-reporting by Meeske et al followed 494 patients for 4 years, 
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specifically looking at age, ethnicity and BMI.  They found younger age (<55 years) 
and elevated BMI (>30 kg/m2) to be risk factors. African-American women were 
more likely to develop BCRL compared with white women in this study, but when 
adjusting for other variables no difference in prevalence was observed.212  Kwan et 
al, however, found there was a differential risk of BCRL according to race and 
ethnicity. It was observed that African-American women, Asian-Americans and 
Hispanics had an increased risk when compared with white women, but this was 
not found to be statistically significant.206  Beaulac et al assessed upper limb volume 
measurements in patients following ALND and found that patients who developed 
BCRL were more likely to be non-white (African-American, Hispanic, Asian and 
Middle-Eastern), and had decreased QoL scores.216  Numerous studies have found a 
correlation between obesity and BCRL.174,206,217,218 A recent meta-analysis found 
strong levels of support for the relationship between BCRL and BMI with 50% of 
BCRL patients being overweight or obese.175  Other studies have suggested risk 
factors for BCRL including higher socio-economic status,206,211 tumour affecting the 
non-dominant side,174,211 menopausal status, 209 tumour stage160 and tumour 
size,173,213 although the level of evidence has been found to be weak.175 
1.9.7 Genetics 
It is has been suggested that there is a possible inherited genetic susceptibility, 
which contributes to the pathophysiology of secondary lymphoedema such as 
BCRL.175,219 Despite identification of the risk factors above, there has been relatively 
little work into the possibility of genetic predisposition.  Vascular endothelial 
growth factor(s) (VEGF) are important in the regulation of lymphangiogenesis and 
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stimulate cellular responses by binding to tyrosine kinase receptors (VEGFR).220 
Mutations of the VEGFR-3 gene have been identified as a major cause of Milroy 
disease (primary congenital hereditary lymphoedema),221 mutations with SOX18 
linked to hypotrichosis-lymphoedema-telangiectasia syndrome222 and FOXC2 
mutations have been linked to lymphoedema-distichiasis.223-225 Newman et al 
(2012) hypothesised that these genes, amongst others, known to be involved in 
lymphangiogenesis may also predispose to BCRL.  They studied 10 genes in a case-
control study of 120 women who had breast cancer surgery.  Blood was taken and 
genomic DNA was extracted and prepared for genotype analysis.  They identified 
genetic loci from VEGFR2, VEGFR3 and RAR-related orphan receptor C (RORC) genes 
as being statistically significantly associated with BCRL (p < 0.05).219  The possibility 
of these genes conferring a predisposition to BCRL lends to potential future work in 
this area, which may lead to the identification of a ‘molecular signature’ that could 
help predict for BCRL.219  If a cohort of genetically susceptible patients is identified 
it might be possible to manage these patients differently, by minimising surgery to 
the axilla or using some of the new surgical techniques currently being trialled to 
prevent BCRL (see section 1.12).  
 
1.10 Assessment of BCRL 
The diagnosis and severity of lymphoedema is assessed on the basis of limb volume, 
shape, skin condition and overall function. Among the quantitative measurements 
of BCRL, the most widespread is assessment of size, based on either circumference 
or direct measurement of upper limb volume.  Other methods for measuring BCRL 
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also exist but are generally only used in the research setting.  These include 
measurements of lymph flow, tonometry and bioimpedance.   
1.10.1 Computer tomography (CT) and magnetic resonance imaging (MRI) 
CT can be used to demonstrate the cross-sectional area of the limb and assess the 
different limb compartments (skin, subcutaneous and muscle).  BCRL has been 
shown to produce markedly increased volume in the subcutaneous compartments 
with thickening of the skin, but the muscle is relatively unaffected.   A ‘honeycomb’ 
pattern is also noted, which is due to fibrosis in the subcutaneous tissues.161,167,226 
MRI findings are similar to those of CT, but offer greater detail of lymphatic 
architecture.182,226  
1.10.2 Ultrasound (US) 
Ultrasound findings in BCRL are those of increased skin and subcutaneous tissue 
thickness and the absence of echogenic bands beneath the subcutaneous tissues.  
Although US has not been much used in lymphoedema, in theory future use could 
include monitoring the results of treatment.167,226 
1.10.3 Water displacement volumetry 
This is one of the earliest recorded methods for volume measurement and is 
sometimes thought of as the ‘gold standard’ with good reproducibility of results.  
However, this method is time-consuming and messy, which limits its routine clinical 
use.  It is also contraindicated in patients with open skin lesions and does not 
provide data about localisation of the oedema and shape of the extremity.227 As a 
tool to assess BCRL, this is now infrequently used. 
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1.10.4 Circumference measurement  
Arm circumferences can be assessed by tape measurements at certain fixed points 
along the limb, e.g. 10cm proximal and distal to the olecranon process, and 
comparison made between the ipsilateral and contralateral limb.  This method does 
not take into account the patchy distribution that can be seen in BCRL and is 
inadequate to accurately quantify BCRL.  However, a tape measure can be used to 
take circumference measurements at 4cm intervals, with a calculation of volume 
based on the formula for a frustrum of a cone (i.e. a truncated cone).  
Vlimb =  Σ(X2 + Y2 + XY)/ 3π 
With X being the circumference at one point on the limb (usually starting at the 
styloid process on the wrist) and Y is the circumference at a point 4cm up the limb 
from X. With good technique, the tape measure method has been found to be a 
reliable method to measure limb volume.226 
1.10.5 Optoelectric volumetry 
The Perometer (350S) is a device, which uses infrared light emitting diodes (LEDs).  
The limb is placed inside a measuring frame, which contains LEDs on two adjacent 
sides and rows.  The limb casts shadows in two planes and on moving the frame 
along the length of the limb, dimensions along the X and Y axis are measured every 
3mm and its volume calculated by a computer.  The shape of the limb is also 
recorded and displayed graphically, and can be used to measure the volume of any 
part of the limb.161,226 The Perometer has been comprehensively evaluated and is 




Objective assessment of the depth of soft tissue pitting has been described using a 
tonometer.  This device applies even pressure to the tissues and the depression is 
recorded in millimetres and serial measurements over time can quantify pitting 
characteristics.  In its current form, it is unsuited to clinical use due to its time-
consuming nature and limited clinical application.161   
1.10.7 Bioimpedance 
Bioimpedance techniques are used in body composition analysis.  The impedance 
spectrum to a small AC current passed through the limb is measured and total 
water and extracellular water calculations are made.226 This allows measurement of 
differences in oedema volume, compared to limb volume measurement, which 
does not take into account the changes in compartment composition. This has been 
shown to be reliable and reproducible and can demonstrate subclinical 
lymphoedema before the development of measurable BCRL.229-231  It has also been 
found to have a high correlation with perometer readings and may be a cheaper 
and more practical alternative to perometry.231,232 A NIHR-funded multicentre study 
is currently recruiting breast cancer patients and assessing the concordance 
between perometer arm measurements and bioimpedance. In addition, the study is 
assessing if bioimpedance can identify patients at the early stages of developing 
BCRL before perometry indicates a significant increase in volume, potentially 




1.11 Management of BCRL 
BCRL is a prevalent and usually irreversible side effect of breast cancer treatment, 
and can lead to progressive swelling and fibrosis requiring lifelong management.  
The extent of treatment varies greatly in different centres, which reflects the lack of 
proven efficacy of any one method and the absence of a ‘gold standard’ for 
management of this condition.   
 
Patients undergoing axillary lymph node surgery are given standard precautions for 
management of the ipsilateral upper limb post-operatively.  They are advised to pay 
special attention to skin care and hygiene, avoidance of injections and wounds to 
the arm, with thorough antisepsis if such an event were to occur.  Patients are also 
advised to avoid rigorous isometric muscle use e.g. carrying shopping.  Although 
infection has been identified as a possible risk factor, there is very little evidence to 
support much of the other information given.  It is largely based on anecdotal 
reports by patients who have found certain events may have precipitated the 
development of swelling.   
 
Once a diagnosis of BCRL has been made, the treatment strategies can be divided 
into three main groups: conservative, pharmacological and surgical.   
1.11.1 Conservative 
 Several reviews have attempted to assess the effectiveness of conservative 
interventions which include compression therapy, manual and lymphatic drainage 
and medical therapies.60,233-235 Recent systematic reviews by McNeely et al (2011) 
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and Oremus et al (2012) have updated evidence from RCTs concerning the benefit 
of conservative treatment for all cancer-related lymphoedema, citing extensive 
inter-study heterogeneity precluding the assessment of whether any one treatment 
method is superior to the others.236,237  
1.11.1.1 Complex decongestive therapy 
Complex decongestive therapy (CDT) is one of the most common forms of 
treatment consisting of many components, including manual lymph drainage (MLD), 
multi-layer compression bandaging, therapeutic exercise, self-management 
education, skin care and elastic compression.238 CDT involves a two-stage treatment 
with the first stage administered over a 4-week period by well-trained therapists in 
an outpatient setting.  It consists of skin care and MLD in combination with a range 
of exercises and a form of compression (typically multi-layered bandaging).  MLD 
uses light massage strokes to first stimulate lymphatic vessels in the trunk and 
contralateral arm, followed by proximal to distal massage of the affected arm.  This 
aims to stimulate contractility of the lymphatic system and break up fibrotic tissue. 
The second stage aims to conserve and optimise the results from the first stage and 
consists of compression garments skin care and continued ‘remedial’ exercise with 
light massage as needed. The second stage is largely patient-led at home.60,156,168 
The wearing of a compression garment has been shown to be significantly better 
when used in conjunction with exercise and self-massage compared to exercise and 




There is controversy over the role of exercise in breast cancer patients who either 
have BCRL or are at risk of developing it.  The Physical Activity and Lymphoedema 
(PAL) trial is the largest RCT to date evaluating the effect of weight lifting in patients 
with BCRL.240 Results suggested that although exercise was found to neither 
exacerbate nor improve arm volume, significant benefit was found in improvement 
of pain/tenderness and reduction in the number of lymphoedema exacerbations, 
which suggests patients can follow exercise programs without fear of worsening 
BCRL.240 Studies have also used active resistive exercises with weights 
demonstrating no worsening of BCRL.240-242  Weight loss has also been found to 
result in a significant reduction in upper limb volume,243 further supporting exercise 
and weight loss as strategies to improve BCRL symptoms.  A follow-up study from 
the Physical activity and lymphoedema PAL trial assessed the impact of the weight 
lifting program compared with no exercise in patients at risk of BCRL following 
axillary lymph node surgery and found that progressive weight lifting did not 
increase the risk of BCRL.242  Although these two studies provide the strongest 
evidence with regard to resistance exercises, other RCTs support their findings.244-
247 The American Lymphoedema Framework Project conducted a systematic review 
and the evidence for combining resistance and aerobic exercise concluded that this 
appeared safe, but recommended that larger and more rigorous studies are 
needed.248 A recent update from the National Lymphedema Framework has 
recommended the use of aerobic and resistance exercises for patients with and at 
risk of BCRL. They advise slow and gradual progression, avoidance of intensity and 
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repetitive overuse and involvement of professionals to tailor exercise 
programmes.249 The Cancer and Leukaemia Group B (CALGB) is currently recruiting 
into a RCT for the prevention of BCRL in patients undergoing ALND. The CALGB 
70305 trial is testing whether an intervention focusing on improving upper limb 
function by providing education about BCRL and combining this with light arm 
weight exercises and using a light compression sleeve during vigorous exercise 
reduces the incidence of BCRL and improves QoL.250   
1.11.1.3 Low level laser therapy (LLLT) 
The use of this method in BCRL was first reported in 1995 after studies suggested it 
could have a stimulatory effect on local fluid circulation and lymphatic vessels, 
stimulate lymphangiogenesis and stimulate macrophages and the immune 
system.251  Despite methodological flaws and lack of uniformity in studies assessing 
the efficacy of LLLT, a systematic review by Omar et al (2012) concluded that there 
was moderate to strong evidence for its use in BCRL.252  Ridner et al conducted a 
RCT randomising 46 patients into three groups of MLD, LLLT or MLD followed by 
LLLT. Clinical and statistical improvement was reported in upper limb volume in all 
patients, but there was no difference between the groups.  They concluded that 
LLLT may be an alternative option to conventional MLD, but acknowledged that the 
study was underpowered.253 Although follow-up was only limited to 30 months, the 
methodology was robust and the conclusions therefore warrant further study.  
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1.11.1.4 Hyperbaric oxygen therapy 
A non-randomised trial of hyperbaric oxygen (HBO) therapy in 21 breast cancer 
patients with BCRL and fibrosis after axillary or supraclavicular radiotherapy 
showed a statistically significant reduction in arm volume at 12 months follow-up. 
Some patients also reported an improvement in shoulder mobility and soft tissue 
symptoms.254 A phase II trial by the same group randomised 58 breast cancer 
patients to receive either HBO or best standard care for lymphoedema.  Results 
showed no beneficial effect of HBO, with no significant difference in arm volumes, 
functional outcome or QoL between the two groups.255 
 
Various other treatments have been described in the literature, such as pneumatic 
compression treatment and deep oscillation devices, and although some studies 
have observed some improvements in symptoms, there have been mixed results 
between studies using these methods.237 A Cochrane review of the literature 
concluded that there was a lack of well-designed, randomised trials in the range of 
physical therapies and therefore all results should be viewed with caution.256   
 
1.11.2 Pharmacological 
Pharmacological treatments for BCRL include benzopyrones, diuretics, antibiotics 
and antioxidants selenium and vitamin E.   
Benzopyrones are a group of drugs based on coumarin and have the potential to 
stimulate proteolysis by tissue macrophages and stimulate lymphatic collectors.  A 
randomised, double-blind, placebo-controlled trial of benzopyrones was studied in 
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BCRL, and a significant improvement in swelling was reported.257 Another study 
found no difference in arm volumes over a period of 12 months when treated with 
benzopyrones for 6 months.258 A Cochrane review (2004) was unable to draw 
conclusions about the effectiveness of benzopyrones in reducing volume, pain or 
discomfort in lymphoedematous limbs due to the poor quality of the trials that had 
evaluated their role.259 Furthermore, benzopyrones are not licensed for use in BCRL 
in the UK and have been linked to liver toxicity.   
 
Diuretics act to limit capillary filtration by reducing circulating blood volume.  This 
increases protein concentration in the interstitium and can actually lead to 
increased fibrosis,156,182 which is why diuretics are not recommended in the 
management of BCRL. 
 
A recent Cochrane review (2009) has found inconclusive evidence for the 
effectiveness of selenium in preventing infective/inflammatory episodes in 
lymphoedema due to the paucity of properly conducted RCTs.260 A double-blind 
placebo-controlled randomised trial of vitamin E and pentoxifylline failed to 
demonstrate any benefit in patients with BCRL.261  Antibiotics should only be used 
in bona fide superimposed cellulitis/lymphangitis.  Mild skin erythema without 




Surgery is generally only considered in cases resistant to conservative measures.  
Treatments are broadly divided into three main approaches: excisional procedures, 
lymphatic reconstruction and tissue transfer.  
 
Charles first described the resection or debulking approach in 1912 for 
lymphoedema of the scrotum,262 and variations on this radical excision of the 
subcutaneous tissue and skin grafting are still used today.  These procedures act to 
remove redundant skin and subcutaneous tissues rather than address underlying 
problems with the lymphatics.182 Although debulking operations are the simplest 
approach to reduce the size of the limb, they result in extensive scars and morbidity 
including ulceration, cellulitis, keloid and lymphatic fistulae.263  More recent 
techniques for excisional treatment of BCRL have been the removal of 
subcutaneous fatty tissue through circumferential liposuction.  Results from the 
largest published case series of 104 patients followed up for 15 years have shown 
that this is an effective method of treatment in patients with non-pitting BCRL who 
have not responded to conservative treatment.264 However, long-term 
management does require patients to continue to wear compression garments 24 
hours a day to maintain results.168,264  
 
Lymphatic reconstruction involves using microsurgical techniques to bypass 
lymphatic obstruction and various methods have been attempted since the 
1960s.238  These include the creation of anastomoses between lymphatic vessels 
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and veins, lymph nodes and veins and proximal and distal lymphatics.182 Initially 
anastomoses were done between lymphatic vessels and larger superficial veins 
such as the saphenous vein, with improvement reported in 44-78% of patients.265-
267 Campisi and Boccardo have shown good long-term results in patients 
undergoing lymphaticovenous anastomoses (LVA), reporting limb volume reduction 
of 69% and an 87% reduction in the incidence of cellulitis.268  However, the 
presence of venous hypertension with subsequent lymphatic outflow obstruction 
led to some high failure rates269 and a move towards using smaller subdermal 
vessels (0.3-1mm diameter) has emerged.265 Koshima et al compared bandaging 
with lymphaticovenous surgery to bandaging alone and found a reduction in 
volume of the lymphoedematous tissue of 47.3% and 11.7% respectively.270  
 
Tissue transfer surgery includes autologous lymph node transplantation (ALNT), 
bone marrow stromal cell transplantation and also lymphatic anastomoses.  
Lymphatic anastomoses use free muscle flap, greater omentum or dermis flap 
transfers in an attempt to divert lymphatic drainage via the deep lymphatics.238,271 
There have been studies combining ALNT with VEGF therapy with results indicating 
an improvement in lymph node transplantation rates.220,224,272,273  Vignes et al 
(2012) challenged the benefits of ALNT and conducted a prospective study of the 
complications of this technique.  They found severe complications existed, such as 
iatrogenic donor site lymphoedema, which may be partly due to the genetic 
predisposition putting these patients at risk as discussed earlier in this 
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chapter.219,274 As a result of this, ALNT remains experimental and has not been 
widely adopted.275   
 
There is no consensus on the timing of surgery in relation to the onset of BCRL, or 
the type of patients who would benefit from surgical intervention.  Very few studies 
are prospective or controlled, making surgical efficacy difficult to ascertain.275 A 
recent systematic review of the surgical treatment of lymphoedema found that 
most reports were based on small numbers of patients with inconsistent 
measurement techniques, procedure complications were rarely reported and long-
term follow-up was lacking.238  The authors concluded that without a clear benefit 
from the different types of surgery for lymphoedema, other conventional 
conservative therapies such as CDT should be utilised and considered the standard 
of care.238 
1.12 Prevention of BCRL 
BCRL remains an incurable condition hence prevention is the ultimate goal.  If it 
could be possible to identify or predict patients who are at risk of developing BCRL 
and intervene in a way to prevent it, then this would help reduce the morbidity of 
this condition and the social and economic costs associated with BCRL.  
 
Axillary reverse mapping (ARM) is a technique which attempts to map the drainage 
of the upper limb using blue dye and preserving these lymphatics at the axilla if it is 
oncologically safe to do so, since these lymphatics are not thought to be involved in 
the drainage of the breast.276 Bennett Britton et al investigated the drainage 
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pattern similarity of the breast and upper limb using dual radioisotope imaging 
(99mTc and 111Indium) in 15 breast cancer patients. Following periareolar and 
intradermal hand webspace injection prior to ALND, 13/15 patients yielded nodes 
that had high activity for either 99mTc or 111Indium, implying that the SLNs for the 
breast and upper limb were different. However, in 2/15 patients, the retrieved 
nodes showed high activity for both isotopes, implying a convergence of the two 
drainage pathways with shared SLNs. It was suggested that these patients might 
have an increased risk of developing BCRL.277 Thompson et al first described the 
ARM procedure, which involves the intradermal or subcutaneous injection of blue 
dye into the webspace of the hand or upper inner arm at the time of surgery to 
identify the upper limb lymphatics. In patients undergoing SLNB, radioisotope was 
used for identification of the SLN as the blue dye was used for upper limb mapping. 
Initially a prospective non-randomised study of 40 patients undergoing SLNB or 
ALND was conducted and a significant variation in drainage of upper limb 
lymphatics was observed.  Blue lymphatics and/or blue nodes were identified in 
11/18 patients undergoing ALND. In the cases where they were able to identify and 
preserve these lymphatics, none of the patients went on to develop BCRL.276  A 
subsequent larger study of 220 patients by this group found ARM lymphatics to be 
in or near the surgical field of SLNB in 40.6% of patients.  It was speculated that if 
these lymphatics had not been identified, they would have been at significant risk 
of disruption during axillary surgery and subsequent progression to BCRL.  A small 
crossover rate (2.8%) i.e. nodes that were positive for ARM and SLN was observed, 
indicating common drainage channels of the upper limb and breast.  There was no 
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evidence of BCRL at 6 months in patients in whom the ARM draining nodes were 
preserved.278  A phase II trial recruited 156 patients in whom all patients initially 
had SLNB with 42 patients undergoing completion ALND.  ARM lymphatics and 
nodes were identified in all patients and preserved in 144/156 patients. BCRL rates 
of 3.5% and 7% were found in SNLB and ALND patients respectively (mean follow-
up 9.4 months), with rates of 2.9% vs. 18.8% if patients had their arm lymphatics 
preserved or transected.279  The follow-up in both these studies is too short to form 
robust conclusions, but the preliminary results appear promising. 
 
Boccardo et al have used ARM in combination with lymphaticovenous anastomoses 
in a procedure called LYMPHA (lymphoedema microsurgical preventative healing 
approach).  This involves performing LVA between arm lymphatics and collateral 
branches of the axillary vein at the same time as ALND to prevent BCRL.280  A 
prospective randomised study by this group compared patients undergoing ALND 
with LYMPHA and a control group of ALND without LYMPHA, with 23 patients in 
each group.  After 18 months follow-up, the LYMPHA group had a rate of BCRL of 
4.3% compared with the control of 30.4%.281 
 
There are a number of problems still to be resolved with the ARM procedure.  One 
issue has been the identification rate of ARM nodes using blue dye alone, but a 
more recent fluorescence imaging system appears to have improved this.282  This 
method utilises injection of water-soluble indocyanine green as a contrast agent, 
which can be detected by near-infrared imaging systems.283  A more important 
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issue is whether it is safe to assume ARM nodes will not be involved in metastasis of 
the primary breast cancer as anatomically there are lymphatic interconnections 
between the drainage of the upper arm and breast.284  
 
The ARM procedure and its combination with LYMPHA show some promising 
results.  However, there is still much work that needs to be done and long-term 
follow-up studies are required before concluding that these methods are effective 
and oncologically safe with regard to preventing BCRL. 
 
1.13 Pathophysiology and pathogenesis of BCRL 
The traditional view of the pathophysiology of BCRL (the stopcock hypothesis) is 
that removal of the axillary nodes reduces lymph flow from the whole arm, 
resulting in the accumulation of protein-rich oedema fluid in the interstitium.178 
However, there are many features of BCRL that are difficult to explain. The majority 
of patients undergoing axillary lymph node clearance (approximately 75%) do not 
develop BCRL, despite undergoing similar surgery to those who do.  In patients 
undergoing the less invasive SLNB, with only 1-2 axillary nodes removed, 5-6% will 
still develop BCRL.  The latent period is also variable, with the post-operative 
swelling never resolving in some patients, many developing BCRL months or years 
after the surgery, and some even developing BCRL 20 years after their breast cancer 
treatment.  The swelling is often non-uniform, sparing some parts of the upper limb 
whilst other areas are grossly abnormal. It might be expected that as all parts of the 
arm drain through the same lymph nodes, so all parts should swell. One study has 
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shown that protein concentration of the interstitial fluid in the ipsilateral swollen 
arm is in fact lower than in the contralateral arm, not higher, and that the decrease 
in concentration is inversely proportional to the degree of swelling.285 A further 
conundrum is the apparent abnormalities reported in the contralateral arm of 
women with BCRL.  A study imaging the upper limbs of patients with BCRL found 
that lymphatic vessels were wider in the contralateral arm of BCRL patients 
compared with the contralateral arm of women treated for breast cancer but 
without BCRL.145 The contralateral arm abnormalities add weight to a constitutional 
predisposition hypothesis.   
 
Research into interstitial fluid characteristics, lymphatic clearance studies and 
lymphovenous communications have all contributed to providing more knowledge 
regarding the pathophysiology of BCRL. 
1.13.1 Lymphatic clearance studies 
Lymph flow from a tissue is difficult to measure directly in humans, because the 
flow is very slow, the vessels fragile and the fluid colourless.58 However, 
radioisotopes can be used to measure the lymphatic clearance rates. This technique 
involves the injection of a radiolabelled macromolecule into the dermis, subcutis or 
muscle and measuring the lymphatic removal rate constant (‘k’) for the 
macromolecule using scintillation detectors (providing radioactive counts but no 
images) or a gamma camera (providing anatomical images and counts) in the 




The choice of radiolabelled macromolecule varies, and much research has been 
done using technetium-99m-human immunoglobulin G (99mTc-HIG).  99mTc-HIG has 
been measured in the forearm epifascial compartment (subcutis and skin), forearm 
subfascial compartment (skeletal muscle) and hand in breast cancer patients with 
and without BCRL.  Lymph flow from the oedematous forearm subcutis was found 
to be moderately impaired compared to the contralateral side, but certainly not 
stagnant, contrary to the concept of lymphostasis.  A comparison of the subfascial 
and epifascial compartments showed that the local lymph flow was 2-3 times faster 
in forearm muscle than the subcutis, indicating a much faster fluid turnover in the 
muscle compartment.  This may reflect the higher density of blood capillaries in 
muscle than subcutis, which would generate more capillary filtrate and hence more 
lymph per unit time.287 The hand is sometimes spared when the rest of the arm is 
swollen. A study of lymph flows from the hands in two groups of women, one with 
hand swelling and one with spared hands, yielded unexpected results. Lymph flow 
was faster in the contralateral hand of the swollen hand group when compared 
with the ipsilateral swollen hand, or with either hand of the spared hand group.288 
This added weight to the possibility of a contralateral arm abnormality in some 
women and a constitutive predisposition to BCRL.58 
1.13.2 Interstitial fluid characteristics 
As previously explained, if BCRL resulted purely from a disturbance in the lymphatic 
drainage, then it would be expected that the reduced outflow of fluid would reduce 
the lymphatic reserve.  If this were correct, then there would be an increased 
filtration rate and this would lead to an increase in the interstitial protein 
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concentration. However, it has been found that the interstitial protein 
concentration is inversely correlated with the increase in arm volume in BCRL.285 It 
has been suggested that the increase in interstitial pressure may cause a chronically 
raised afterload on smooth muscle function in the lymphatic walls.  This would 
cause pump failure, as occurs in hypertensive cardiac failure.289     
 
A sustained increase in venous pressure leads to an increase in capillary pressure 
and filtration rates. This translates into higher lymph flow, which alters drainage 
from the limb.147 Bates et al found venous pressure was not elevated in patients 
with long-standing BCRL,285 but there is no evidence in the literature regarding 
venous pressures in patients prior to development of BCRL. If there is a 
constitutional problem in patients who develop BCRL then an elevated venous 
pressure may be contributing to development of this condition. 
1.13.3 Lymphovenous communications 
The lymphatic system terminates in the thoracic duct or lymphatic duct, and drains 
into the venous system. The rate of return of lymph to the blood via the lymphatic 
system can also be measured.  An example is by measuring the accumulation of 
injected radiolabelled HIG in blood by taking serial blood samples from the 
antecubital vein of the contralateral arm.  This would represent the rate at which 
the lymphatic system returns lymph to blood.  The lymphatic clearance rates 
(measured as kdepot) have been shown to correlate with rates of accumulation in 




The existence of lymphovenous communications (LVCs) was first suggested by 
Threefoot in the 1960s and several animal and human studies have since shown the 
presence of LVCs, albeit in differing circumstances.58,291,292 Aboul-Enein et al 
investigated the presence of LVCs in breast cancer patients using direct intra-
lymphatic infusion of labelled albumin followed by ipsilateral and contralateral 
blood sampling.  In patients who did not develop BCRL, the radioisotope appeared 
in the blood stream earlier than in patients with BCRL or healthy controls.  This 
suggested that in patients who did not develop BCRL, the presence of LVCs 
provided something akin to a protective effect.293  O’Mahony et al investigated the 
delivery of radio-labelled blood cells to lymphatic vessels using intradermal 
injection.  Radiolabelled-erythrocytes were injected simultaneously into the hands 
of 4 normal subjects, intradermally on one side and subcutaneously on the other. 
Erythrocytes would only be able to access local blood through LVCs or needle 
trauma. Following intradermal injection, scintigraphy revealed abundant axillary 
activity, indicating erythrocyte transport up upper limb lymphatics. This was not 
observed following subcutaneous injection. When there was no evidence of cell-
bound activity in ipsilateral blood, this indicated neither LVCs nor needle trauma. 
When similar studies were performed in four patients 3 months after axillary 
surgery, however, intradermally injected labelled erythrocytes were recovered 
bilaterally in central blood in one patient.  Whether this confers any protection 
against BCRL is still not known. Of note, this patient was the only one in this group 
of patients who did not go on to develop BCRL, although this study was limited by a 




This thesis aims to investigate and provide insight into the complex physiological 
processes that take place in women undergoing axillary lymph node surgery for 
breast cancer.  Patients will be studied to see if the changes that take place are 
related to the development of BCRL.  These studies will investigate if there are 
characteristics in some patients that may offer protection from BCRL. The main 
focus will be on whether patients have an increased susceptibility to BCRL, which 
manifests as a constitutional predisposition.  There will be specific focus on the 
muscle lymph flow in the upper limb to see if there is any abnormality observed in 
those patients who subsequently develop BCRL.  In addition to this, examining for 
the presence of lymphovenous communications in the upper limb will determine to 
what extent these exist in breast cancer patients and whether they confer a 
protective mechanism against BCRL.   Finally, by studying the lower limb lymphatics 
in women who subsequently developed BCRL and comparing them with those who 
did not, it may be possible to assess if there is an underlying ‘global’ constitutional 
element that predisposes to the development of BCRL.   
Hypotheses:   
I. Women who develop BCRL following breast cancer treatment have a higher 
lymph flow in the muscle compartment of both upper limbs prior to axillary lymph 
node surgery compared with women who do not develop BCRL.  
II. Lymphovenous communications are present in women who do not develop BCRL.  
These communications open as a rescue mechanism after axillary lymph node 
surgery and confer a level of protection against the development of BCRL  
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III. There is an inherent predisposition to lymphoedema, which manifests as a 





2 General Methods 
The studies presented in this thesis share a number of similar methodology that are 
described below.  Study specific methods are detailed in the relevant individual 
chapters. 
2.1 Overview of studies 
Study 1 (Hypothesis I): A prospective investigation of muscle lymph drainage 
in the upper limbs of breast cancer patients undergoing axillary lymph node 
dissection.  Lymphoscintigraphy was used to assess lymph flow and axillary nodal 
activity. Patients were studied pre- and post-operatively and followed up to see if 
they developed BCRL.  
Study 2a (Hypothesis II): A prospective investigation of the possible presence of 
lymphovenous communications in the upper limb of breast cancer patients 
undergoing axillary lymph node dissection.  Radiolabelled red blood cells were 
injected into the ipsilateral hand of patients and blood samples taken from both 
upper limbs to test for lymphovenous communications. Patients were studied pre- 
and post-operatively and followed up to see if they developed BCRL. 
Study 2b (Hypothesis II): An investigation of the possible presence of 
lymphovenous communications in the upper limb of breast cancer patients at least 3 
years post-axillary lymph node surgery. Radiolabelled red blood cells were injected 
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into the ipsilateral hand and blood samples taken from both upper limbs. Patients 
with and without BCRL were studied. 
Study 3 (Hypothesis III): An investigation of the lower limb lymphatic function 
in breast cancer patients with and without BCRL.  Lower limb lymphoscintigraphy 
was performed in breast cancer patients who had been treated with axillary lymph 
node dissection at least three years previously.  Patients were divided into those 
who had developed BCRL and those who had not. Patients were assessed for the 
presence of a constitutional ‘global’ lymphatic dysfunction. 
 
2.2 Ethics approval 
Ethics approval was granted by the Outer North East London Research Ethics 
Committee (REC); reference number 09/H0701/112 (Study 1, 2a and 2b); reference 
number 11/LO/0892 (Study 3).  All studies were approved by the Administration of 
Radioactive Substances Advisory Committee (ARSAC), reference number RPC 
204/2035/25873.  All study participants gave written informed consent. 
 
2.3 Recruitment of patients 
All study participants were women diagnosed with breast cancer.  Studies 1 and 2a 
required prospective recruitment of such patients prior to any surgical treatment.  
These patients were screened from multi-disciplinary team (MDT) meetings at the 
Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust (GSTT) and Brighton and 
Sussex University Hospitals NHS Trust (BSUH).  For Studies 2b and 3, patients had to 
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be at least 3 years following initial breast cancer surgical treatment and these 
patients were screened from surgical and oncology follow-up clinics as well as from 
the lymphoedema clinics at GSTT and BSUH. 
 
Potential participants were approached at outpatient clinics, by post or by 
telephone contact and then followed up.  Patient information sheets were given to 
potential participants outlining the aims of the study and what was required.  They 
were informed that the study could potentially be of no therapeutic benefit to 
them and would include exposure to radioactive material and blood sampling 
where necessary.  All patients were given at least 24 hours to consider the study.  
Patients’ General Practitioners were informed of their participation.   
2.4 Power of studies and sample size 
Study 1 
The assessment of pre-operative muscle lymph drainage (k) has not previously been 
done, so there is nothing in the literature to guide a power calculation for this 
specific study. Based on previous work by Stanton et al294 looking at post-operative 
muscle k, it was thought that recruitment of 40 patients would be sufficient for this 
study. 
Study 2a and 2b 
These were observational studies and did not require a power calculation.  
Study 3 
In a recent quantitative lymphoscintigraphic study, the quantity of tracer 
accumulating in contralateral ilio-inguinal lymph nodes of patients with unilateral 
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lymphoedema and a normal contralateral limb was 70% (SD 38%) of the tracer 
accumulating in the nodes of patients with bilateral normal lymphoscintigraphy and 
no clinical evidence of lymphoedema in either limb.295 The SD in the latter group 
was 67% (mean = 100%). This is the closest scenario to the current proposal and if 
repeated would be significant, using an unpaired t test, at the 5% level for n = 30 (2 
limbs analysed separately) in each group. No analogous data are available for k. 
 
2.5 Clinical assessment and volume measurement of the upper limb  
The ipsilateral upper limb was checked for the presence of oedema by carefully 
examining and comparing both upper limbs.  The upper limbs were examined for 
decreased visibility of subcutaneous veins on the forearm and dorsum of the hand, 
smoothening or fullness of the medial elbow and distal upper limb contours, and 
increased skin and subcutis thickness by pinching the tissues between finger and 
thumb.  Applying digital pressure for 60 seconds was the method used for testing 
for pitting oedema.   
 
The Perometer 350S (Pero-system, Wuppertal, Germany) was used to measure 
total upper limb volume i.e. forearm and upper arm volume starting from the ulna 
styloid.  The Perometer uses infrared light emitting diodes and corresponding 
sensors within a moveable square frame to measure upper limb size (Figure 3).  The 
infrared transmitters are spaced 2.54mm apart and along two sides of the frame, 








Figure 4 Diagrammatic cross-section of the Perometer measuring frame. 
 Reproduced by kind permission of Pero-system, Germany. 
 
The upper limb is placed inside the frame and the photosensors identify where the 
upper limb is obstructing the light beams.   On moving the frame in the direction of 
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the arrow (Figure 3), pairs of diameters (in the vertical and horizontal plane) are 
measured every 5 mm and the derived volume is calculated by a computer.  The 
shape (contour) of the upper limb is also recorded and displayed graphically (Figure 
5); the circumference at any point and the volume between any desired limits can 
also be measured.161,226 The Perometer has been comprehensively evaluated and 
compared with other methods of limb measurement.  It is a highly reproducible and 
convenient tool for the measurement of limb volume.228 
 
Figure 5 Two dimensional image of an upper limb (side-view) constructed by the 
computer. 
 
2.6 Venous pressure measurement 
A cannula (20G) or butterfly needle (20G) was inserted into a vein in the upper limb, 
usually in the antecubital fossa, flushed with sterile 0.9% saline and connected to a 
graduated manometer (central venous pressure set; Becton Dickinson, Oxford) 
(Figure 6).  The manometer was positioned at the level of the manubriosternal 
angle (angle of Louis), approximately 5-6 cm above mid-right atrium level, and this 
level was adjacent to ‘0’ on the scale by using the built-in rod and spirit level on the 






Figure 6 Manometer system attached to a cannula in the antecubital vein  
 
The sterile giving set and manometer tubing consisting of a 3-way tap and tubing 
were attached to the manometer.  All lines were primed with saline.  The 
manometer tubing was then attached to the patient’s cannula. The manometer was 
opened to the patient and the height of the column of saline in the tubing fell and 
stabilised at a new lower level, which was recorded as the venous pressure (Pv) 5–6 
cm above mid-right atrium level. 
 
2.7 Lymphoscintigraphy 
Lymphoscintigraphy, or isotope lymphography, is a well-established, safe and 
relatively non-invasive technique involving injection of a radiolabelled tracer in the 
distal aspect of a limb followed by subsequent imaging of the lymphatic vasculature 
with a gamma camera.  This can provide information about the lymphatic anatomy 
103 
 
as well as lymphatic function.  Clinical applications of lymphoscintigraphy are 
summarised in Table 15 296,297  
 
General Application Specifics 
Diagnosis Differentiation of lymphoedema from other causes of 
swelling 
Assessment Assessing the lymphatic pathway drainage 
Identification Identification of sentinel nodes in patients with cancer 
Identify degree and level of lymphatic dysfunction or 
delineate lymphatic malformations 
Quantitation Quantification of lymph flow 
Table 15 Clinical applications of lymphoscintigraphy 
 
Lymphoscintigraphy assesses three aspects of lymphatic function: 
 The local rate of removal of interstitial macromolecules by small lymphatics 
over a few cm2 of tissue 
 Transport of label up the limb axis by larger lymphatics 
 Transport through and retention by regional lymph nodes 
 
Qualitative lymphoscintigraphy provides static images, which can show the gross 
anatomy of lymph vessels and lymph nodes, dilatation of lymphatic vessels, 
existence of collaterals and the presence of dermal backflow.  There are alternative 
methods for assessing lymphatic function/structure under development, but 
lymphoscintigraphy is currently the method of choice. 286  Figure 7 shows 
lymphoscintigraphy images from a normal lower limb. There is symmetrical 
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accumulation in the ilio-inguinal lymph nodes, with no evidence of collaterals or 
dermal backflow. 
 
Figure 7 Normal lymphoscintigraphy of the lower limbs; anterior and posterior 
images at 45 and 150 min after injection. 
 
2.8 Injection Site 
Lymphoscintigraphy of the limbs involves distal injection of radiolabelled materials 
into the interstitial space.  The choice of injection depth varies from intradermal 
(very rapid visualization of lymphatics), to subdermal and subcutaneous, where 
transit to the lymphatics is slower.297 A common injection site is the 2nd or 3rd 
webspace of the limb, although the dorsum of the hand or foot has also been 
used.297 Data suggest that the optimal route of injection may vary depending on the 
tracer used, with subcutaneous injection being optimal for colloidal agents.296  A 
study by O’Mahony et al (2004) concluded that intradermal (id) injection resulted in 
better image definition of lymph vessels immediately after injection when 
compared with subcutaneous (sc) injection, regardless of whether the 
Posterior 150 min Posterior 45 min Anterior 45 min Anterior 150 min 
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radiopharmaceutical was a colloid (99mTc-Nanocolloid) or macromolecule (99mTc-
human IgG {HIG}).298  This finding was explained by the high concentration of 
lymphatic capillary plexuses in the dermis, which provides a high surface area for 
uptake of the agent and also the exertion of high interstitial pressure within the 
dermis, which increases the uptake of tracer by the lymphatics.298 Intradermal 
injection also delivers intact radiolabelled erythrocytes to lymphatic vessels and 
lymph nodes, which allows for the investigation of LVCs.299 In Study 2a and 2b, the 
99mTc-erythrocytes were injected intradermally into the 2nd webspace of the hand 
of the ipsilateral side for lymphoscintigraphy images.  The sample was prepared as 
outlined in Chapter 4 and Appendix 4. 
 
Subfascial injection of radiotracers can be used for investigation of deep 
lymphatics.286,296 The injected radiolabelled tracers are removed by local clearance 
by the lymphatic capillary network, and with the use of the gamma camera, can be 
used to calculate lymph flow per unit tissue volume (k).286 
 
2.9      Radiopharmaceuticals 
There have been many radiopharmaceuticals evaluated for use in 
lymphoscintigraphy.  They are generally classified as: 
 Macromolecules 
 Particulate structures 
Examples of macromolecules include labelled dextrans, monoclonal antibodies and 
human serum albumin (HSA), whereas particulate structures include labelled 
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colloids or liposomes.300  It is thought that the injected agents travel through the 
lymphatic channels to the regional lymph node groups.300  They either enter the 
lymphatic capillaries passively, e.g. in the case of macromolecules, or through 
phagocytosis by macrophages and are transported within lymphatic channels, 
which occur with colloids.301,302      
 
Particles need to be of a certain size to be effective in lymphoscintigraphy – if 
particles are too small then they enter the blood stream and if they are too large 
then move slower through the interstitium.  In animal studies, the optimal particle 
size has been estimated to be 5 nm for lymphatic drainage studies.302  If smaller 
than this (0.05 nm – 5 nm) the particles usually leak into blood capillaries and 
therefore become unavailable to migrate through lymphatic channels.302  Larger 
particles are prevented from entering the blood capillaries by a basement 
membrane and endothelial layer.300,302 Larger particles (> 100 nm) move very slowly 
from injection site to lymphatics leading to a lower accumulation in the lymph 
nodes, making them less suitable for lymphoscintigraphy.300,302 Large particles have 
been detected in venous blood immediately after subcutaneous injection, which is 
thought to be due to localised trauma from the injection site.296,301,302    
 
Optimal images of the lymphatic system would require the radiolabel to be taken 
up by lymphatics, retained with the nodes and not access blood vessels.  The choice 
of radiolabel tracer (including its size and stability), the type and site of injection 
and the pharmacokinetics all influence the clinical information obtained.  The 
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selection of the tracer depends on what information is required from the 
study.301,302  198Au-colloid was the first agent that was widely used, but as a 
significant amount of the dose remained at the injection site causing radiation 
burden, agents with more favourable characteristics were sought.  198Au was 
replaced by the technetium-labelled tracers (99mTc).296,302 These have a short half-
life of 6 hours and are ideal for imaging using the gamma camera 303  The main 
agents used are 99mTc-antimony sulphide colloid, 99mTc-sulfur colloid, 99mTc-albumin 
colloid, 99mTc-labelled HSA and 99mTc-Nanocolloid.  The non-colloidal agents that 
have been used (labelled HSA, dextrans and human immunoglobulins) are soluble 
macromolecules, and have shown a more rapid uptake by lymphatics than colloids.  
However, as they are not particulate they are minimally retained by the lymph 
nodes and therefore less suitable for lymph node imaging.296,302      
 
In Europe, 99mTc-Nanocolloid (5-100 nm) is routinely used in the clinical 
setting.296,302 It is commonly available, has favourable properties, gives 
comparatively low radiation exposure and has an optimal gamma emission for 
imaging.302 This therefore made 99mTc the radiopharmaceutical of choice for 
investigating the lymphatic system in these studies. Technetium (Tc) is a transition 
metal element and decays by emission of gamma radiation of 140 kilo electron-
Volts (keV). Tc has a half-life of approximately 6 hours, allowing for sufficient time 
for imaging and does not result in an excessive radiation dose to the patient.  It is 
also cheap and easy to produce, it can be easily bound to other molecules, it is non-
toxic and associated with a low incidence of adverse reactions.304 
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2.9.1 Quality control performed by the Radiopharmacy Department 
The stability of the bond between the radiolabel and the Nanocolloid is important 
because blood will clear any unbound or dissociating label at a rate that is two 
orders in magnitude faster than lymphatic clearance147 which would cause k to be 
an overestimation of lymph flow.  Radiochemical purity (RCP) is the radiochemical 
form that determines the bio-distribution of the radiopharmaceutical.  Impurities 
will have different patterns of bio-distribution and these may obscure the 
diagnostic image obtained and alter the results of the investigation.  A level of RCP 
accepted by the radiopharmacy department is 95%.  At GSTT and BSUH the RCP of 
99mTc was performed weekly. 
2.9.2 Radiation risk and safety procedures 
The dose of radiation was the minimum needed for each of the investigations. The 
Radiation Protection Adviser calculated the radiation dose in millisieverts (mSv) 
before submission to the REC. The average background radiation dose in the U.K. is 
2.5mSv per annum.  The studies involved a radiation dose of 0.1mSv per patient.  
The studies were done in accordance with the Ionising Radiation Medical Exposure 
Regulations (IRMER).  At all times, transport, usage and storage regulations for 
99mTc were adhered to. 
2.9.3 Preparation of radiopharmacetical 
The radiopharmacetical preparation for each study is explained below: 
Study 1: 99mTc-Nanocoll was prepared by the addition of 1000 MBq sodium 
99mTc-pertechnetate to a Nanocoll kit and diluting to 250 MBq/ml.  A dose of 20 
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MBq of 0.2 ml 99mTc-Nanocoll was drawn into two 1 ml syringes with 25-gauge 
needles. 
Study 2a and 2b:     A blood sample was taken from the patient using a needle 
and heparinised syringe.  The details of preparation of 99mTc-labelled red blood cells 
are described in Appendix 4.  The 99mTc-labelled red blood cells were drawn into a 1 
ml syringe using a 25-gauge needle.      
Study 3:  99mTc-Nanocoll was prepared as described above.   A dose of 20 MBq 
of 0.1 ml 99mTc-Nanocoll was drawn into two 1 ml syringes with 25-gauge needles.   
 
2.10 Imaging with the gamma camera 
The gamma camera is an imaging device for nuclear medicine and it consists of a 
large detector in front of which the patient is positioned.305  Gamma rays emitted 
from radiopharmaceuticals cause scintillation of the crystal within the gamma 
camera apparatus, which produces light that is detected by sensors and an image 
can be constructed based on this data (scintigraphy). A collimator modifies the 
gamma ray flux and is a lead plate consisting of an array of small holes.  Only the 
gamma rays that travel along a hole axis will pass into the large NaI(Tl) scintillation 
crystal.  Those gamma rays that approach at an oblique angle will hit the septa and 
be absorbed. Image resolution decreases with distance from the collimator, 
therefore resolution is better if the imaged organ is near the detector (Figure 8).306 
Gamma cameras have separate collimators for the different energy of radionuclides 
used and the type of investigation to be performed.  For these studies, a low energy, 




Figure 8 The collimator 
Photons perpendicular to the plane (A) pass through the collimator to interact with 
the detector. B would also be registered. C-F events would not be included in the 
final image. G-H shows how increasing the distance would increase error.306   
 
 
Figure 9 Schematic diagram of the gamma camera.306  
PMT, photomultiplier tubes; PHA, pulse height analyser  




The detector assembly is responsible for converting the gamma rays from the 
patient into a form, which allows visible images to be produced. The first stage is 
when the gamma radiation from the patient is absorbed by the scintillation crystal 
and converted into ultraviolet light.  The second stage involves transformation of 
these light signals into electronic signals by an array of photomultiplier tubes (PMT).  
Position circuitry provides x and y coordinates for the incident and this coordinate is 
registered if a z signal is received.  The z signal represents the energy deposited in 
the crystal by the gamma ray.307 The pulse height analyser (PHA) tests whether the 
energy of the gamma ray is within the range expected for the specific radionuclide 
being imaged (Figure 9).  
 
A gamma camera can provide the following measures: 
 The rate of disappearance of radioactivity, which can be quantified from a 
region of interest (ROI) that encompasses the entire depot and a 
surrounding zone of unlabelled tissue.   
 The increase in radioactivity over proximal limb segments assesses the 
transport along large contractile vessels. Lymphoedema characteristically 
shows ‘dermal backflow’ which is re-routing of the tracer from the main 
trunks into collateral lymphatics of the proximal skin 
 Lymph node activity by assessing the arrival and retention of the tracer at 




Imaging was performed with a single-headed camera (Symbia Gamma Camera, 
Germany or Sopha Medical Camera, France) with a low-energy high resolution 
collimator, which have been used for similar studies of this nature.308 (Table 16) A 
256 x 256 matrix was used for all images with one pixel representing 0.238 x 0.238 




Detector Field of view Collimator 
Siemens Symbia 15mm NaI 53 x 39 cm Low energy, high 
resolution 
Sopha Medical DSX 13mm NaI 45 x 40 cm Low energy, high 
resolution 
Table 16 Gamma camera details 
 
2.11 Measurement of lymph drainage constant k 
Measurement of the rate of clearance of the radiolabelled Nanocolloid was the 
method used for measuring lymph flow quantitatively. An explanation of the theory 
relating k to lymph flow is given in Appendix 3. Investigation of factors known to 
influence lymph flow and capillary filtration rate, e.g. exercise, adrenaline and 
inflammation have produced expected changes in k.286,288,309-311 k is therefore the 
best method currently used for quantitative assessment of lymphatic clearance. 
 
k was measured by calculating the rate of disappearance of radioactivity from the 
depot site and this indicated the rate of removal of the protein by lymphatic 
drainage.  Local clearance rates are calculated using the region of interest (ROI).  
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The counts in the ROI begin to fall as the depot is cleared by the lymphatics, as well 
as secondary to decay of the tracer.  A plot of loge of residual counts (corrected for 
radioactive decay and background activity) against time should be a negative mono-
exponential slope.  The slope of the plot is the lymphatic rate constant (k), which 
provides an estimate of the local lymph flow per unit volume of distribution of 
radiotracer in the interstitial fluid.  The rate constant (min-1) has the units of 




CHAPTER 3   
3 Study 1:  An investigation into the muscle lymph drainage 
of the upper limb 
3.1 Introduction 
In breast cancer patients, with and without BCRL, k has been previously measured 
in the forearm epifascial compartment (subcutis or skin), forearm subfascial 
compartment (skeletal muscle) and hand (subcutis).288,294,308,310 Muscle lymph 
drainage has been shown to correlate with degree of limb swelling in BCRL, unlike 
subcutis drainage, which has no correlation, thereby making this a more accurate 
measurement tool.308,310 
 
In a previous study, k for 99mTc-human polyclonal IgG (99mTc-HIG) was measured 
bilaterally in forearm muscle in 43 women at 7 and 30 months after surgery for 
breast cancer.294  At 7 months after surgery none of the patients had BCRL. By 30 
months 19% of patients (n = 7) had developed mild BCRL, the ipsilateral upper limb 
being 5.8  2.0% larger than the contralateral upper limb. When the BCRL-destined 
(pre-BCRL) and non-BCRL groups were compared at 7 months, k was found to be 
significantly higher in the pre-BCRL group. Muscle k was found to be 22% higher in 
the muscle of the ipsilateral upper limb of the pre-BCRL group than in the non-BCRL 
group. Moreover there was a similar, significant difference in the contralateral 
upper limb k values, and also in subcutis k values on both sides. This led to the ‘high 
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filterers’ hypothesis, namely that some women have a constitutively high rate of 
capillary fluid filtration and hence high fluid loading of the lymphatic system, which 
predisposes them to secondary lymphoedema, independent of the number of 
axillary nodes removed.294  
 
 The above study did not address the question of whether the high fluid loading was 
innate, i.e. whether it existed prior to surgery, or whether it was the response of a 
subset of patients (those who subsequently developed BCRL), to axillary lymph 
node surgery. Therefore, the purpose of this prospective study was to address this 
distinction, with the aim of studying patients due to undergo axillary lymph node 
surgery prior to any surgical intervention and to determine if there was any 
difference in patients who developed BCRL compared with those who did not. Local 
lymph flow (k) was measured in the upper limbs of newly diagnosed breast cancer 
patients.  
3.2 Study Aim 
The aim of this study is to test the hypothesis that women who develop BCRL 
subsequent to breast cancer treatment have higher lymph flow in the muscle 
compartment of both upper limbs prior to axillary lymph node surgery compared 
with women who do not develop BCRL.  In addition, a further aim of this study is to 
determine whether axillary lymph node surgery substantially impairs lymph 
drainage from the forearm muscle compartment in the short term. 
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3.3 Study Design 
This was a prospective observational study using quantitative lymphoscintigraphy 
(QL) to investigate the local lymph flow (k) in the subfascial compartment of the 
forearms of newly diagnosed breast cancer patients.  In all, 38 patients had a 
diagnosis of unilateral breast cancer and had not previously had any axillary lymph 
node surgery.  Both upper limbs were studied pre-operatively and post-operatively.  
The study of both the ipsilateral and contralateral side provided a control value for 
k in each patient.  The technique has previously been validated by the significant 
correlation (r = 0.51, p < 0.01) between measurements in the two upper limbs of 
the same patient, i.e. side-to-side comparison; repeated methodological 
measurements on the same limb would be unethical.290  Patients were studied both 
prior to surgery and approximately 4-6 weeks after axillary lymph node surgery.  
The post-operative study timing was kept flexible within this time to allow patients 
time to recover from their surgery.  Patients were then followed up to see which 
patients subsequently developed BCRL and assessed for any correlation between 
lymph flow and the onset of BCRL.  This enabled establishment of whether the 
lymph drainage rate was higher before the axillary lymph node surgical intervention 
in the group that subsequently developed BCRL. Lymph drainage was measured in 
forearm skeletal muscle rather than subcutis because muscle capillary filtration rate, 
and hence lymph flow, is higher than in the subcutis, and thus contributes the 
majority of total upper limb lymph flow.  99mTc-HIG is no longer available so the 
radioisotope used was 99mTc-Nanocoll.  This has a particle size of approximately 80 
nm, which is too large a particle to be cleared into the blood, but small enough to 
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be cleared by the lymphatic system, as confirmed by its appearance in upper limb 
lymphatics and axillary lymph nodes.286,298   
3.4 Methods 
3.4.1 Recruitment of patients 
Patients recently diagnosed with invasive breast cancer and due to undergo 4NAS 
at Brighton and Sussex University Hospitals NHS Trust (BSUH) or level II/III ALND at 
BSUH or Guy’s and St Thomas’ NHS Foundation Trust (GSTT) were recruited from 
the Breast Clinic. As per the power calculation (section 2.4), pre-operative muscle 
lymph drainage (k) has not previously been studied, so there was nothing in the 
literature to guide the power calculation for this specific study. Based on previous 
work by Stanton et al294 examining post-operative muscle k, it was thought that 
recruitment of 40 patients undergoing axillary lymph node dissection (ALND) would 
be sufficient for this study. With an incidence of BCRL of approximately 20-25% in 
patients undergoing ALND, this number should have given sufficient power to the 
study. However, there were problems with recruitment as the patients were 
concerned with regard to the risk of BCRL development if they were to have 
injections into the ipsilateral upper limb after axillary surgery. As a consequence of 
this, it was decided that it would be appropriate to include patients due to undergo 
4NAS, accepting that patients undergoing this procedure have a lower risk of 
developing BCRL (approximately 5%312). In all, 210 patients at BSUH were screened, 
of whom 23 gave consent to take part in the study (20 due to undergo 4NAS and 3 
ALND); 115 patients due to undergo ALND at GSTT were screened, of whom 15 gave 
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consent to take part in this study. Following written informed consent, patients 
were studied in the Nuclear Medicine departments at either BSUH or GSTT. Patients 
attended on three occasions: pre-operatively, two to six weeks post-operatively 
and 1 year post-operatively (follow-up visit).  On the pre-operative and post-
operative visits, the following procedures were performed:  
(i) Clinical assessment for the presence of lymphoedema;  
(ii) Upper limb volume measurement;  
(iii) Muscle lymph drainage estimation by quantitative lymphoscintigraphy; 
(iv) Axillary lymph node gamma camera imaging.  
Venous pressure was only measured pre-operatively and only clinical and upper 
limb volume assessments were performed at the follow-up visit. 
3.4.2 Injection site and patient positioning 
The injection site was the thickest and fleshiest part of the proximal forearm.   This 
site was identified on the ipsilateral upper limb and two short lines were drawn 
transversely on the forearm on either side of the selected site, and two short lines 




Figure 10 Diagram showing the position of the injection site 
 
The position was calculated by measuring the distance from this site to the end of 
the fully extended middle finger and also measuring its distance from the mid-line 
of the forearm (in mm). These measurements were used to calculate the injection 
site on the contralateral upper limb and for injections on subsequent visits.  Once 
the injection site was identified, the patient acclimatised for at least 20 minutes and 
was then seated with both upper limbs resting on a table. The palms were placed 
together with fingers and thenar eminences touching, i.e. the forearms were semi-
pronated.  A single-headed camera (Symbia Gamma Camera, Siemens, Germany or 
Sopha Medical Camera, France) with a low-energy high-resolution collimator was 
positioned ~ 20 cm above the upper limbs.  The ipsilateral upper limb was injected 
first.  The skin, subcutis and muscle of the forearm were pinched up between 
thumb and forefinger and the 25G needle was inserted perpendicularly to its full 
length (25mm, or 1 inch).  The grip was relaxed and the 99mTc-Nanocoll (~20 MBq) in 
0.2ml (G.E. Ltd., Amersham, Bucks, UK) was injected intramuscularly in each 
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forearm at the selected site over 2-3 seconds and the needle withdrawn.  The 
opposite upper limb was injected similarly.   
3.4.3 Image acquisition 
The scans were conducted in a temperature-controlled room.  Skin temperature 
(Tsk) was recorded with a thermometer using thermistor probes (4600 Precision 
Thermometer, Measurement Specialties Inc., USA).  The camera height was kept 
the same for each acquisition and the upper limbs were repositioned as closely as 
possible. An outline of the patient’s upper limbs was drawn to on the Incopad to 
facilitate placement of the upper limbs (Figure 11A).  The first forearm acquisition 
was obtained approximately 2 minutes post-injection. Each acquisition took 60 
seconds. Subsequent acquisitions were performed at 15, 30, 45, 60, 90, 120, 150 
and 180 minutes post-injection. 
 
Figure 11 The Siemens Symbia gamma camera  





The upper arms and axillae were imaged less frequently than the forearms.  For this, 
the table was removed and the patient was seated in front of vertically oriented 
camera head with shoulders as close as possible to the camera for ventral viewing 
(Figure 11B). It was ensured that both entire upper arms and axillae were in the 
field of view.  A 180 sec acquisition of images was performed at 50, 125 and 185 
minutes post-injection. An outline acquisition using the cobalt-57 pen marker was 
performed at 130 minutes post-injection, which involved drawing around the 
shoulder starting at the acromion process continuing downwards to the lower limit 
of the camera field of view, and then up again on the inside of the upper limb.  All 
images were marked in the top right-hand corner with the cobalt-57 pen marker.  
The patient was allowed to sit in the waiting room in between acquisitions. 
3.5 Image analysis 
3.5.1 Calculation of the lymphatic removal rate constant (k) 
The clearance of radiotracer from the interstitial depot was quantified in a circular 
region of interest (ROI) of area 37.5cm2, which encompassed the entire forearm 
depot.  The fraction of the counts remaining in the depot (corrected for 
radionuclide physical decay) was plotted semi-logarithmically. The slope of the 
linear plot of loge fraction versus time gave the fraction of tracer removed per 
minute. Multiplying by 100 gave k in units of % tracer removed per min. This equals 
the local lymph flow (ml/min) per 100ml of interstitial fluid in which the tracer was 
distributed. The theory relating k to lymph flow has been explained in section 
1.13.1 and discussed extensively in the literature.286,288,309-311  
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3.5.2 Axillary lymph node activity  
The arrival and retention of the radioactive tracer in the regional lymph nodes was 
quantified by drawing a ROI over the axillae. After correcting for decay and 
background activity, the activity in the axillary and supraclavicular nodes was 
expressed as a percentage of the counts from the first acquisition of the depot at 
each time-point. Data were acquired for 35 patients pre-operatively and 27 patients 
post-operatively. 
3.6 Statistical analysis 
Results are shown as the mean ± standard deviation (SD).  Group comparisons were 
made using paired and unpaired t tests and 2-way ANOVA.  The normal distribution 
of data was first ascertained by the Kolmogorov-Smirnov test. Linear regression 
analysis was used to analyse the mono-exponential slope of the depot clearance 
plot.  Fisher’s exact test was used for categorical data due to the small sample sizes.  
Pearson’s r test was used for correlation.  Analysis was performed using GraphPad 
Prism (version 6; San Diego, CA, USA). A p value of ≤ 0.05 was regarded as 
statistically significant. 
3.7 Results 
Patients who subsequently developed BCRL are referred to as ‘pre-BCRL’ patients in 
the pre-operative and post-operative visits described below.   
3.7.1 Patient data 
Pre-operative measurements were performed in 38 women, of whom 33 attended 
the post-operative study and 31 patients attended the follow-up visit. One patient 
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died prior to her follow-up visit.  The mean age of patients at the time of surgery 
was 57 ± 9 years (range: 32-75 years) and the body mass index (BMI) was 29.0 ± 6.7 
kg/m2. Clinical, surgical and pathological details are summarised in Table 17. The 
intervals between surgery and subsequent assessments were 8 ± 6 weeks (post-
operative visit) and 58 ± 9 weeks (follow-up visit). Seven patients developed BCRL 
using the clinical criteria for diagnosis at 6 ± 6 months after surgery, giving an 
overall incidence of 18%, based on clinical examination. Three patients developed 
BCRL in their dominant arm and four in their non-dominant arm. In all, 35/38 
patients (92%) were right hand-dominant and 3/38 (8%) left hand-dominant. A total 
of 16/38 (42%) of patients had surgery to their dominant side.   
 
The age of the BCRL patients and the non-BCRL patients did not differ significantly 
(p = 0.46, unpaired t test); see Table 18. The pre-operative body mass index (BMI) 
was not significantly different between the pre-BCRL and non-BCRL groups (28.2 ± 
6.5 kg/m2 vs. 32.4 ± 7.0 kg/m2, p = 0.18). There was correlation between BMI and 
ipsilateral arm volume (r = 0.73, p < 0.0001, Figure 12). The mean did not change 
significantly over the course of three visits (p = 0.08, repeated measures one-way 
ANOVA). There was, however, significant correlation between the 
increase/decrease in individual BMI from pre-operative to post-operative visits and 
the increase/decrease in ipsilateral upper limb volume (r = 0.36, p = 0.04, Pearson’s 





Patient ID Age 
(yrs) 





           Grade Type Size 
(mm) 
ER status 
001B 56 WLE ANS  4 (0) 3 IDC 40 + 
002B 67 WLE ANC  17 (13) 2 IDC 18 + 
003B* 75 WLE ANS  8 (0) 2 IDC 18 + 
004B 66 WLE ANC  11 (3) 2 IDC 54 + 
005B 61 WLE ANS  7 (0) 2 IDC 21 + 
006B 59 WLE ANS  5 (0) 2 IDC 12 + 
007B 76 WLE ANS  4 (0) 1 IDC 8 + 
008B 55 Mx ANS  5 (2) 2 IDC 15,18 + 
009B 51 WLE ANS  7 (0) 1 IDC 15 + 
010B 47 Mx ANC  9 (9) 2 ILC 50 + 
011B 51 WLE ANS  9 (2) 2 IDC 6 + 
012B 52 WLE ANS  7 (0) 2 ILC 95 + 
013B 69 WLE ANS  6 (0) 2 IDC 29 + 
014B 51 WLE ANS  6 (0) 2 IDC& ILC 20,6 + 
015B 49 WLE ANS  2 (0) 3 IDC 11 + 
016B 65 WLE ANS  5 (0) 2 IDC 22 + 
017B 66 WLE ANS  4 (0) 2 IDC 20 + 
018B 50 WLE ANS  10 (0) 1 IDC 12,6,2 + 
019B 60 WLE ANS  8 (0) 2 ILC 20 + 
020B 56 WLE ANS  5 (0) 2 IDC 11 + 
021B 45 WLE ANS  4 (0) 1 IDC 15 + 
022B 57 WLE ANS  6 (0) 2 IDC 15 + 
023B 64 WLE ANS  4 (0) 3 IDC 16 - 
007G 46 Mx ANC  13 (1) 3 IDC 30 + 
008G* 56 Mx ANC  5 (0) 2 ILC 17,11 + 
009G 51 Mx ANC  8 (1) 2 IDC 28 + 
010G 71 Mx ANC  13 (2) 2 IDC 44 - 
011G 66 Mx ANC  20 (11) 3 IDC 30 - 
012G* 49 WLE ANC  9 (1) 3 IDC 10 + 
013G* 67 WLE ANC  5 (0) 3 IDC 0 - 
014G 52 WLE ANC  7 (1) 2 IDC 12 + 
015G* 62 WLE ANC  8 (3) 2 ILC 31 + 
016G 44 Mx ANC  29 (28) 2 ILC 28 + 
017G* 52 Mx ANC  4 (3) 2 IDC 120 + 
018G* 53 WLE ANC  15 (2) 2 IDC 29 + 
019G 57 WLE ANC  14 (1) 2 IDC & ILC 17 + 
020G 33 WLE ANC  19 (1) 2 IDC 14 + 
024G 49 Mx ANC  15 (7) 3 IDC 17 - 
Table 17 Clinical, surgical and histopathological details of patients 
*patients who developed BCRL; ANS, axillary node sampling; ANC, axillary clearance surgery; ER, oestrogen receptor; WLE, 




 BCRL (n = 7)  Non-BCRL (n = 31)  p 
        
       
Age (years) 59 ± 9  56 ± 9  0.46 
BMI (kg/m
2
) 32.4 ± 7.0  28.2 ±6.5  0.18 
Nodes removed 7.7 ± 3.7  9.1 ± 6.0  0.44 
Positive nodes 1.3 ± 1.4  2.7 ± 5.8  0.25 
ANC surgery 6 (86%)  12 (39%)  0.038 
ANS surgery 1 (14%)  19 (61%)  0.038 
Wide local excision 5 (71%)  23 (74%)  1.0 
Mastectomy 2 (29%)  8 (26%)  1.0 
Chemotherapy 3 (43%)  9 (29%)  0.66 
Neo-adjuvant 
chemotherapy 
4 (57%)  10 (32%)  0.39 
SCF radiotherapy 4 (57%)  8 (26%)  0.18 
       
Table 18 Comparison between pre-BCRL and non-BCRL groups 




Figure 12 Correlation of BMI (kg/m2) and ipsilateral arm volume (ml) of patients 
at the pre-operative visit. 
BMI, body mass index; r = 0.73, p < 0.0001.    
 































Figure 13 Change in BMI (kg/m2) plotted against change in ipsilateral upper limb 
volume (ml)  Each point corresponds to a patient. There was significant correlation 
between the change in BMI from pre-operative to post-operative visits and the 
change in ipsilateral upper limb volume (r = 0.36, p = 0.04, Pearson’s r test). 
 
There were no differences between groups in the number of nodes (and the 
number of positive nodes) removed or the proportion of patients undergoing 
systemic therapy.  Axillary lymph node clearance surgery rather than axillary node 
sampling appeared to be a significant risk factor for BCRL (p = 0.038, unpaired t 
test). The incidence of BCRL was 33% (6/18) in patients undergoing ANC compared 
with 5% (1/20) in those undergoing ANS. The average number of nodes removed in 
patients undergoing ANC was 12.1 ± 6.4 (median 11, range 4 -29) compared with 
6.0 ± 2.3 in patients undergoing ANS (median 5.5 range 2 – 11). The extent of the 
breast surgery and whether or not radiotherapy was administered to the 
































supraclavicular fossa did not differ between the BCRL and non-BCRL groups. (Table 
18) 
3.7.2 Upper limb volume changes 
Upper limb volume changes are summarised in Table 19.  Although pre-BCRL 
patients tended to have larger upper limb volumes bilaterally than non-BCRL 
patients, the differences were not statistically significant (ipsilateral p = 0.29; 
contralateral p = 0.37, p = 0.16, unpaired t test). On pooling pre-operative ipsilateral 
and contralateral upper limb volume data for the pre-BCRL group (n = 14) and 
comparing with the non-BCRL group (n = 62), there was also no significant 
difference (p = 0.16, unpaired t test). There was no significant difference in BMI 
between the two groups. 
At the post-operative visit, the ipsilateral upper limb of the pre-BCRL patients was 
5.6 ± 2.7 % (140 ± 95 ml) larger than the contralateral upper limb (n = 6, p = 0.004, 
paired t test). Three of these patients demonstrated clinical signs of BCRL in the 
ipsilateral upper limb, which would demonstrate an initial swelling of the upper 
limb, with a mean 6.7% excess volume. The excess volume was 5.1% in those with 
no clinical swelling.  
At the follow-up visit, 7 patients were diagnosed with BCRL, based on the previously 
defined clinical criteria. The Perometer showed an increase in BCRL ipsilateral upper 
limb volume, relative to the contralateral upper limb, of only 5% (135 ± 275 ml), a 
difference that was not statistically significant (p = 0.24, paired t test). In marked 
contrast to the BCRL group, both upper limb volumes in non-BCRL patients were 
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remarkably constant at all time points, including the post-operative period (Table 
19).  
3.7.3 Pre-operative muscle lymph drainage rates in pre-BCRL patients compared 
with non-BCRL patients (Table 20) 
99mTc-Nanocoll clearance from the forearm injection depot was evident from the 
earliest time points, without the initial plateau previously reported for 99mTc-HIG 
clearance.286 The median (interquartile) correlation coefficient of the exponential fit 
to the data points (n = 142) (both sides and both visits pooled) was 0.95 (0.93-0.96).  
In the pre-operative patients there was a significant correlation between ipsilateral 
k (kipsilateral) and contralateral k (kcontralateral), as expected for a valid measure of fluid 
drainage (r = 0.52, p = 0.001, Pearson’s r test). Likewise, in the subgroup of 7 
patients who later developed BCRL the pre-operative kipsilateral (0.0906 ± 
0.0207 %/min) did not differ significantly from kcontralateral (0.1017 ± 0.0442 %/min, p 
= 0.38, paired t test.    To test the hypothesis of constitutively high fluid turnover 
rates in pre-BCRL patients, their pooled k values (n = 14) were compared with those 
of non-BCRL patients (n = 62) (Figure 14). On average the pre-BCRL patients had a 
16.5% higher k (i.e. muscle lymph drainage rate) than the non-BCRL patients 
(0.0962 ± 0.0337 %/min vs. 0.0826 ± 0.0188 %/min, respectively).  The higher k of 
the pre-BCRL group was statistically significant (p = 0.042, unpaired t test). This 
finding was in line with the ‘high filterers’ hypothesis.  However, due to the small 
numbers of patients in the pre-BCRL group (n = 7), there is the possibility of a type 1 





In the post-operative group the BCRL patients showed no significant difference 
between kipsilateral (0.0772 ± 0.0231 %/min) and kcontralateral (0.0828 ± 0.0033 %/min, p 
= 0.59).  The non-BCRL patients similarly showed no significant differences between 
upper limbs.  kipsilateral for the BCRL group (0.0772 ± 0.0231 %/min) was not 
significantly lower than that for the non-BCRL group (0.0849 ± 0.0178 %/min, p = 
0.47, unpaired t test).  Two-way ANOVA was performed to test whether k was 
affected significantly by surgery (pre- vs. post-operative k values) or by side 
(ipsilateral vs. contralateral k values).  The analysis indicated that k was not 
significantly affected by the surgery (pre- vs. post-operative p = 0.31) or side 
(ipsilateral vs. contralateral p = 0.43). The most marked difference, a fall in mean 
kipsilateral from 0.0906 ± 0.021 %/min pre-operatively to 0.0772 ± 0.023 %/min post-
operatively, was not significant (p = 0.38, paired t test). The change in kipsilateral was 
not dependent on whether patients had ANS or ANC (p = 0.90 and p = 0.49 
respectively, paired t test). The results thus indicated that axillary lymph node 
surgery did not alter lymphatic drainage from forearm muscle (Figure 15).  
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Figure 14 Muscle lymph drainage rates (k) at the pre-operative stage in patients 
who later developed BCRL (0.0962 ± 0.034 %/min) compared with those who did 
not develop BCRL (0.0830 ± 0.019 %/min). Pooled ipsilateral and contralateral k 




Figure 15 Joined plots for pre- and post-operative k measured in the subfascial 
compartment of the ipsilateral upper limb 
 
















3.7.4 Axillary activity 
The axillary activity as a percentage of the injected activity increased over time in 
nearly all patients (Figure 16). In the non-BCRL patients there was a smooth, 
curvilinear increase over 185 min pre-operatively (n = 28), and the marginally 
reduced accumulation post-operatively was not statistically significant in either 
upper limb (n = 23) (ipsilateral upper limb p = 0.19, contralateral upper limb p = 
0.15; t test). In the BCRL patients the ipsilateral pre-operative accumulation pattern 
was more variable (n = 4) and the contralateral axilla showed a more pronounced 
post-operative reduction in accumulation rate.  However, these patient numbers 
are small so the significance of the observation is limited (Figure 17).   
  
The axillary activity was not significantly different pre- and post-surgery in patients 
undergoing ANS or ANC (p = 0.10 and p = 0.11 respectively, paired t test). The 
axillary accumulation data indicated that surgery did not cause a major change in 
axillary activity, despite patients undergoing surgical excision of axillary lymph 
nodes.  
3.7.5 Relationship between k and other variables 
There were no significant correlations between kipsilateral and upper limb volume in 
either the BCRL or non-BCRL group (r ≤ 0.1; p > 0.1).  Further analysis tested the 
relationships between change in kipsilateral (post-operative vs. pre-operative) and 
various potential risk factors namely age, BMI and size of tumour The average 
number of nodes removed was different between the groups; ANC 12.3 ± 6.4 (n = 
18) and ANS was 5.8 ± 2.1 (n = 20).  However, when comparing k between the 
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patients undergoing ANS or ANC or correlating k with the number of lymph nodes 
removed, k was not significantly different when comparing either the type of 
surgery performed or the number of nodes removed, indicating that the extent of 
surgery was not a confounding variable in this study. In the BCRL group there was 
no association between the change in kipsilateral and age (r = –0.12; p > 0.1), BMI (r = 
–0.71; p > 0.1), the number of lymph nodes resected (r = –0.03; p > 0.1), type of 
surgery (r = -0.07; p > 0.1) or size of tumour (r = 0.14; p > 0.1).  Similarly, there was 
no association between change in kipsilateral and these factors in the non-BCRL group, 
with p > 0.1 for all categories. The time between surgery and post-operative visits 
was variable depending on when was convenient for the patient to attend.  
Although this ranged from 2 to 19 weeks, the timing of the postoperative visit was 
not related to change in kipsilateral. Venous pressure was measured in 16 patients 
(11.9 ± 2.5 cm H20) and there was no correlation between k and venous pressure (r 
= 0.4; p > 0.1).  Upper limb dominance was not found to be a significant factor in 
the rate of muscle lymph drainage.  No difference was found between the 
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Figure 16 Mean axillary activity as percentage of depot injection in all patients 
(both non-BCRL and pre-BCRL), pre-operatively (n = 35) and post-operatively (n = 
27). 
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Figure 17  Axillary activity as a percentage of depot injection in the ipsilateral and 
contralateral upper limbs of the pre-BCRL patients 
(n = 7 pre-operatively, n = 4 postoperatively) and non-BCRL groups (n = 28 pre-





This study demonstrates that there is no early (i.e. after 8 weeks) effect of axillary 
lymph node surgery on lymph flow measured in the ipsilateral forearm muscle 
despite the obvious partial disruption of the axillary drainage route. There was 
similarly no effect on ipsilateral upper limb volume when comparing pre-operative 
to post-operative measurements. This indicates that BCRL is not caused directly by 
an acute obstruction to lymph flow at the time of surgery. 
3.8.1 Incidence of BCRL 
The overall incidence of BCRL in this study was 18% (7/38).  It has been reported 
that approximately 75% of cases of BCRL occur within the first year after surgery 
and 90% of cases will present within three years.164,174,313 Although the follow-up 
period in this study is relatively short (58 ± 9 weeks), it is probable that 1 or 2 
further patients might develop BCRL, which would make minimal difference to the 
overall conclusions of the study. 
 
There is conflicting evidence in the literature regarding the association between 
increased incidence of BCRL and more extensive breast surgery.171,172 191 In this 
study, the extent of breast surgery did not affect the incidence of BCRL, with there 
being no significant difference in incidence between mastectomy and breast 
conserving surgery (WLE).   
 
Several retrospective studies have suggested that lymph node positivity is related 
to the development of BCRL.160,173,174,210,314 However, the patients in those studies 
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had axillary radiotherapy administered if they were found to be node positive, 
which would have affected the prevalence of BCRL.  The association between nodal 
positivity and the development of BCRL was examined in a recent analysis of two 
prospective studies of 212 patients undergoing ALND. It was observed that positive 
nodal status was inversely related to upper limb volume in all patients, after 
correcting for changes in the contralateral upper limb, raising the possibility that 
the inverse relationship may be due to node positive patients developing collateral 
lymphatic drainage prior to ANC.214   
 
The total number of nodes removed rather than the specific surgical procedure has 
been found to have a greater association with BCRL development.210-213 The 
incidence of BCRL is comparable to previous studies, affecting 33% of patients 
undergoing ANC and only 5% in those undergoing ANS.91,171,172,294    
3.8.2 Upper limb volumes 
BCRL group.  At the post-operative visit, three patients exhibited clinical signs of 
BCRL and the ipsilateral upper limb of the BCRL patients was on average 6% larger 
than the contralateral upper limb. This can be explained by the BCRL being early 
and mild and the clinical examination being more sensitive in detecting subtleties 
rather than an isolated statistical comparison of pre-operative and post-operative 
upper limb volumes. Similarly, BCRL diagnosis cannot be based simply on the 
comparison of ipsilateral and contralateral upper limb volumes, because there may 
be changes in contralateral upper limb volumes resulting from changes in body 
weight or structure, which would invalidate the comparison.315 When patients were 
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diagnosed with BCRL, the upper limb volume was only considered relevant in the 
presence of additional clinical signs and symptoms of BCRL. Notably, by the follow-
up visit at 58 ± 9 weeks there was no significant upper limb volume difference 
remaining either between upper limbs or between visits (Table 19). This can 
possibly be attributed to early referral of patients to the lymphoedema clinic and 
the commencement of compressive treatment.   
 
Non-BCRL group.  There was no significant difference in upper limb volume in 
patients who had not developed BCRL, either between ipsilateral and contralateral 
upper limbs or between pre-operative, post-operative and follow-up visits (Table 
19). 
3.8.3 Axillary activity  
Post-operative axillary activity measurements confirmed substantial transport from 
the depot after surgery. This indicates that the lymphatics remained active after 
surgery, contrary to the lymphostasis or stopcock hypothesis. There was a general 
trend towards reduced axillary tracer levels, as might be expected following nodal 
excision, but the number of studies was too small to assess the reduction 
statistically.  Presumably residual axillary nodes after surgery continue to drain the 
upper limb, which is why axillary activity is evident and why most upper limbs 
showed no traces of oedema at 8 weeks.  Additionally, some lymph may drain into 
the supraclavicular nodes, which were included in the observed regions of activity. 
Also a lymphatic imaging study has demonstrated additional vessels post-
operatively, consistent with re-routing of the lymph.316 In lymph node positive 
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patients, the lymphatic system may already have started to compensate by re-
routing lymph through newly developed/expanded collaterals prior to surgery – a 
view supported by the finding that positive lymph nodal status is inversely related 
to upper limb volume in patients undergoing axillary lymph node dissection.214 
3.8.4 Constitutively high fluid turnover in forearm muscle of BCRL-prone 
patients 
Previous work has reported k in forearm muscle of 43 women without BCRL at 7 
and 30 months after breast cancer surgery.  A subgroup that subsequently 
developed BCRL had a 22% higher local muscle lymph flow (k) than non-BCRL 
patients. Moreover, there was a corresponding difference in the contralateral 
upper limb k values, and also in the subcutis k values on both sides.294 This indicated 
that women destined to develop BCRL experienced a greater fluid load on the 
lymphatic system. Chronic overload could lead to eventual lymphatic pump failure, 
which is a proven feature of established BCRL.289 Since lymph is generated from 
capillary filtrate, high lymph flows imply high microvascular filtration rates - the 
‘high filterer’ hypothesis. Supporting and extending this hypothesis, the present 
results showed a significantly higher mean k in the pre-BCRL patients than in the 
non-BCRL patients. Since these patients had not yet undergone surgery, this new 
finding indicates a constitutional difference in fluid turnover, rather than a 




3.8.5 Short-term effect of surgery on lymphatic drainage. 
The k results showed that muscle lymph drainage was not significantly affected by 
axillary lymph node surgery at the 8-week time point.  In this study there was a 
small (15%) reduction in mean kipsilateral at 8 weeks post-operatively but this did not 
reach significance, so it is not possible to conclude that there was no reduction at 
all. The inherent variability in human tissue and methodology, along with the low 
incidence of BCRL, limits the resolution of this study. No major reduction in lymph 
drainage was found at 8 weeks, such as would occur if ANC had a simple stopcock 
effect (lymphostasis).  
3.8.6 
99mTc-Nanocoll versus 99mTc-HIG 
One technical difference to be noted between the present study and that of 
Stanton et al, is the use of 99mTc-Nanocoll tracer rather than 99mTc-HIG, which is no 
longer available. The 99mTc-Nanocoll method appears to be robust, as shown by the 
highly significant correlation in pre-operative k between the two upper limbs.  The 
absolute values of k for 99mTc-Nanocoll were approximately half those for the 
smaller 99mTc-HIG molecule.294  In animal studies, the optimal particle size has been 
estimated at 5 nm for lymphatic drainage studies.302 If smaller than this (0.05 nm – 
5 nm) the particles usually diffuse into blood capillaries and therefore become 
unavailable to migrate through lymphatic channels.302  Larger particles are 
prevented from entering the blood capillaries by a basement membrane and 
endothelial layer.300,302 However, if particles are larger than 100 nm, it is thought 
that they become trapped in the interstitial compartment for a relatively long 
period and show a significantly lower accumulation rate in the lymph nodes.296,302  
139 
 
Large particles have been detected in venous blood immediately after 
subcutaneous injection, which is thought to be due to localised trauma from the 
injection site.296,301,302   Particle uptake by the lymphatic system is temperature 
dependent, enhanced by increasing temperature.317 
Binding of radiopharmaceuticals to plasma proteins is greatly influenced by: 
 Charge on radiopharmaceutical molecule 
 pH 
 nature of protein 
 concentration of anions in plasma 
Protein binding affects the tissue distribution and plasma clearance of a 
radiopharmaceutical and its uptake by the organ/tissue of interest.318  For proteins 
and particles with sizes of 1-50 nm, there could be a combination of effects 
affecting velocity through tissue interstitium.  Reddy et al (2006) assessed 
interstitial convection.  Larger molecules may be restricted to smaller number of 
pores (e.g. only larger pores), but they would have higher fluid velocities. However, 
large molecules could also interact with the extracellular matrix, with physical 
hindrance or charge interactions, and this would lead to a slower velocity.  There 
could be a combination of both of these factors.  Flexible and deformable chains 
would also move more easily through pores and be able to avoid hindrances 
compared with rigid shapes.  Anionic molecules were also found to move faster 




Nanocolloid is an aggregate of denatured human serum albumin (HSA) colloid. 
According to the manufacturer ~95% of particles are <80nm.  However, mean size 
has been documented as 6.6-30 nm.318,320-323 The reported diameter of single HSA 
particles is 7 nm.324  Nanocoll particles consist of about 10 HSA particles so the 
molecular weight is expected to be ten times that of HSA (i.e. 10 x 67000 
daltons).320 Only 30-40% of Nanocolloid in a subcutaneous depot enters the 
lymphatic system and a fraction of the injected dose is phagocytised by histiocytes 
at the injection site. Another fraction appears in the blood and accumulates mainly 
in the reticulo-endothelial system of the liver, spleen and bone marrow; faint traces 
are eliminated via the kidneys (GE Healthcare).  Therefore its clearance may be 
further complicated and could account for the differences with 99mTc-HIG. 325  
Differences in the size of Nanocoll particles could lead to an underestimation of the 
true depot half-life.  This is due to the fact that the larger sized particles may be 
removed faster and smaller sized particles may be limited by diffusion.  In this 
situation the initial washout would appear monoexponential, but prolonged 
measurements might reveal a different trend.326  99mTc-HIG is technetium-labelled 
human polyclonal immunoglobulin (HIG) and has been found to be superior to 
99mTc-HSA for measuring of lymphatic function, which was attributed to its 
improved stability of labelling.327  HIG has a molecular weight of 150,000 daltons.328  
In animal studies HIG preferentially follows the lymphatic route and has a high 
uptake by lymph nodes.  It is able to demonstrate discrete lymph nodes and 




Mahony et al. (2004) aimed to find an optimal method for imaging lymphatic 
vessels of the upper limb and compared 99mTc-HIG and 99mTc-Nanocoll.  After 
intradermal injection, mean removal rate constant (k) was similar for both 
radiopharmaceuticals and subcutaneous injection was approximately three times 
slower.  99mTc-Nanocoll was also found to produce only marginally inferior images 
than 99mTc-HIG.298  In contrast, Fowler et al. (2007) found 99mTc-HIG to be inferior to 
99mTc-Nanocoll with regard to SLN identification.329 These studies confirm that 
99mTc-Nanocoll is a suitable agent to use for lymphoscintigraphy.  
 
Despite these differences 99mTc-Nanocoll generated results that again supported 
the higher filterer hypothesis, and moreover indicated a similar magnitude of 
difference (16%) as the 99mTc-HIG study (22%). In addition, it shows that lymph flow 
in the ipsilateral forearm muscle did not change post-surgery in either the patients 
who developed BCRL or in those who did not (Figure 15). 
3.9 Conclusion 
These findings indicate that axillary lymph node surgery does not significantly 
change local muscle lymph drainage (k) in patients with BCRL or the non-BCRL 
patients.  The data appear to be robust as demonstrated by the high correlation 
coefficients between the 2 pre-operative k values.  The greater mean k in pre-
operative patients progressing to BCRL later was statistically significant, which is in 
agreement with the highly significant 22% difference reported in a previous 
study.294 In this respect the hypothesis of higher lymph flow in patients who 
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develop BCRL remains valid, supporting a constitutive difference between BCRL-
prone and non-BCRL patients.  
 
In conclusion, axillary lymph node surgery does not have an acute effect on local 
muscle lymph flow, and BCRL is not caused solely by acute, surgical obstruction of 






Subgroup  Pre-operative visit n = 38 Post-operative visit n = 33 Follow-up visit n = 31  
   Ipsilateral Contralateral p* Ipsilateral Contralateral p*  Ipsilateral Contralateral p* 
           
BCRL
a
  2846 ± 382 2805 ± 373 0.43 2943 ± 476 2780 ± 448 0.004  2861 ± 601 2726 ± 431  0.24 
Non-BCRL
b
  2527 ± 760 2540 ± 729 0.66 2562 ± 773 2570 ± 732 0.69  2515 ± 795 2496 ± 760 0.45 
p** 0.29 0.37  0.15 0.38   0.24 0.32  
Table 19 Ipsilateral and contralateral upper limb volumes (ml) measured by perometry (mean ± SD). 
a
 n = 7 at pre-operative visit, n = 6 at post-operative visit;   
b
 n = 33 at pre-operative visit, n = 27 at post-operative visit. 
*Ipsilateral versus contralateral upper limb volumes (paired t test) shows a significant difference at the post-operative visit in the BCRL group (p = 0.004). There is no 
significant difference at either pre-operative or post-operative visit in the BCRL group and the non-BCRL group at any of the visits.  















Table 20 Lymphatic removal rate constants k (%/min, mean ± SD) measured in the forearm by quantitative lymphoscintigraphy 
a
 n = 7 at pre-operative visit, n = 6 at post-operative visit;  
b
 n = 33 at pre-operative visit, n = 27 at post-operative visit 
* Ipsilateral versus contralateral k (paired t test) shows no significant difference at either pre-operative or post-operative visit in the BCRL group or the non-BCRL group. 
** BCRL vs. non-BCRL group (unpaired t test) shows no significant difference in k in the ipsilateral or contralateral upper limbs at the pre-operative and post-operative visit. 
 
 
Subgroup Pre-operative visit  n = 38  Post-operative visit  n = 33 
   Ipsilateral Contralateral p*  Ipsilateral Contralateral p* 
        
BCRL
a
  0.0906 ± 0.0207 
 
0.1017 ± 0.0442 
 
0.38  0.0772 ± 0.0231 0.0828 ± 0.0033 0.59 
Non-BCRL
b
  0.0857 ± 0.0217 
 
0.0803 ± 0.0157 
 
0.14  0.0849 ± 0.0178 
 
0.0797 ± 0.0190 0.23 
 




4 Study 2: An investigation of lymphovenous 




All lymph eventually drains into the venous system, primarily via the thoracic or 
lymphatic duct in the neck. Studies have shown the presence of communications 
between peripheral veins and lymphatics, although the significance of these 
remains unclear, but raises the possibility of peripheral vascular drainage of lymph. 
It has been suggested that these peripheral lymphovenous communications (LVCs) 
respond to lymphatic hypertension following axillary lymph nodal surgery and 
provide something akin to a protective effect.293,330 Local vascular clearance of 
lymph via peripheral LVCs could in theory potentially minimise or prevent BCRL.  
 
Previous work by this group investigated the delivery of radiolabelled autologous 
red blood cells to lymphatic vessels by intradermal injection. Radiolabelled-
erythrocytes were injected intradermally into the hands of 4 normal subjects.  
Labelled erythrocytes could only access local blood through LVCs or needle trauma. 
Following intradermal injection, scintigraphy revealed abundant axillary activity, 
146 
 
indicating erythrocyte transport up upper limb lymphatics. There was no evidence 
of cell-bound activity in ipsilateral blood, indicating neither LVCs nor needle 
trauma.291 A further study was performed in four patients 3 months after axillary 
surgery and intradermally injected labelled erythrocytes were recovered bilaterally 
in central blood in one patient. This was the only patient in this group who did not 
go on to develop BCRL.291 As this study assessed only small numbers of patients 
post-operatively, it was difficult to know if  LVCs existed prior to surgery, or simply 
opened up as a result of surgical intervention to the axilla. This study aims to 
further investigate the presence or absence of LVCs in breast cancer patients. 
 
4.2 Study Aim 
To investigate the presence or absence of lymphovenous communications (LVCs) in 
the upper limb in breast cancer patients, and to see if these act as a rescue 
mechanism in patients who do not develop BCRL. 
 
4.3 Study Design 
This study was divided into two parts: 2a and 2b. Study 2a was a prospective 
observational study involving patients who were recently diagnosed with unilateral 
breast cancer and due to undergo axillary lymph node surgery.  Study 2b was 
designed as a retrospective observational study of patients who underwent axillary 
lymph node surgery for breast cancer at least three years previously; within which 




Patients in both studies were assessed for the presence of LVCs by injecting 
radiolabelled autologous RBCs into the 2nd webspace of the hand of the affected 
side.  Images of the axilla and hand were obtained using a gamma camera and 
bilateral blood samples obtained from each antecubital fossa.  Images were 
performed for qualitative lymphoscintigraphy and for calculating depot clearance 
from the hand.  Study 2a patients (henceforth referred to as Group 1 patients) were 
followed up to see if they developed BCRL.  Study 2b patients (Group 2 patients) 
were compared to firstly assess if there were any LVCs, and secondly to see if there 
was any difference between patients with and without BCRL.  
 
4.4 Methods 
4.4.1 Recruitment of patients 
Patients studied pre-operatively (Group 1) 
Six patients with recently diagnosed invasive breast cancer and due to undergo 
surgery, which included a level II/III ALND, at GSTT were recruited.  Patients were 
studied in the Nuclear Medicine department. Patients attended on three occasions: 
pre-operatively, two to six weeks post-operatively and follow-up visits.  On pre- and 
post-operative visits the following procedures were performed:  
(i) Clinical assessment of the upper limbs for presence of BCRL;  
(ii)  Upper limb volume measurement;  
(iii) Venous pressure measurement; 
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(iv) Lymphoscintigraphy and venepuncture for circulating erythrocyte and 
plasma 99mTc concentrations (calculated as % of administered activity to assess 
for the presence of LVCs). 
 
Clinical and upper limb volume assessments were performed at follow-up visits (as 
detailed in Chapter 2). 
Patients studied > 3 years post-surgery (Group 2) 
Ten patients with invasive breast cancer diagnosed at least three years ago and 
who underwent level II/III ALND as part of their surgical treatment were recruited.  
Two groups of patients were identified; those who had not developed 
lymphoedema post-operatively and those who had.  Patients attended on one 
occasion only and underwent procedures (i)-(iv) as described above. 
4.4.2 Blood sampling preparation  
An intravenous cannula (18G green cannula) was inserted into a vein in the 
antecubital fossa of the contralateral upper limb and 5 ml blood withdrawn and 
radiolabelled.  A three-way tap containing heparinised (2.5units/ml) saline was 
connected to the cannula.  A second intravenous cannula (with three-way tap and 
heparinised saline) was inserted into a vein in the antecubital fossa of the ipsilateral 
upper limb for collection of blood samples.   
4.4.3 Blood sample processing  
For labelling with 99mTc, 1 ml heparinised whole blood was incubated for 5 min with 
stannous pyrophosphate (Mallinckrodt Medical, Petten, The Netherlands) 
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containing 0.66 μg stannous chloride and then washed with 5 ml saline.  An aliquot 
of 0.1 ml pre-tinned packed autologous erythrocytes was incubated with 250 MBq 
sodium 99mTc-pertechnetate (Drytec; GE Healthcare, Bucks, UK) for 15 min and then 
washed twice with 5 ml saline.  The 99mTc-labelled erythrocyte preparations were 
each reconstituted to a final haematocrit of 10% with saline.  Labelling efficiency 
was 86.4 ± 10.2% (Appendix 4).   
4.4.4 Injection site 
The skin was cleaned and 0.10 ml of 99mTc-erythrocyte solution (containing 
approximately 20 MBq was injected intradermally into the 2nd metacarpo-
phalangeal joint interspace of the ipsilateral hand using a 5/8” 25G needle (0.5mm 
outer diameter).  
Blood samples were taken as soon as injection was complete (which took two 
minutes), and further samples were obtained at 15, 30, 60, 120 and 180 minutes 
after injection.  At each time point a 5 ml sample of venous blood was taken from 
both upper limbs.  
4.4.5 Image acquisition 
The scans were conducted in a temperature controlled room; ambient temperature 
(Ta).  Skin temperature (Tsk) was recorded with a thermometer using thermistor 
probes (4600 Precision Thermometer, Measurement Specialties Inc., USA).  A single 
camera headed camera was required for imaging, using a 256x256 matrix, low-
energy high-resolution collimator.  Each image took 300 sec (5 min).  Images were 




At each time point two images were obtained:  
 Image 1: Head one positioned above patient to include the injection site and 
patient’s upper limb on the ipsilateral side.  
 Image 2: Head one positioned above patient to include axilla on the 
ipsilateral side 
 
Images were analysed using the HERMES software system.   
 
4.5 Image analysis 
4.5.1 Lymphoscintigraphy analysis 
Scans were assessed for evidence of activity in the axilla after intradermal injection, 
to ensure accurate injection technique. In addition, lymphoscintigraphic images 
were reviewed for evidence of abnormal findings, especially transport through 
small skin lymphatics (‘dermal back flow’). 
4.5.2 Calculation of removal rate constant (k) 
As per section 3.5.1, the clearance of radiotracer from the intradermal depot was 
quantified using a circular region of interest (ROI) of 37.5 cm2 encompassing the 
entire ipsilateral hand injection depot.  Counts were recorded at 2, 15, 30, 60, 120 
and 180min post-injection.  The fraction of the counts remaining in the depot 
(corrected for radionuclide physical decay) was plotted semi-logarithmically against 
time. The slope of the linear plot of loge fraction versus time gave the fraction of 
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tracer removed per minute. Multiplying by 100 gave k in units of % tracer removed 
per min. The theory relating k to lymph flow has been discussed extensively 
elsewhere.286,288,309-311  
 
4.6 Blood sample analysis 
4.6.1 Assessing for evidence of lymphovenous communications 
After injection of 0.1 ml of 99mTc-erythrocyte, 5 ml of each of the blood samples 
taken was transferred into a counting tube and processed (Appendix 4).  In 
summary, a 2 ml aliquot of each blood sample was diluted with 8 ml saline and 
centrifuged (500 g, 5 min) to wash away free 99mTc-pertechnetate released by the 
erythrocytes.  The supernatant was discarded and the remaining ~1 ml of packed 
erythrocytes (i.e. from the 2 ml whole blood sample) was suspended in 8 ml saline.  
A 1 ml aliquot of this suspension was transferred to a counting tube and the 
remaining 8 ml suspension was centrifuged (500 g, 5 min).  Finally, 1 ml aliquot of 
the supernatant was taken and all tubes were assayed in a gamma counter (Wallac 
Wizard, Perkin Elmer, UK).   
 
A difference in the counts/ml in the cell suspension (99mTc-erythrocytes plus free 
99mTc) and counts/ml x (1 – 0.11) in the supernatant (free 99mTc) that was deemed 
significant (see below) was interpreted as evidence of intact 99mTc-labelled 
erythrocytes in the circulation. In such cases, this difference was considered to 
represent shunted labelled erythrocytes and expressed as % of injected activity per 
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litre of blood. Blood volume was estimated from weight and height331 and applied 
to contralateral samples only to calculate the % of injected labelled cells in the 
general circulation.   
 
Blood volume = Red cell mass + plasma volume 
Red cell mass (ml) = 822 x Surface Area  
Plasma volume (ml) = 1395 x Surface Area 
Surface area (m2) = weight(kg)0.425 x  height(cm)0.725 x 0.007184 
 
Excess activity in ipsilateral samples, over and above the activity in contralateral 
samples, that would be consistent with shunting between the ipsilateral antecubital 
fossa and injection site (see Statistical analysis section 4.7), was noted but not 
quantified. 
4.6.2 Correcting for activity remaining in depot in patients with LVCs. 
Residual activity in the hand injection depot was calculated from the counts in the 
ROI from the lymphoscintigraphic images. From the depot residual activity the 
quantity of erythrocytes that had left the depot was calculated. The quantity that 
had arrived in the circulation, calculated from the contralateral sample (see 
previous section) was expressed as a fraction of the quantity that had left the depot. 




4.7 Statistical analysis 
Results are shown as the mean ± standard deviation (SD). Linear regression analysis 
was used to analyse the slope of the semi-logarithmic depot clearance plot, which 
was assumed to be mono-exponential.  Group comparisons were made using 
Student’s unpaired t test. Fisher’s exact test was used for categorical data due to 
the small sample sizes.  Analysis was performed using GraphPad Prism (version 6; 
San Diego, CA, USA). A p value of ≤ 0.05 was accepted as significant. To calculate 
the difference between cell suspension (WB) and supernatant (SN) counts, the SD 
of the total counts was calculated as (WB counts + SN counts)0.5. A difference in 
counts between cell suspension and supernatant of >2 SDs was considered 
significant and to indicate lymphovenous communication. 
 
4.8 Results 
4.8.1 Patient data 
Group 1 
Pre-operative measurements were performed in six women.  No images or blood 
samples were obtained for one of these patients and she was therefore excluded 
from further analysis.  The remaining five patients attended both the post-
operative study and the follow-up visit. The mean age of patients at the time of 
surgery was 54 ± 3 years (range: 48 - 56 years) and the body mass index (BMI) was 
23.6 ± 2.3 kg/m2 (Table 21). The intervals between surgery and subsequent 
assessments were 9 ± 6 weeks (post-operative visit) and 19 ± 5 months (follow-up 
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visit). None of the patients developed BCRL. All five patients were right hand-
dominant and a total of 3/5 (60%) of patients had surgery to their dominant side.   
 
  
(n = 5) 
 
   
Age (years) 53.8 ± 3.2  
BMI (kg/m
2
) 23.6 ± 2.3  
Ipsilateral arm volume (ml) 2242 ± 260  
Nodes removed 15.8 ± 7.9  
Positive nodes 0.4 ± 0.6  
     
   
Table 21 Group 1 patients’ clinical details (mean ± SD) 
 
Group 2 
We recruited ten patients of whom seven patients had BCRL and three patients did 
not. All patients were at least three years after axillary lymph node dissection for 
breast cancer. All patients had previously undergone axillary node clearance 
surgery (ANC) with an average of 21.4 ± 4.6 nodes removed, of which 6.4 ± 10.1 
nodes were found to be positive. Comparing the BCRL and non-BCRL patient groups 
revealed a statistical difference in the number of nodes removed, with more nodes 
removed in patients in the BCRL group (unpaired t test p = 0.04) although the 
number of positive nodes remained insignificant (p = 0.96).  The BMI difference 
approached significance with a higher BMI in patients in the BCRL group compared 
with the non-BCRL group (p = 0.05). The other significant difference was the 
ipsilateral upper limb volume, which was significantly larger in the BCRL group 




BCRL (n = 7) Non-BCRL (n = 3) P* 
 
     
Age (years) 50.2 ± 9.2 46.7 ± 9.0 0.58  
BMI (kg/m
2
) 30.4 ± 3.1 25.7 ± 1.8 0.05  
Nodes removed 21.2 ± 4.5 14.3 ± 1.5 0.04  
Positive nodes 4.7 ± 9.5 4.0 ± 4.0 0.96  
Ipsilateral arm volume (ml) 3155 ± 426 2220 ± 481 0.02  
        
     
Table 22 Group 2 patients’ clinical details: Comparison between BCRL and non-
BCRL patients (mean ± SD) 
*unpaired t test. 
 
4.8.2 Intradermal lymph drainage (k) 
99mTc-labelled erythrocyte clearance from the ipsilateral hand injection depot was 
evident from the earliest time points.  The fraction of the counts remaining in the 
depot (corrected for radionuclide decay) was plotted semi-logarithmically (Figure 
18). To assess the proportion of variability of measurement of k in our data set, the 
results from patients in both Group 1 and 2 were pooled. The median 
(interquartile) correlation coefficient of the exponential fit to the data points (n = 
18) was 0.97 (0.95-0.99).  Activity rapidly reached the axilla (within 15 min) in all 
patients.  In all seven patients with BCRL in Group 2, prominent activity was seen in 
the dermal lymphatics throughout the affected arm indicating that the injected 








Figure 19 Images of the axilla 15, 30 and 180 min after intradermal injection of 
99mTc-RBC showing activity in dermal lymphatic vessels. 
 
4.8.3 Quantitative studies 
Depot clearance rates 
There was no significant change in k between pre- and post-operative studies in 
Group 1 patients, with corresponding mean values of 0.25 ± 0.06 and 0.26 ± 
0.10 %/min, respectively.  
 
When the pre- and post-operative k values in Group 1 were pooled, the mean value 



































Time since injection  (min) 
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Group 2, with respective values of 0.28 ± 0.11 and 0.39 ± 0.12 %/min, although the 
difference was of marginal significance (p = 0.087). The mean k for non-BCRL 
patients in Group 2 was 0.36 ± 0.26 %/min.  
 
Shunting through LVCs 
Group 1 contralateral evidence: Contralateral blood samples were obtained from 
Group 1 patients in 4 pre-operatively and 4 post-operatively. No shunting could be 
detected in 2/4 pre-operative studies and 2/4 post-operative studies. However in 4 
studies, shunting was detected with maximum values of 1.6% and 1.8% (pre-
operatively and post-operatively, respectively, in the same patient) and 6.6% and 
2.3% (pre-operatively and post-operatively in separate patients, respectively) of 
activity that had left the depot.  
 
Group 2 contralateral evidence: Contralateral blood samples were obtained from 7 
patients in Group 2. No shunting could be detected in 4 of them, including all 3 
patients without BCRL. However, shunting was detected in 3 patients, all with BCRL, 
with maximum values of 0.1%, 0.7% and 0.5% of activity that had left the depot.  In 
subjects showing contralateral evidence of shunts, the labelled red cells 
accumulated progressively in the contralateral samples over time, indicating that 
the shunt is continuous in its operation. (Figure 20) 
 
Ipsilateral samples were obtained in 5 Group 1 studies and 7 Group 2 studies. 
Ipsilateral shunting located between the depot site and antecubital fossa was 
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inferred when erythrocyte-associated activity was higher in ipsilateral than 
simultaneous contralateral samples.  
 
 Group 1 ipsilateral evidence: Excess ipsilateral activity was seen in only one study, 
in the 15 min sample of a patient who did not have contralateral shunting. There 
was no ipsilateral excess in the other 4 studies, in 2 of which there was evidence of 
shunting in the contralateral samples. 
 Group 2 ipsilateral evidence:  Ipsilateral counts indicating shunting in 2 subjects of 
group 2; unfortunately no contralateral samples were available in either subject. In 
2 patients with shunting based on contralateral samples, no excess ipsilateral 
activity was detected. So, in general, the criterion of ipsilateral excess counts did 
not provide convincing evidence of shunting in the distal ipsilateral arm. 
 
Comparison of removal rate constant and shunting  
There was no difference in k values between patients with and without evidence of 
LVC shunting in the contralateral blood, with corresponding values of 0.36 ± 0.14 (n 







Figure 20 Counts in blood samples from the contralateral limb. A; The increase in 
counts in a Group 2 patient with BCRL indicated evidence of LVCs. B; There was no 
evidence of LVCs in a Group 2 patient without BCRL in which there was no 
significant difference in counts. Vertical bars are the SDs of individual counts. 
 
4.9 Discussion 
Study 2a was designed to study patients in a prospective manner, but there was 
considerable difficulty in patient recruitment.  Patients found the study to be both 
time-intensive and invasive. Venepuncture of the ipsilateral upper limb soon after 
axillary lymph node surgery also caused some concern for patients regarding the 
perceived risk of the development of BCRL. Several patients were also undergoing 
chemotherapy peri-operatively, which made venous access for the study more 
difficult. In addition, due to the preliminary nature of this study and after assessing 
initial results, it was difficult to predict how long it would take for potential LVCs to 
develop or present themselves after surgery. The decision was made to suspend 
Study 2a after recruiting six patients and to commence Study 2b; the planned 
retrospective study. Study 2b was less time-intensive for patients and as it only 
involved one visit. Furthermore, those who had not developed BCRL were less 






































apprehensive about venepuncture as they were at least 3 years after axillary lymph 
node surgery. 
 
The ability to deliver intact red cells to lymphatic vessels is itself of great interest, 
especially in the context of the general intra-lymphatic administration of particulate 
materials, liposomes and intact blood cells. Moreover the rate of removal of the red 
cells by lymphatic transport was similar to the rate of removal of intradermal 
human immunoglobulin (0.24 - 0.47%/min), in keeping with unimpeded transport 
by bulk flow along the lymphatics.332  
 
This results from this study showed evidence of shunting of labelled erythrocytes 
from the interstitial depot in the hand into the blood circulation in a subsection of 
subjects. Since erythrocytes are presumably unable to pass through the axillary 
lymph nodes to reach the bloodstream, their passage appears to indicate the 
presence of LVCs more distally in the arm.  Needle trauma was considered as a 
potential artefactual source of activity from depot into the circulation. However, 
trauma would be expected to result in (i) a rapid, unsustained appearance of 
labelled cells in blood, unlike the slow, continuous accumulation evident in Figure 
20, and (ii) a clear ipsilateral excess over contralateral counts. Although rapid 
ipsilateral appearance of labelled cells was observed in one patient, the 
contralateral samples provided no evidence of shunting in that patient. The likeliest, 
though unproved, location of lymphovenous shunting is therefore the upper arm or 
axilla. With respect to the axilla, this may be the post-operative consequence of 
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axillary lymph node resection followed by regeneration of lymphatic vessels. 
Alternatively, in order to explain pre-operative shunting, lymph vessel-to-lymph 
vessel shunting may take place so that the labelled erythrocytes bypass lymph 
nodes.  
 
Shunting, as indicated by contralateral cell-bound counts, was much more marked 
in terms of the percentage of shunting in Group 1 patients, who on follow-up did 
not show any clinical evidence of BCRL. On the other hand, the 3 patients in Group 
2 who did not develop BCRL, displayed no evidence of shunting from contralateral 
sampling, whilst of the 3 with evidence of a very small degree of shunting, 3 had 
BCRL.  
4.10 Conclusion 
The findings make it difficult to conclude that LVCs pre-exist constitutionally and/or 
develop in response to axillary surgery. Furthermore, the patient numbers are 
insufficient to determine whether, or the extent to which, LVCs protect against 
BCRL. Since the size of the shunt was typically less than 1-2% of the lymph flow, it 
seems unlikely that LVCs are a major factor influencing the likelihood of BCRL 
development. Given the paucity of explanations for the development of BCRL in 
only a minority of breast cancer patients undergoing broadly similar treatment to 




5 Study 3: An investigation into a constitutional ‘global’ 
lymphatic dysfunction in patients with BCRL  
5.1 Introduction 
There have been studies into BCRL that have yielded observations indicating that 
some breast cancer patients may be more prone to developing BCRL than others 
who have had similar treatment. Abnormalities have also been found in the 
lymphatic vessels of the contralateral, non-swollen upper limbs of patients with 
BCRL in addition to the ipsilateral swollen upper limb.  These findings point to a 
constitutional predisposition to BCRL. 
 
A significant drawback of studying patients with established BCRL is that 
compensatory changes may take place in the contralateral upper limb if the patient 
is inclined to preferentially use this limb.  Changes that may take place in the 
contralateral upper limb would preclude any opportunity to study constitutional 
factors.   If there is a constitutional lymphatic disturbance that predisposes patients 
to BCRL, it would be reasonable to hypothesise that there is a global impairment of 
lymphatic function and that consequently it may be possible to detect lymphatic 
abnormalities in lower limbs.  
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5.2 Study Aim 
To investigate if there is a functional disturbance in the lymphatics of the lower 
limbs in breast cancer patients with BCRL compared with those without BCRL. 
5.3 Study Design 
This is a prospective, non-randomised, multicentre study of a cohort of women 
diagnosed with breast cancer.  All patients were studied using quantitative 
lymphoscintigraphy of the lower limbs.  None of the patients had any known lower 
limb pathology. 
5.4 Methods 
5.4.1 Recruitment of patients 
Thirty patients with invasive breast cancer diagnosed at least three years previously 
and who underwent level II or III ALND as part of their surgical treatment were 
recruited.  Two groups of fifteen patients were identified: those who had developed 
BCRL post-operatively and those who had not.  Patients attended on one occasion 
and the following procedures were performed:  
(i) Clinical assessment for the presence of BCRL in upper and lower limbs  
(ii)  Upper limb volume measurement  
(iii) Lymphoscintigraphy 
 
5.4.2 Lymphoscintigraphy: injection technique and image acquisition 
Differing techniques for lower limb lymphoscintigraphy include intradermal 
injection compared with subcutaneous injection, varying amounts of limb exercise 
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of the lower limb in between imaging, timing of images and using different 
radiopharmaceuticals.317  For the patients in this study, subcutaneous injection was 
used as per British Nuclear Medicine Society Guidelines.  Lymphoscintigraphy was 
conducted in a temperature-controlled room.  With the participant positioned 
supine, aliquots of 0.1 ml of 99mTc-Nanocoll solution (each containing 20 MBq) were 
injected subcutaneously into the first web-spaces of both feet using a 25 gauge 
needle (outer diameter 0.51mm, Terumo, Belgium).  To confirm that blood vessels 
were not penetrated, the syringe was aspirated prior to injection.  With the 
participant lying supine, gamma camera images of the full body from chest 
downwards were obtained at 5, 45 and 150 min after injection. The injection depot 
was also imaged in order to calculate depot clearance rate (k) (Figure 21).  
 
Dedicated static images were performed for quantification of ilio-inguinal nodal 
activity at 45 and 150 min post-injection.  This involved placement of a known 
quantity of radioactivity (a ‘standard’) on the thigh within the field of view of the 
camera (Figure 22).  Whole body images took approximately 17 min to acquire, 








Figure 22 Gamma camera positioning for quantification image 
5.5 Image analysis 
All scans were reviewed independently by two observers who have extensive 
experience in lymphoscintigraphy, and who were blinded to the clinical details of 
patients. Lymphoscintigraphy was classified as normal or abnormal using 
conventional criteria as outlined below. Scans were deemed abnormal if they 
showed evidence of delay in lymph flow to inguinal nodes or abnormalities related 




5.5.1 Calculation of the removal rate constant (k) 
As per section 3.5.1, the clearance of radiotracer from the interstitial depot was 
quantified using a circular region of interest (ROI) of 37.5cm2 encompassing the 
entire foot injection depot.  Counts were recorded at 5, 45 and 150 min.  The 
fraction of the counts remaining in the depot (corrected for radionuclide physical 
decay) was plotted semi-logarithmically against time. The slope of the linear plot of 
loge fraction versus time gave the fraction of tracer removed per minute. 
Multiplying by 100 gave k in units of % tracer removed per min. This equals the 
local lymph flow (ml/min) per 100ml of interstitial fluid in which the tracer is 
distributed.  
Abnormalities related to delay  No activity in ilio-inguinal nodes by 45 min 
 Obviously reduced activity in ilio-inguinal 
nodes by 150 min 
 Asymmetry in ilio-inguinal nodes at 150 min 
(>50%) 
 
Abnormalities related to lymph 
diversion 
 Dermal backflow 
 Popliteal node visualisation 
Table 23 Criteria for abnormal lymphoscintigraphy 
 
5.5.2 Quantification analysis 
The percentage of injected radioactivity accumulating in the ilio-inguinal nodes was 
calculated at the 45 and 150 min time-points.  This involved the placement of the 
‘standard’ in close proximity to the ilio-inguinal nodes and within the field of view 
of the camera.  The same sized ROIs were drawn over the anterior images at both 
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time-points, encompassing (1) the ‘standard’ (2) right ilio-inguinal nodes and (3) left 
ilio-inguinal nodes.  Counts were corrected for background and decay. 
5.6 Control group 
A retrospective control patient group was identified and images analysed by the 
same method as described above.  This group comprised 24 female patients, all of 
whom were referred for lower leg lymphoscintigraphy for a range of clinical 
indications.  None of the patients demonstrated clinical evidence of lower limb 
lymphoedema. These patients underwent lymphoscintigraphy with the aim of 
confirming normal lymphatic function. Quantification was also recorded as normal 
in this group.  Clinical details and final diagnoses for these patients are shown in 
Table 24.  
5.7 Statistical analysis 
Results are shown as the mean ± standard deviation. Linear regression analysis was 
used to analyse the slope of the semi-logarithmic depot clearance plot, which was 
assumed to be mono-exponential.  Group comparisons were made using Student’s 
unpaired t test. Fisher’s exact test was used for categorical data due to the small 
sample sizes.  Analysis was performed using GraphPad Prism (version 6; San Diego, 





Presentation Other clinical information Final diagnosis 
   
Bilateral leg swelling Family history of leg swelling Normal 
Bilateral leg swelling  Lipoedema 
Bilateral knee effusions Arthritis, obesity Rheumatic swelling 
Bilateral leg swelling Family history of 'big legs' Lipoedema 
Bilateral leg swelling  Lipoedema 
Bilateral leg swelling Hamartoma of left leg Normal 
Bilateral leg swelling Short stature Normal 
Bilateral leg swelling Dercum's disease Lipoedema 
Bilateral leg swelling Prada Willi syndrome Obesity  
Bilateral leg swelling Family history of lipoedema, obese Lipoedema 
Bilateral leg swelling  Normal 
Bilateral leg swelling Family history of lipedema, anorexia Lipoedema 
Bilateral leg swelling  Normal 
Bilateral leg swelling Lipodermatosclerosis Lipoedema 
Minor transient leg swelling Leg swelling after flights Normal 
Painful legs  Dercum's disease 
Bilateral leg swelling  Lipoedema 
Bilateral leg swelling  Lipoedema 
Left arm swelling Breast implants Normal 
Bilateral leg swelling  Lipoedema 
History of left foot swelling Previous cellulitis Cellulitis 
Bilateral leg swelling Panniculitis, small varicosities Erythema nodosum 
Bilateral leg swelling  Normal 
Bilateral leg swelling Family history of lipedema Lipoedema 
   
 
Table 24 Clinical details of control group. All patients had normal 





5.8.1 Patient data 
In all, in addition to the control group, 30 patients were recruited into this study of 
whom 15 patients had BCRL and 15 patients did not.  Patients in the non-BCRL 
group were at least three years after having undergone axillary lymph node 
dissection for breast cancer.  None of these patients demonstrated any obvious 
clinical abnormality of the lower limbs.  Clinical, surgical and pathological details for 
patients are summarised in Table 25.  The average time for onset of BCRL after 
surgery was 12.5 ± 17.4 months (range 1-48 months).  Thirteen of 15 patients (87%) 
developed BCRL within a year of surgery.  All patients underwent axillary node 
clearance surgery (ANC) with an average of 14.9 ± 6.0 nodes removed, of which 3.0 
± 6.4 nodes were found to be positive.  A significant number of patients had 
systemic therapy for their breast cancer, either in the form of endocrine therapy 
(80%) or chemotherapy (90%).  There was only one patient who did not have any 
form of systemic therapy.  Comparing the BCRL and non-BCRL patient groups 
revealed no statistical differences in patient factors (Table 26). The patients in each 
group were well matched.  The only significant difference was the ipsilateral upper 
limb volume, which was significantly larger in the BCRL group than the non-BCRL 




Patient ID Age 
(yrs) 




           Grade Type Size 
(mm) 
ER status 
100B* 59 WLE ANC  14 (12) 2 IDC 25 + 
101B* 56 WLE ANC  4 (0) 3 IDC 6 - 
102B* 55 Mx ANC  13 (1) 3 IDC 25,14 - 
103B* 63 Mx ANC  33 (33) 2 IDC 42 + 
104B* 59 WLE ANC  12 (3) 2 IDC 22 + 
105B* 62 Mx ANC  18 (2) 2 IDC& ILC 35 + 
100G* 58 WLE ANC  13 (0) 2 IDC 28 - 
101G 46 Mx ANC  12 (1) 3 IDC 50 - 
102G* 49 WLE ANC  16 (2) 2 IDC 20 + 
103G 53 WLE ANC  16 (1) 1 IDC 20 + 
104G 66 Mx ANC  21 (1) 2 IDC& ILC 11,11 + 
105G 38 Mx ANC  22 (0) 2 ILC 15 + 
106G* 52 WLE ANC  16 (2) 2 ILC 32 + 
107G* 53 WLE ANC  19 (0) 3 IDC 22 + 
108G* 39 WLE ANC  17 (0) 3 IDC 12,17 + 
109G* 66 WLE ANC  17 (1) 2 IDC 20 + 
110G* 41 WLE ANC  8 (1) 3 IDC 57 + 
111G* 48 Mx ANC  14 (1) 2 IDC 47 + 
112G 43 Mx ANC  18 (6) 3 IDC 80 + 
113G 40 WLE ANC  7 (0) 2 MUC 50 + 
114G 48 Mx ANC  10 (5) 2 IDC 36,8 + 
115G* 61 Mx ANC  22 (1) 2 MIC 57 + 
116G 46 WLE ANC  13 (5) 3 IDC 32 + 
117G 60 WLE ANC  14 (0) 2 IDC 28 - 
118G 52 Mx ANC  6 (0) 2 IDC 21 + 
119G 67 WLE ANC  14 (1) 1 TUB 10.5 + 
120G 51 WLE ANC  13 (3) 2 IDC 6,2,2,2 + 
121G 44 Mx ANC  3 (0) 3 IDC 50 - 
122G 61 WLE ANC  19 (2) 2 IDC 17 + 
123G 68 Mx ANC  22 (11) 1 CRI 16,6 + 
Table 25 Clinical, surgical and histopathological details of patients 
*patients with BCRL; ANC, axillary clearance surgery; ER, oestrogen receptor; WLE, wide local excision; Mx, mastectomy; IDC, 
invasive ductal carcinoma no special type; ILC, invasive lobular carcinoma; MUC, mucinous carcinoma; MIC, micropapillary 




  BCRL (n = 15) Non-BCRL (n = 15) p  
     
Age (years) 55.0 ± 7.2 54.8 ± 7.8 0.44  
Body mass index (kg/m
2
) 29.9 ± 4.7 27.8 ± 4.8 0.25  
Ipsilateral arm volume (ml) 3231 ± 774 2561 ± 357 0.01  
Nodes removed 15.7 ± 6.5 14.7 ± 5.6 0.48  
Positive nodes 3.9 ± 8.6 2.4 ± 3.1 0.49  
Endocrine therapy 12 (80%) 12 (80%) 1  
Chemotherapy 14 (93%) 13 (80%) 1  
Chemotherapy (taxane-based) 7 (47%) 6 (40%) 1  
No systemic therapy 0 1 1  
Abnormal scans 10 (67%) 7 (47%) 0.46  
        
Table 26 Comparison between BCRL and non-BCRL groups 
5.8.2 Image analysis   
In this study, none of the control group patients (n = 24) demonstrated clinical 
evidence of lymphoedema in their lower limbs.   The scans all confirmed normal 
lymphatic function bilaterally, with no evidence of delay in lymph transit or 
diversion of flow. In complete contrast, 17/30 breast cancer patients were found to 
have abnormal lower limb lymphoscintigraphy compared with 0/24 in the control 
group, which was highly significant (p < 0.0001, Fisher’s exact test).  Despite this 
finding, there was no difference in the number of abnormal scans in the BCRL group 
compared with the non-BCRL group, with 10/15 and 7/15 abnormal scans 
respectively (p = 0.46, Fisher’s exact test).   
 
Table 27 categorises scans based on whether they were normal or abnormal.  
Unpaired t test showed no obvious differences in the patient factors of either group, 
including difference in BMI (p = 0.77), number of nodes removed (p = 0.14), 
endocrine therapy (p = 0.67) or chemotherapy (p = 0.56).     
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  Normal scans (n = 13) Abnormal scans (n = 17) p  
     
Age (years) 54.3 ± 9.4 52.9 ± 8.7 0.66  
Body mass index (kg/m
2
) 28.6 ± 3.6 29.1 ± 5.7 0.77  
Nodes removed 13.4 ± 5.1 16.9 ± 7.0 0.14  
Positive nodes 2.4 ± 3.7  4.0 ± 8.9 0.55  
Endocrine therapy 11 (85%) 13 (76%) 0.67  
Chemotherapy 11 (85%) 16 (94%) 0.56  
Chemotherapy (taxane-based) 5 (38%) 8 (47%) 0.72  
No systemic therapy 0 1 1  
Patients with BCRL 5 (38%) 10 (59%) 0.46  
         
Table 27 Patients grouped according to whether images were normal or abnormal 
 
The image analysis for the abnormal scans (Table 28) details the individual findings 
for these patients.   
Patient ID Image analysis findings 
100B* Popliteal node visualisation L side 
101B* No activity 45 min R side 
102B* No activity 45 min bilaterally 
105B* No activity 45 min R side 
100G* Asymmetry at 150 min 
102G* Asymmetry at 150 min 
104G No activity 45 min bilaterally and popliteal node visualisation L side 
106G* No activity 45 min bilaterally 
108G* Popliteal node visualisation bilaterally 
110G* Asymmetry at 150min 
111G* No activity 45 min R side 
113G Asymmetry at 150 min 
114G No activity 45 min bilaterally and asymmetry at 150 min 
116G Popliteal node visualisation R side 
117G Popliteal node visualisation R side 
118G No activity 45 min bilaterally 
123G Popliteal node visualisation L side 
    
Table 28 Abnormal image findings in BCRL and non-BCRL patients 
*patients with BCRL; L, left, R, right 
 
Six of 17 patients demonstrated popliteal node visualisation indicating lymphatic 
diversion (Figure 23).  None of the patients demonstrated dermal backflow. Twelve 
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of 17 patients showed either no activity at 45 min or asymmetry at 150 min, which 
are both categorised as abnormalities related to delay in lymph flow (Figure 24 and 
Figure 25). 
 
Figure 23 Images of the lower limbs, including foot depots. Popliteal node activity, 
signifying lymph diversion, is evident in the right lower limb. Popliteal nodes are 
seen most clearly on posterior images.  This image also shows asymmetry in the 













Figure 24 Images of the lower limbs. There is asymmetry of the activity in the ilio-
inguinal nodes at 150 minutes, with decreased activity in the ilio-inguinal nodes of 





Figure 25 Images of the lower limbs. There is no activity in ilio-inguinal nodes at 45 
minutes.  The 150 min scan of the same patient also shows asymmetry in the ilio-
inguinal nodes. 
 
5.8.3 Lymph flow (k) 
The rate of 99mTc-Nanocoll elimination from each foot injection depot was 
calculated for all 30 patients. However, there are only 14 sets of data available for 
analysis.  The remaining 16 sets of data were not used because the time-related 
changes in decay-corrected count values were not interpretable. The counts were 
recorded at three time-points, but in several cases the number of counts (once 
corrected for decay) actually increased over time.  This led to very low correlation 
coefficients for the exponential fit. For all imaging time-points, the distance of the 
patient from the camera was kept as constant as possible.  To ensure that 
inconsistency in counts was not due to the patient being placed at a slightly 
different distance from the camera, the sensitivity of the camera was tested.  A 
standard containing 25 MBq of 99mTc-Nanocoll was placed at varying distances (in 
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2.5cm increments) from the camera with each image taking 1 minute.   The counts 
were recorded using a ROI over the activity and corrected for decay (Table 29).  The 
results showed that although the number of counts and sensitivity of the camera 
appeared to decrease, the difference caused by the varying the distance between 
the source of radioactivity and the camera was not clinically significant (Figure 26).  
Distance of radioactive 
source from camera head 
(cm) 
Counts (corrected for 
decay) 
Sensitivity of the camera 
(counts per second per 
MBq) 
5 121662 86.7 
7.5 120829 86.1 
10 120777 86.0 
12.5 119673 85.2 
15 119826 85.3 
17.5 118949 84.7 
20 117583 83.7 
Table 29 Measurement of corrected counts of 99mTc-Nanocoll at varying distances 
from the camera head and corresponding sensitivity of the camera (in counts per 
second per MBq) 
 
Figure 26 Plot of corrected counts for radioactive source at varying distance from 































The results for those patients included in the analysis are shown in Table 30 and 
Table 31.  Mean k for the BCRL group (n = 8) was 0.12 ± 0.06 %/min and 0.14 ± 
0.09 %/min for the non-BCRL group (n = 6) (p = 0.58, unpaired t test) (Table 32). 
When separating patients according to whether they had normal (n = 6) or 
abnormal scans (n = 8), k was 0.12 ± 0.05 %/min and 0.14 ± 0.08 %/min respectively 
(p = 0.36, unpaired t test) (Table 33 k (%/min) values for both limbs when 
comparing normal and abnormal scans (mean ± SD).  The results for these 
individual patients are shown in tables Table 34 and Table 35. Some patients had 
unilaterally abnormal scans (n = 7) with the contralateral limb appearing normal on 
lymphoscintigraphy.  To assess if k was significantly different depending on whether 
lymphoscintigraphy was normal or not, k for normal limbs (0.13 ± 0.08 %/min) was 
compared with the abnormal limbs (0.13 ± 0.06 %/min).  This was not significant (p 
= 0.98, unpaired t test).         
5.8.4 Quantification of ilio-inguinal nodal activity 
Quantification was calculated for 22/30 patients, 8 in the BCRL group and 14 in the 
non-BCRL group. The failure of quantification in the remaining 8 patients was a 
technical problem with inaccurate image acquisition, rather than patient factors. 
The results are shown in Table 36 &Table 37.  At 45 minutes the mean ilio-inguinal 
nodal activity, calculated as a percentage of activity of the depot injection, was not 
significantly different in the lower limbs of patients with BCRL compared with non-
BCRL patients (0.75 ± 1.4% vs. 0.84 ± 1.2%; p= 0.82). However, at 150 minutes, the 
activity was found to be significantly lower in the lower limbs of patients with BCRL 
compared with non-BCRL patients. When the quantification was calculated for 
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individual lower limbs of the BCRL and non-BCRL patients, the mean ilio-inguinal 
nodal activity was 2.7 ± 2.5% and 5.9 ± 4.8% respectively, p = 0.006 (Table 38). 
When the quantification was averaged for each patient, rather than considering 
each limb individually, the difference in mean ilio-inguinal nodal activity between 
the BCRL and non-BCRL patients remained significant (2.4 ± 1.9% vs. 5.9 ± 4.2%, p = 
0.026).  This provides objective evidence of abnormal lymphatic function in the 
lower limbs of patients with BCRL compared to those without BCRL.      
5.9 Discussion 
The aim of this study was to explore the possibility that patients who develop upper 
limb BCRL have a constitutional global lymphatic abnormality that may be 
detectable in their lower limbs.  This study has demonstrated that patients with 
upper limb BCRL have reduced lower limb lymphatic function as evidenced by lower 
ilio-inguinal quantification when compared with non-BCRL patients. An additional 
important observation was that a large percentage of breast cancer patients had 
abnormal lower limb lymphatic function irrespective of whether they had upper 
limb BCRL or not and this was observed in the absence of any lower limb clinical 
abnormalities. This was in sharp contrast to patients in the control group all of 
whom had completely normal scans.  
 
The criteria we used to establish which patients had normal or abnormal scans 
were based on other studies that have used similar injection techniques and 
radiotracers.295,333-335 Lymphoscintigraphy imaging is a sensitive method of 
objectively differentiating between abnormal limb swelling due to lymphatic 
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pathology or that of non-lymphatic origin.317,335 The 24 patients in the ‘control 
group’ did not show any evidence of lymphoedema and had normal 
lymphoscintigraphy, despite the majority demonstrating swollen lower limbs.  This 
confirms that patients can have swollen limbs for other reasons, and that 
lymphoscintigraphy is important to confirm a normal lymphatic system.  Several of 
the control group (n = 13) were diagnosed with lipoedema, which is one of the 
differential diagnoses of lymphoedema.  Lipoedema is a genetic disorder 
characterised by abnormal deposition of subcutaneous fat in the lower limbs, often 
with associated mild oedema and in the early stages lymphatic function is 
normal.295,336 
 
Patients with normal lymphatic anatomy and function should show symmetrical 
transport through lymphatic vessels and proximal lymph node uptake.  All patients 
in the BCRL and non-BCRL groups who had abnormal images demonstrated 
abnormalities that are deemed pathognomonic of abnormal lymphatic function.  A 
total of 6/30 patients (20%) showed uptake in popliteal nodes, indicating lymph re-
routing through the deep system, raising the possibility of longer duration of 
lymphatic dysfunction.334  Dermal backflow is another indicator of abnormal 
lymphatics, which occurs when lymph re-routes through the skin.  A recent study 
investigating lymphoedematous lower limbs has shown a strong correlation 
between popliteal node visualisation and dermal backflow.334  None of the patients 
in our study demonstrated dermal backflow, which is perhaps due to the fact that 
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these patients did not demonstrate any swelling in the subcutis of the lower limbs, 
which is where this abnormality would present itself.  
 
It was only possible to include the removal rate clearance of 14 patients, but there 
did not appear to be any differences in the clearance patterns either between BCRL 
and non-BCRL patients or between patients with normal and abnormal scans.  As 
counts were only measured at 3 time-points over 150 min there was a larger 
potential for error compared to imaging at more frequent time points. However, it 
was not possible to explain why the counts were increasing in number, despite 
keeping the methodology consistent for all patients. It is clear that radioactivity 
cannot increase in amount. Therefore, these spurious results therefore must reflect 
an artefact, the cause of which has not yet been identified.  
Despite this, previous studies have also shown that clearance of tracer from the 
depot site is not a reliable method for diagnosing lymphoedema of the lower 
limb.326,337   
 
Quantification, which is the uptake in the lymph nodes expressed as a percentage 
of the injected depot, is thought to be a more reliable method for diagnosing 
lymphoedema.  Mostbeck et al assessed quantification after subcutaneous injection 
of 99mTc-Nanocoll in 25 healthy patients and 12 patients with lower limb 
lymphoedema. They found significantly lower quantification in lymphoedematous 
legs compared with normal legs (2.0 ± 2.5% vs. 14.3 ± 4.2%, p < 0.001).337  A recent 
study noted that in the presence of unilateral lymphoedema, the contralateral limb 
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was often found to be abnormal, highlighting the possibility of a pre-existing 
constitutional weakness of the lymphatics.295 The quantification in this current 
study showed there was a significant difference in ilio-inguinal activity at 150 min, 
with patients in the BCRL group showing significantly lower activity when compared 
to the non-BCRL group, despite not demonstrating lymphoedema of the lower limb.  
These results support the hypothesis of a constitutional abnormality in patients 
who develop BCRL.  On reflection, this study did not correct for depth of the ilio-
inguinal nodes and their distance from the camera head.  Although these patients 
were matched with regard to BMI, thereby minimising this error, a more accurate 
method of quantification should include posterior images in the analysis to allow 
calculation of the geometric mean, which would remove this error altogether.  
Accurate quantification results would have strengthened the diagnosis of normal or 
abnormal scans by providing quantitative results in addition to the qualitative 
results of lymphoscintigraphic images.  Nevertheless, the number of scans found to 
be abnormal would have remained the same or even increased in number had 
quantification been taken into account as a criterion of abnormality on imaging. 
 
This study has shown that a significant number of patients who had previously 
undergone treatment for breast cancer had abnormal lower limb 
lymphoscintigraphy irrespective of whether they developed upper limb BCRL or not. 
This was an unexpected and novel finding.  Almost all the breast cancer patients in 
this study, either with or without BCRL, had systemic therapy in the form of 
endocrine therapy or chemotherapy.  The patients in this study had large tumours 
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and were heavily node positive, which would explain why so many required 
aggressive treatment in the form of chemotherapy.  Taxanes (paclitaxel and 
docetaxel) have emerged as important newer chemotherapeutic drugs in the 
treatment of patients with breast cancer.  Early clinical trials involving docetaxel 
noticed a progressive development of peripheral oedema and non-malignant 
effusions, which were severe enough to warrant discontinuation of therapy.338-341 A 
suggested mechanism of action is that repeated docetaxel exposure induces 
endothelial inflammation leading to abnormal capillary permeability.208,342 Studies 
into the mechanism of the development of oedema in patients receiving taxanes 
have been conducted with capillaroscopy and capillary filtration tests using 99mTc-
albumin and have concluded that there is an abnormality in the capillary 
permeability and also progressive accumulation of proteins in the interstitial 
space.208 A study using the wick and wick-in-needle method to assess transcapillary 
forces also confirmed treatment-induced capillary protein leakage.342 Although 
these studies are specifically looking at oedema rather than lymphoedema, it is 
apparent that these agents cause a systemic disruption, which can have a long-
lasting effect on the lymphatics.  There have been studies linking systemic 
chemotherapy to BCRL, although the mechanism for this remains unclear.206,343-345 
A prospective analysis of BCRL in early breast cancer patients undergoing 
concomitant post-operative radiotherapy and anthracycline-based chemotherapy 
+/- taxanes found an incidence of BCRL of 44% in the group receiving taxanes, three 
times higher than the non-taxane group.207  Several patients in this current study 
also had taxanes as part of their chemotherapy regimen and it could be that BCRL 
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was precipitated in susceptible patients exposed to such chemotherapy agents. 
However, such drug-induced changes may not fully explain the high prevalence of 
abnormal lymphoscintigraphy. Moreover, none of the breast cancer patients 
displayed evidence of lower limb swelling.    
5.10 Conclusion 
In summary, this study has shown that a large proportion of breast cancer patients 
have abnormal lymphatics.  The hypothesis was that patients who develop BCRL 
have abnormal lower limb lymphatics, indicating a global problem with lymphatic 
function.  This was reflected in the quantification results.  Although the majority of 
patients with BCRL did demonstrate abnormal lymphatics, there were also several 
patients without BCRL who had abnormal lymphatic function, which cannot be fully 
explained by this hypothesis.  One distinct possibility is that it is systemic therapy 
causing abnormalities of lymphatic function, even though there was no lower limb 
swelling.  There is also the possibility that there is an unidentified association 








k (%/min) R 
lower limb 
k (%/min) L lower 
limb 
Normal or Abnormal scan 
    
100B 0.1777 0.1058 Abnormal 
101B 0.2080 0.1504 Abnormal 
102B 0.0811 0.2165 Abnormal 
103B 0.1587 0.0807 Normal 
104B 0.1387 0.1956 Normal 
105B 0.0911 0.0849 Abnormal 
100G 0.0555 0.1461 Abnormal 
109G 0.0508 0.0344 Normal 
Mean ± SD 0.120 ± 0.06 0.127 ± 0.06  
Table 30 Depot clearance k (%/min) in lower limbs of patients with BCRL (n = 8)  
 
  k (%/min) R lower limb k (%/min) L lower limb 
Normal or Abnormal 
scan 
    
105G 0.0915 0.1265 Normal 
112G 0.0544 0.1439 Normal 
116G 0.1772 0.3693 Abnormal 
117G 0.1194 0.1771 Abnormal 
120G 0.1459 0.1809 Normal 
123G 0.0268 0.0690 Abnormal 
Mean 
± SD 
0.103 ± 0.06 0.178 ± 0.10 
 








BCRL patients (n = 16) 0.124 ± 0.06  
   
Non-BCRL patients (n = 12) 0.140 ± 0.09  
   
P* 0.58  
   
Table 32 Average k (%/min) values when comparing both limbs of BCRL and non-
BCRL patients (mean ± SD) 




















Table 33 k (%/min) values for both limbs when comparing normal and abnormal 
scans (mean ± SD) 




k (%/min) right lower 
limb 
k (%/min) left lower 
limb 
   
103B* 0.1587 0.0807 
104B* 0.1387 0.1956 
105G 0.0915 0.1265 
109G* 0.0508 0.0344 
112G 0.0544 0.1439 
120G 0.1459 0.1809 
Mean 
± SD 
0.107 ± 0.05 0.127 ± 0.06 
Table 34 Depot clearance k (%/min) in lower limbs of patients with normal scans 
(n = 8) 
*patients with BCRL 
 
  
k (%/min) right lower 
limb 
k (%/min) left lower 
limb 
   
100B* 0.1777 0.1058 
101B* 0.2080 0.1504 
102B* 0.0811 0.2165 
105B* 0.0911 0.0849 
100G* 0.0555 0.1461 
117G 0.1194 0.1771 
120G 0.1459 0.1809 
123G 0.0268 0.0690 
Mean 
± SD 
0.117 ± 0.06 0.165 ± 0.10 
Table 35 Depot clearance k (%/min) in lower limbs of patients with abnormal 
scans (n = 8) *patients with BCRL  





Normal scan (n = 12) 0.117 ± 0.05  
   
Abnormal scan (n = 16) 0.141 ± 0.08  
   
P* 0.36  





Ilio-inguinal nodal activity as % of depot 
injection 
 





















100G 0.4 0.1 3.7 0.2 A 
102G 0 0.1 0.4 3.6 A 
106G 0.2 0.1 0.8 0.8 A 
107G 1.2 0.8 3.4 3.9 N 
108G 0.1 0 4.2 3.3 A 
109G 0.3 0.2 0.8 1.5 N 
110G 0.5 1.8 0.7 2.6 A 
115G 0.5 5.7 2.8 10.6 N 
Mean ± 
SD 0.4 ± 0.4 1.1 ± 2.0 2.1 ± 1.6 3.3 ± 3.2  
Table 36 Ilio-inguinal nodal activity as a percentage of depot injection at 45 and 
150 min in BCRL patients 
 
  
Ilio-inguinal nodal activity as % of depot 
injection 
 





















101G 0.1 0.2 0.3 0.5 N 
104G 0 0 1.6 1.2 A 
105G 0.1 0.4 6 9.3 N 
112G 2 4.9 3.5 7.3 N 
113G 0.5 0.2 0.4 2.1 A 
114G 0 0 10.1 4.5 A 
116G 0.8 2.1 5.1 7.6 A 
117G 0.7 3 4.5 7.9 A 
118G 0 0 23.3 8.4 A 
119G 0.2 1 0.8 2.5 N 
120G 0.1 0.6 11 10.4 N 
121G 0.4 0.2 5.5 4.3 N 
122G 2.7 1.9 10.6 7.5 N 
123G 1 0.5 3.7 4.8 A 
Mean ± 
SD 0.6 ± 0.8 1.1 ± 1.4 6.2 ± 6.1 5.6 ± 3.2  
Table 37 Ilio-inguinal nodal activity as a percentage of depot injection at 45 and 





  Quantification 45 min  Quantification 150 min  
  (Ilio-inguinal activity as % of depot injection) 
   
BCRL patients (n = 16) 0.75 ± 1.4 2.7 ± 2.5 
   
Non-BCRL patients (n = 28) 0.84 ± 1.2 5.9 ± 4.8 
   
p 0.82 0.006 
   
Table 38 Average ilio-inguinal nodal activity as percentage of depot injection for 














Summary and Conclusion 
The aim of the studies in this thesis was to further understand the pathophysiology 
of BCRL.  The traditional view has been that the removal of axillary nodes leads to 
obstruction of lymph flow in the upper limb, which causes the accumulation of 
lymph in the interstitium. Previous observations have indicated that the mechanism 
is more complex than this simple stopcock hypothesis.  The investigations in this 
thesis concentrated on the hypothesis that there may be a constitutive 
predisposition to BCRL.   
 
The first study investigated the muscle lymph flow in the upper limb of women 
undergoing surgery for breast cancer.  The lymphatic clearance rate was measured 
to see if there was an abnormality in the lymph flow prior to axillary lymph node 
surgery.  This would pose a constitutional risk for the development of BCRL.  
Secondly, patients were assessed for the presence of upper limb lymphovenous 
communications with a view to establishing if these act as a protective mechanism 
against BCRL.  Lastly, the lymphatic system of the lower limbs in patients previously 
treated for breast cancer was assessed.  This was performed with the aim of 
determining whether there was a disturbance in lymphatic function in patients who 




Study 1:  An investigation into the muscle lymph drainage of the upper limb 
In a previous study investigating forearm muscle lymph flow at time intervals after 
breast cancer surgery it was found that women who went on to develop BCRL had a 
higher lymph flow rate than non-BCRL patients, reflecting a high rate of capillary 
fluid filtration, describing this as a ‘high filterer’ hypothesis.  It was not possible to 
ascertain if this finding existed prior to surgery or was a response to axillary lymph 
node surgery.  The aim of this study was to address this distinction.  The main 
findings were as follows: 
 There was a significantly higher mean k in patients who went on to develop 
BCRL compared with non-BCRL patients. This indicated a constitutional 
difference in the fluid turnover rather than a response to surgery. 
 At 8 weeks post-surgery, there was no major change in muscle lymph 
drainage, which would be expected if there were truly a stopcock effect. 
 Measurement of the axillary activity pre- and post-operatively showed no 
significant change in activity, indicating that lymphatics and lymph flow 
remain active after surgery. This is also contrary to the theory of 
lymphostasis, which is postulated by the stopcock hypothesis. 
 
There was a significant side-to-side correlation of k, reinforcing evidence that 
quantitative lymphoscintigraphy produces a reproducible measure of lymph 
drainage, and further validating the use of the contralateral arm as a control.  The 
high fluid filtration could be promoting an imbalance between lymph drainage and 




Study 2: An investigation into the presence or absence of lymphovenous 
communications in the upper limb in breast cancer patients  
Previous studies have shown the presence of lymphovenous communications 
(LVCs) in patients, although the significance remains unknown. The aim of this 
study was to investigate the presence or absence of LVCs in breast cancer patients 
and to see if this correlated with the development of BCRL. 
The key findings were as follows: 
 There was clear evidence of shunting of labelled erythrocytes in several 
breast cancer patients. 
 When shunting was present, it was more marked in patients who did not 
develop BCRL. 
Whilst this study did confirm the presence of LVCs in women undergoing surgery 
for breast cancer, it could not determine for certain whether LVCs opened up in 
response to surgery, thereby making it difficult to confirm or refute the hypothesis 
that LVCs protect against the development of BCRL. 
 
Study 3: An investigation into a constitutional global lymphatic dysfunction in 
patients with BCRL 
Studies have found abnormalities in the lymphatic vessels of the contralateral, non- 
swollen upper limbs of patients who developed BCRL in addition to abnormalities in 
the ipsilateral limb. These findings have contributed to the hypothesis of a 
predisposition to BCRL, which would affect the global lymphatic system.  Therefore, 
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lower limb lymphatic function was studied, which allowed comparison of patients 
with and without BCRL. The main findings were: 
 Patients with BCRL and clinically normal lower limbs showed significant 
reduction in lower limb ilio-inguinal nodal activity, which was reflected in 
the significant difference in quantification when compared to non-BCRL 
patients.  This suggested impaired lymph transport in their lower limbs in 
comparison with those without BCRL.   
 Several patients with BCRL were found to have abnormal lower limb 
lymphoscintigraphy, but an unexpected and intriguing finding was that 
there were a number of patients without BCRL who also had abnormal 
lower limb lymphoscintigraphy. 
 
The finding of a high prevalence of abnormal scans in all breast cancer patients has 
not been reported previously, and images indicate lymphatic dysfunction in the 
absence of clinical lower limb lymphoedema.  It was noted that the vast majority of 
breast cancer patients studied had undergone systemic therapy as part of their 
breast cancer treatment, and it has raised the question as to whether this 
treatment is a contributory factor for this unpredicted observation.  A combination 
of constitutive predisposition and systemic therapy, particularly with the use of 
taxanes, could contribute to the observed abnormality of lymphatic function. 
Another possibility is that there is an unidentified association between axillary 





The work described in this thesis has demonstrated that the pathophysiology of 
BCRL is complex and cannot be adequately explained by a simple stopcock 
hypothesis.  On the contrary, the results have shown that the development of BCRL 
may be inevitable in some patients and secondary to an inherent predisposition. 
This constitutional susceptibility, in conjunction with systemic breast cancer 
treatment, could explain why some patients continue to develop BCRL despite the 
use of better locoregional and systemic therapies. Greater focus on the 
contribution of genetic predilection to BCRL may be the key to help identify those 
patients at a higher risk of developing the condition, with a view to introducing 
better preventative measures and earlier intervention to minimise the 







It is uncertain from these studies whether LVCs pre-exist constitutionally or develop 
in response to surgery. Future work need not necessarily be based on labelled red 
cells but perhaps instead on a less labour-intensive method using other labelled 
particles, such as engineered liposomes.  These can be labelled with stable particles 
and perhaps be combined with MRI scanning to look at the axilla pre- and post-
surgery to assess delivery to lymphatics and response to surgery.  
 
Genetic susceptibility is an area that is receiving more interest and future work 
should focus on biomarkers, which could help identify individuals who are more at 
risk of developing BCRL. 
 
The unexpected finding of abnormal lower limb lymphatics in patients with and 
without BCRL has raised the possibility of systemic breast cancer treatment or the 
susceptibility to breast cancer contributing to this finding. Future work should aim 
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